entrez_gene	entrez_id	variant	variant_hgvs	variant_origin	Disease	DOID	Drug	pubchem_id	Evidence Type	Evidence Direction	Clinical Significance	Statement	Level	Source	Text	Type of study	Comments	Curator	stars	Include?	Variant Group	
MAP2K1	5604	protein:p.F133L/; MAP2K1 F133L missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 F133L missense mutation resistance	OHSU Import; MAP2K1 F133L missense mutation; 	preclinical	19915144						1				N/A						1	
GNA11	2767	protein:p.Q209P/; GNA11 Q209P missense mutation		Unknown	Melanoma, NOS	6367	PI3K pathway inhibitors + MEK inhibitors	N/A	response	Supports	GNA11 Q209P missense mutation response	OHSU Import; GNA11 Q209P missense mutation; 	preclinical	22733540						1				N/A						1	
MAP2K1	5604	protein:p.F129L/; MAP2K1 F129L missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERK inhibitors	N/A	sensitivity	Supports	MAP2K1 F129L missense mutation sensitivity	OHSU Import; MAP2K1 F129L missense mutation; 	preclinical	23614898						1				N/A						1	
MAP2K1	5604	protein:p.L215P/; MAP2K1 L215P missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERK inhibitors	N/A	sensitivity	Supports	MAP2K1 L215P missense mutation sensitivity	OHSU Import; MAP2K1 L215P missense mutation; 	preclinical	23614898						1				N/A						1	
MAP2K1	5604	protein:p.I103N/; MAP2K1 I103N missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERK inhibitors	N/A	sensitivity	Supports	MAP2K1 I103N missense mutation sensitivity	OHSU Import; MAP2K1 I103N missense mutation; 	preclinical	23614898						1				N/A						1	
MAP2K1	5604	protein:p.P124/; MAP2K1 P124 missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERK inhibitors	N/A	sensitivity	Supports	MAP2K1 P124 missense mutation sensitivity	OHSU Import; MAP2K1 P124 missense mutation; 	preclinical	23614898						1				N/A						1	
MAP2K1	5604	protein:p.I99T/; MAP2K1 I99T missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 I99T missense mutation resistance	OHSU Import; MAP2K1 I99T missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.L115/; MAP2K1 L115 missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 L115 missense mutation resistance	OHSU Import; MAP2K1 L115 missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.G128D/; MAP2K1 G128D missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 G128D missense mutation resistance	OHSU Import; MAP2K1 G128D missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.F129L/; MAP2K1 F129L missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 F129L missense mutation resistance	OHSU Import; MAP2K1 F129L missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.V211D/; MAP2K1 V211D missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 V211D missense mutation resistance	OHSU Import; MAP2K1 V211D missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.L215P/; MAP2K1 L215P missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 L215P missense mutation resistance	OHSU Import; MAP2K1 L215P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.I103N/; MAP2K1 I103N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 I103N missense mutation resistance	OHSU Import; MAP2K1 I103N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.K104N/; MAP2K1 K104N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 K104N missense mutation resistance	OHSU Import; MAP2K1 K104N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.I111N/; MAP2K1 I111N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 I111N missense mutation resistance	OHSU Import; MAP2K1 I111N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.H119P/; MAP2K1 H119P missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 H119P missense mutation resistance	OHSU Import; MAP2K1 H119P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.E120D/; MAP2K1 E120D missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 E120D missense mutation resistance	OHSU Import; MAP2K1 E120D missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.167A>C; protein:p.Q56P/p.Gln56Pro; MAP2K1 Q56P missense mutation	15:66727451-66727451 (A->C)	Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 Q56P missense mutation resistance	OHSU Import; MAP2K1 Q56P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.P124/; MAP2K1 P124 missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 P124 missense mutation resistance	OHSU Import; MAP2K1 P124 missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.D67N/; MAP2K1 D67N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 D67N missense mutation resistance	OHSU Import; MAP2K1 D67N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.I99T/; MAP2K1 I99T missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 I99T missense mutation resistance	OHSU Import; MAP2K1 I99T missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.L115/; MAP2K1 L115 missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 L115 missense mutation resistance	OHSU Import; MAP2K1 L115 missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.G128D/; MAP2K1 G128D missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 G128D missense mutation resistance	OHSU Import; MAP2K1 G128D missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.F129L/; MAP2K1 F129L missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 F129L missense mutation resistance	OHSU Import; MAP2K1 F129L missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.V211D/; MAP2K1 V211D missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 V211D missense mutation resistance	OHSU Import; MAP2K1 V211D missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.L215P/; MAP2K1 L215P missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 L215P missense mutation resistance	OHSU Import; MAP2K1 L215P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.I103N/; MAP2K1 I103N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 I103N missense mutation resistance	OHSU Import; MAP2K1 I103N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.K104N/; MAP2K1 K104N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 K104N missense mutation resistance	OHSU Import; MAP2K1 K104N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.I111N/; MAP2K1 I111N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 I111N missense mutation resistance	OHSU Import; MAP2K1 I111N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.H119P/; MAP2K1 H119P missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 H119P missense mutation resistance	OHSU Import; MAP2K1 H119P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.E120D/; MAP2K1 E120D missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 E120D missense mutation resistance	OHSU Import; MAP2K1 E120D missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.F133L/; MAP2K1 F133L missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 F133L missense mutation resistance	OHSU Import; MAP2K1 F133L missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.167A>C; protein:p.Q56P/p.Gln56Pro; MAP2K1 Q56P missense mutation	15:66727451-66727451 (A->C)	Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 Q56P missense mutation resistance	OHSU Import; MAP2K1 Q56P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.P124/; MAP2K1 P124 missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 P124 missense mutation resistance	OHSU Import; MAP2K1 P124 missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.D67N/; MAP2K1 D67N missense mutation		Unknown	Malignant neoplasm, NOS	5074	MEK inhibitors	N/A	resistance	Supports	MAP2K1 D67N missense mutation resistance	OHSU Import; MAP2K1 D67N missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.371C>T; protein:p.P124L/p.Pro124Leu; MAP2K1 P124L missense mutation	15:66729163-66729163 (C->T)	Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K1 P124L missense mutation resistance	OHSU Import; MAP2K1 P124L missense mutation; 	case report	19915144						1				N/A						1	
MAP2K1	5604	protein:p.P124/; MAP2K1 P124 missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K1 P124 missense mutation resistance	OHSU Import; MAP2K1 P124 missense mutation; 	early trials	N/A						1				N/A						1	
MAP2K1	5604	cdna:c.362G>C; protein:p.C121S/p.Cys121Ser; MAP2K1 C121S missense mutation	15:66729154-66729154 (G->C)	Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K1 C121S missense mutation resistance	OHSU Import; MAP2K1 C121S missense mutation; 	case report	21383288						1				N/A						1	
MAP2K1	5604	cdna:c.607G>A; protein:p.E203K/p.Glu203Lys; MAP2K1 E203K missense mutation	15:66774131-66774131 (G->A)	Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K1 E203K missense mutation resistance	OHSU Import; MAP2K1 E203K missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.167A>C; protein:p.Q56P/p.Gln56Pro; MAP2K1 Q56P missense mutation	15:66727451-66727451 (A->C)	Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K1 Q56P missense mutation resistance	OHSU Import; MAP2K1 Q56P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	protein:p.P124S/; MAP2K1 P124S missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	sensitivity	Supports	MAP2K1 P124S missense mutation sensitivity	OHSU Import; MAP2K1 P124S missense mutation; 	case report	22588879						1				N/A						1	
MAP2K1	5604	protein:p.I111S/; MAP2K1 I111S missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	sensitivity	Supports	MAP2K1 I111S missense mutation sensitivity	OHSU Import; MAP2K1 I111S missense mutation; 	case report	22588879						1				N/A						1	
MAP2K1	5604	cdna:c.371C>T; protein:p.P124L/p.Pro124Leu; MAP2K1 P124L missense mutation	15:66729163-66729163 (C->T)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 P124L missense mutation resistance	OHSU Import; MAP2K1 P124L missense mutation; 	case report	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.171G>T; protein:p.K57N/p.Lys57Asn; MAP2K1 K57N missense mutation	15:66727455-66727455 (G->T)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 K57N missense mutation resistance	OHSU Import; MAP2K1 K57N missense mutation; 	case report	23444215						1				N/A						1	
MAP2K1	5604	cdna:c.362G>C; protein:p.C121S/p.Cys121Ser; MAP2K1 C121S missense mutation	15:66729154-66729154 (G->C)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 C121S missense mutation resistance	OHSU Import; MAP2K1 C121S missense mutation; 	case report	21383288						1				N/A						1	
MAP2K1	5604	cdna:c.607G>A; protein:p.E203K/p.Glu203Lys; MAP2K1 E203K missense mutation	15:66774131-66774131 (G->A)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 E203K missense mutation resistance	OHSU Import; MAP2K1 E203K missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.167A>C; protein:p.Q56P/p.Gln56Pro; MAP2K1 Q56P missense mutation	15:66727451-66727451 (A->C)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 Q56P missense mutation resistance	OHSU Import; MAP2K1 Q56P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.371C>T; protein:p.P124L/p.Pro124Leu; MAP2K1 P124L missense mutation	15:66729163-66729163 (C->T)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 P124L missense mutation resistance	OHSU Import; MAP2K1 P124L missense mutation; 	case report	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.171G>T; protein:p.K57N/p.Lys57Asn; MAP2K1 K57N missense mutation	15:66727455-66727455 (G->T)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 K57N missense mutation resistance	OHSU Import; MAP2K1 K57N missense mutation; 	case report	23444215						1				N/A						1	
MAP2K1	5604	cdna:c.362G>C; protein:p.C121S/p.Cys121Ser; MAP2K1 C121S missense mutation	15:66729154-66729154 (G->C)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 C121S missense mutation resistance	OHSU Import; MAP2K1 C121S missense mutation; 	case report	21383288						1				N/A						1	
MAP2K1	5604	cdna:c.607G>A; protein:p.E203K/p.Glu203Lys; MAP2K1 E203K missense mutation	15:66774131-66774131 (G->A)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 E203K missense mutation resistance	OHSU Import; MAP2K1 E203K missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.167A>C; protein:p.Q56P/p.Gln56Pro; MAP2K1 Q56P missense mutation	15:66727451-66727451 (A->C)	Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K1 Q56P missense mutation resistance	OHSU Import; MAP2K1 Q56P missense mutation; 	preclinical	19915144						1				N/A						1	
MAP2K1	5604	cdna:c.362G>C; protein:p.C121S/p.Cys121Ser; MAP2K1 C121S missense mutation	15:66729154-66729154 (G->C)	Unknown	Melanoma, NOS	6367	E6201	10172827	sensitivity	Supports	MAP2K1 C121S missense mutation sensitivity	OHSU Import; MAP2K1 C121S missense mutation; 	preclinical	24448821						1				N/A						1	
MAP2K1	5604	protein:p.K57E/; MAP2K1 K57E missense mutation		Unknown	Melanoma, NOS	6367	vemurafenib	42611257	resistance	Supports	MAP2K1 K57E missense mutation resistance	OHSU Import; MAP2K1 K57E missense mutation; 	case report	23569304						1				N/A						1	
MAP2K1	5604	cdna:c.607G>A; protein:p.E203K/p.Glu203Lys; MAP2K1 E203K missense mutation	15:66774131-66774131 (G->A)	Unknown	Melanoma, NOS	6367	vemurafenib	42611257	resistance	Supports	MAP2K1 E203K missense mutation resistance	OHSU Import; MAP2K1 E203K missense mutation; 	case report	23569304						1				N/A						1	
MAP2K1	5604	cdna:c.167A>C; protein:p.Q56P/p.Gln56Pro; MAP2K1 Q56P missense mutation	15:66727451-66727451 (A->C)	Unknown	Melanoma, NOS	6367	vemurafenib	42611257	resistance	Supports	MAP2K1 Q56P missense mutation resistance	OHSU Import; MAP2K1 Q56P missense mutation; 	case report	23569304						1				N/A						1	
IDH2	3418	cdna:c.419G>A; protein:p.R140Q/p.Arg140Gln; IDH2 R140Q missense mutation	15:90631934-90631934 (C->T)	Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	IDH inhibitors	N/A	response	Supports	IDH2 R140Q missense mutation response	OHSU Import; IDH2 R140Q missense mutation; organ=Bone marrow; 	early trials	N/A						1				N/A						1	
GNA11	2767	cdna:c.626A>T; protein:p.Q209L/p.Gln209Leu; GNA11 Q209L missense mutation	19:3118942-3118942 (A->T)	Unknown	Melanoma, NOS	6367	PI3K pathway inhibitors + MEK inhibitors	N/A	response	Supports	GNA11 Q209L missense mutation response	OHSU Import; GNA11 Q209L missense mutation; 	preclinical	22733540						1				N/A						1	
GNA11	2767	cdna:c.626A>T; protein:p.Q209L/p.Gln209Leu; GNA11 Q209L missense mutation	19:3118942-3118942 (A->T)	Unknown	Melanoma, NOS	6367	selumetinib	10127622	response	Supports	GNA11 Q209L missense mutation response	OHSU Import; GNA11 Q209L missense mutation; 	early trials	N/A						1				N/A						1	
GNA11	2767	protein:p.Q209P/; GNA11 Q209P missense mutation		Unknown	Melanoma, NOS	6367	selumetinib	10127622	response	Supports	GNA11 Q209P missense mutation response	OHSU Import; GNA11 Q209P missense mutation; 	early trials	N/A						1				N/A						1	
MAP2K2	5605	protein:p.Q60P/; MAP2K2 Q60P missense mutation		Unknown	Melanoma, NOS	6367	BRAF + MEK inhibitors	N/A	resistance	Supports	MAP2K2 Q60P missense mutation resistance	OHSU Import; MAP2K2 Q60P missense mutation; 	case report	24265154						1				N/A						1	
MAP2K2	5605	protein:p.V35M/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.L46F/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.N126D/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.C125S/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.Q60P/; MAP2K2 Q60P missense mutation		Unknown	Melanoma, NOS	6367	ERK inhibitors	N/A	sensitivity	Supports	MAP2K2 Q60P missense mutation sensitivity	OHSU Import; MAP2K2 Q60P missense mutation; 	preclinical	24265154						1				N/A						1	
MAP2K2	5605	protein:p.V35M/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	ERK inhibitors	N/A	sensitivity	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation sensitivity	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.L46F/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	ERK inhibitors	N/A	sensitivity	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation sensitivity	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.N126D/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	ERK inhibitors	N/A	sensitivity	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation sensitivity	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.C125S/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	ERK inhibitors	N/A	sensitivity	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation sensitivity	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.V35M/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.L46F/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.N126D/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.C125S/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.V35M/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.L46F/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.N126D/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
MAP2K2	5605	protein:p.C125S/; MAP2K2 V35M, L46F, N126D, C125S missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	MAP2K2 V35M, L46F, N126D, C125S missense mutation resistance	OHSU Import; MAP2K2 V35M, L46F, N126D, C125S missense mutation; 	preclinical	24265153						1				N/A						1	
JAK3	3718	protein:p.R657Q/; JAK3 R657Q missense mutation		Unknown	Acute megakaryoblastic leukaemia	3951	JAK inhibitors	N/A	sensitivity	Supports	JAK3 R657Q missense mutation sensitivity	OHSU Import; JAK3 R657Q missense mutation; organ=Bone marrow; 	preclinical	18397343						1				N/A						1	
JAK3	3718	protein:p.I87T/; JAK3 I87T missense mutation		Unknown	Acute megakaryoblastic leukaemia	3951	JAK inhibitors	N/A	sensitivity	Supports	JAK3 I87T missense mutation sensitivity	OHSU Import; JAK3 I87T missense mutation; organ=Bone marrow; 	preclinical	18397343						1				N/A						1	
JAK3	3718	protein:p.Q501H/; JAK3 Q501H missense mutation		Unknown	Acute megakaryoblastic leukaemia	3951	JAK inhibitors	N/A	sensitivity	Supports	JAK3 Q501H missense mutation sensitivity	OHSU Import; JAK3 Q501H missense mutation; organ=Bone marrow; 	preclinical	18397343						1				N/A						1	
JAK3	3718	protein:p.A572V/; JAK3  A572V missense mutation		Unknown	Natural killer (NK) cell lymphoblastic leukaemia/lymphoma	1035	JAK inhibitors	N/A	sensitivity	Supports	JAK3  A572V missense mutation sensitivity	OHSU Import; JAK3  A572V missense mutation; 	preclinical	22705984						1				N/A						1	
JAK3	3718	protein:p.A573V/; JAK3  A573V missense mutation		Unknown	Natural killer (NK) cell lymphoblastic leukaemia/lymphoma	1035	JAK inhibitors	N/A	sensitivity	Supports	JAK3  A573V missense mutation sensitivity	OHSU Import; JAK3  A573V missense mutation; 	preclinical	22705984						1				N/A						1	
PIK3R2	5296	protein:p.A171V/; PIK3R2 A171V missense mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	sensitivity	Supports	PIK3R2 A171V missense mutation sensitivity	OHSU Import; PIK3R2 A171V missense mutation; organ=Endometrium; 	preclinical	19962665						1				N/A						1	
PIK3R2	5296	protein:p.N561D/; PIK3R2 N561D missense mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	sensitivity	Supports	PIK3R2 N561D missense mutation sensitivity	OHSU Import; PIK3R2 N561D missense mutation; organ=Endometrium; 	preclinical	21984976						1				N/A						1	
PIK3R2	5296	protein:p.A171V/; PIK3R2 A171V missense mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	sensitivity	Supports	PIK3R2 A171V missense mutation sensitivity	OHSU Import; PIK3R2 A171V missense mutation; organ=Endometrium; 	preclinical	19962665						1				N/A						1	
PIK3R2	5296	protein:p.N561D/; PIK3R2 N561D missense mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	sensitivity	Supports	PIK3R2 N561D missense mutation sensitivity	OHSU Import; PIK3R2 N561D missense mutation; organ=Endometrium; 	preclinical	21984976						1				N/A						1	
DDR2	4921	protein:p.I638F/; DDR2 I638F missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	DDR2 I638F missense mutation sensitivity	OHSU Import; DDR2 I638F missense mutation; organ=Lung; 	preclinical	22328973						1				N/A						1	
DDR2	4921	protein:p.L239R/; DDR2 L239R missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	DDR2 L239R missense mutation sensitivity	OHSU Import; DDR2 L239R missense mutation; organ=Lung; 	preclinical	22328973						1				N/A						1	
DDR2	4921	protein:p.G253C/; DDR2 G253C missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	DDR2 G253C missense mutation sensitivity	OHSU Import; DDR2 G253C missense mutation; organ=Lung; 	preclinical	22328973						1				N/A						1	
DDR2	4921	protein:p.G774V/; DDR2 G774V missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	DDR2 G774V missense mutation sensitivity	OHSU Import; DDR2 G774V missense mutation; organ=Lung; 	preclinical	22328973						1				N/A						1	
DDR2	4921	protein:p.L63V/; DDR2 L63V missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	DDR2 L63V missense mutation sensitivity	OHSU Import; DDR2 L63V missense mutation; organ=Lung; 	preclinical	22328973						1				N/A						1	
DDR2	4921	cdna:c.1513G>A; protein:p.G505S/p.Gly505Ser; DDR2 G505S missense mutation	1:162741822-162741822 (G->A)	Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	DDR2 G505S missense mutation sensitivity	OHSU Import; DDR2 G505S missense mutation; organ=Lung; 	preclinical	22328973						1				N/A						1	
DDR2	4921	protein:p.S768R/; DDR2 S768R missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	DDR2 S768R missense mutation sensitivity	OHSU Import; DDR2 S768R missense mutation; organ=Lung; 	preclinical	22328973						1				N/A						1	
DDR2	4921	protein:p.S768R/; DDR2 S768R missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib + erlotinib	N/A	response	Supports	DDR2 S768R missense mutation response	OHSU Import; DDR2 S768R missense mutation; organ=Lung; 	case report	22328973						1				N/A						1	
MTOR	2475	protein:p.F2108L/; MTOR F2108L missense mutation		Unknown	Malignant neoplasm, NOS	5074	everolimus	6442177	resistance	Supports	MTOR F2108L missense mutation resistance	OHSU Import; MTOR F2108L missense mutation; 	case report	25295501						1				N/A						1	
MTOR	2475	protein:p.F2108L/; MTOR F2108L missense mutation		Unknown	Malignant neoplasm, NOS	5074	mTOR inhibitors	N/A	sensitivity	Supports	MTOR F2108L missense mutation sensitivity	OHSU Import; MTOR F2108L missense mutation; 	preclinical	25295501						1				N/A						1	
MTOR	2475	protein:p.L1460P/; MTOR L1460P missense mutation		Unknown	Malignant neoplasm, NOS	5074	rapamycin	5284616	sensitivity	Supports	MTOR L1460P missense mutation sensitivity	OHSU Import; MTOR L1460P missense mutation; 	preclinical	24631838						1				N/A						1	
MTOR	2475	protein:p.S2215Y/; MTOR S2215Y missense mutation		Unknown	Malignant neoplasm, NOS	5074	rapamycin	5284616	sensitivity	Supports	MTOR S2215Y missense mutation sensitivity	OHSU Import; MTOR S2215Y missense mutation; 	preclinical	24631838						1				N/A						1	
MTOR	2475	protein:p.R2505P/; MTOR R2505P missense mutation		Unknown	Malignant neoplasm, NOS	5074	rapamycin	5284616	sensitivity	Supports	MTOR R2505P missense mutation sensitivity	OHSU Import; MTOR R2505P missense mutation; 	preclinical	24631838						1				N/A						1	
MTOR	2475	protein:p.Q2223K/; MTOR Q2223K missense mutation		Unknown	Clear cell carcinoma	7267	everolimus	6442177	response	Supports	MTOR Q2223K missense mutation response	OHSU Import; MTOR Q2223K missense mutation; organ=Kidney; 	case report	24622468						1				N/A						1	
MTOR	2475	protein:p.E2014K/; MTOR E2014K missense mutation		Unknown	Urothelial carcinoma	6166	everolimus	6442177	response	Supports	MTOR E2014K missense mutation response	OHSU Import; MTOR E2014K missense mutation; organ=Bladder; 	case report	24625776						1				N/A						1	
MTOR	2475	protein:p.E2419K/; MTOR E2419K missense mutation		Unknown	Urothelial carcinoma	6166	everolimus	6442177	response	Supports	MTOR E2419K missense mutation response	OHSU Import; MTOR E2419K missense mutation; organ=Bladder; 	case report	24625776						1				N/A						1	
GNAS	2778	transcript:CCDS13472.1;  amino_acid:201-201;  GNAS R201 missense mutation		Unknown	Malignant neoplasm, NOS	5074	JAK inhibitors	N/A	sensitivity	Supports	GNAS R201 missense mutation sensitivity	OHSU Import; GNAS R201 missense mutation; 	preclinical	21835143						1				N/A						1	
AR	367	protein:p.F877L/; AR  F876L missense mutation		Unknown	Adenocarcinoma	299	ARN-509	24872560	resistance	Supports	AR  F876L missense mutation resistance	OHSU Import; AR  F876L missense mutation; organ=Prostate; 	case report	23779130						1				N/A						1	
AR	367	protein:p.T878A/; AR  T877A missense mutation		Unknown	Adenocarcinoma	299	ARN-509	24872560	sensitivity	Supports	AR  T877A missense mutation sensitivity	OHSU Import; AR  T877A missense mutation; organ=Prostate; 	preclinical	23779130						1				N/A						1	
AR	367	transcript:CCDS14387.1;  amino_acid:742-742;  AR  W741 missense mutation		Unknown	Adenocarcinoma	299	ARN-509	24872560	sensitivity	Supports	AR  W741 missense mutation sensitivity	OHSU Import; AR  W741 missense mutation; organ=Prostate; 	preclinical	23779130						1				N/A						1	
AR	367	transcript:CCDS14387.1;  amino_acid:742-742;  AR  W741 missense mutation		Unknown	Adenocarcinoma	299	bicalutamide	2375	resistance	Supports	AR  W741 missense mutation resistance	OHSU Import; AR  W741 missense mutation; organ=Prostate; 	preclinical	12517791						1				N/A						1	
AR	367	protein:p.F877L/; AR  F876L missense mutation		Unknown	Adenocarcinoma	299	enzalutamide	15951529	resistance	Supports	AR  F876L missense mutation resistance	OHSU Import; AR  F876L missense mutation; organ=Prostate; 	case report	23779130						1				N/A						1	
AR	367	protein:p.T878A/; AR  T877A missense mutation		Unknown	Adenocarcinoma	299	enzalutamide	15951529	sensitivity	Supports	AR  T877A missense mutation sensitivity	OHSU Import; AR  T877A missense mutation; organ=Prostate; 	preclinical	23779130						1				N/A						1	
AR	367	transcript:CCDS14387.1;  amino_acid:742-742;  AR  W741 missense mutation		Unknown	Adenocarcinoma	299	enzalutamide	15951529	sensitivity	Supports	AR  W741 missense mutation sensitivity	OHSU Import; AR  W741 missense mutation; organ=Prostate; 	preclinical	23779130						1				N/A						1	
AR	367	protein:p.T878A/; AR  T877A missense mutation		Unknown	Adenocarcinoma	299	flutamide	3397	resistance	Supports	AR  T877A missense mutation resistance	OHSU Import; AR  T877A missense mutation; organ=Prostate; 	case report	2260966						1				N/A						1	
BTK	695	protein:p.C481S/; BTK C481S missense mutation		Unknown	Chronic lymphocytic leukaemia/small lymphocytic lymphoma	8144	ibrutinib	24821094	resistance	Supports	BTK C481S missense mutation resistance	OHSU Import; BTK C481S missense mutation; organ=Lymph Node; 	early trials	24869598						1				N/A						1	
BTK	695	transcript:CCDS14482.1;  amino_acid:481-481;  BTK C481 missense mutation		Unknown	Mantle cell lymphoma	0050746	ibrutinib	24821094	resistance	Supports	BTK C481 missense mutation resistance	OHSU Import; BTK C481 missense mutation; organ=Lymph Node; 	case report	25082755						1				N/A						1	
EPHA2	1969	protein:p.G391R/; EPHA2 G391R missense mutation		Unknown	Squamous cell carcinoma	1749	dasatinib	3062316	sensitivity	Supports	EPHA2 G391R missense mutation sensitivity	OHSU Import; EPHA2 G391R missense mutation; organ=Lung; 	preclinical	20360610						1				N/A						1	
EPHA2	1969	protein:p.G391R/; EPHA2 G391R missense mutation		Unknown	Squamous cell carcinoma	1749	mTOR inhibitors	N/A	sensitivity	Supports	EPHA2 G391R missense mutation sensitivity	OHSU Import; EPHA2 G391R missense mutation; organ=Lung; 	preclinical	20360610						1				N/A						1	
EPHA2	1969	protein:p.G391R/; EPHA2 G391R missense mutation		Unknown	Squamous cell carcinoma	1749	mTOR inhibitors	N/A	sensitivity	Supports	EPHA2 G391R missense mutation sensitivity	OHSU Import; EPHA2 G391R missense mutation; organ=Lung; 	preclinical	20360610						1				N/A						1	
IDH1	3417	cdna:c.395G>A; protein:p.R132H/p.Arg132His; IDH1 R132H missense mutation	2:209113112-209113112 (C->T)	Unknown	Glioma	3070	IDH inhibitors	N/A	sensitivity	Supports	IDH1 R132H missense mutation sensitivity	OHSU Import; IDH1 R132H missense mutation; organ=Brain; 	preclinical	23558169						1				N/A						1	
ERBB4	2066	protein:p.E317K/; ERBB4 E317K missense mutation		Unknown	Melanoma, NOS	6367	lapatinib	208908	sensitivity	Supports	ERBB4 E317K missense mutation sensitivity	OHSU Import; ERBB4 E317K missense mutation; 	preclinical	19718025						1				N/A						1	
ERBB4	2066	protein:p.E452K/; ERBB4 E452K missense mutation		Unknown	Melanoma, NOS	6367	lapatinib	208908	sensitivity	Supports	ERBB4 E452K missense mutation sensitivity	OHSU Import; ERBB4 E452K missense mutation; 	preclinical	19718025						1				N/A						1	
ERBB4	2066	protein:p.E542K/; ERBB4 E542K missense mutation		Unknown	Melanoma, NOS	6367	lapatinib	208908	sensitivity	Supports	ERBB4 E542K missense mutation sensitivity	OHSU Import; ERBB4 E542K missense mutation; 	preclinical	19718025						1				N/A						1	
ERBB4	2066	protein:p.R544W/; ERBB4 R544W missense mutation		Unknown	Melanoma, NOS	6367	lapatinib	208908	sensitivity	Supports	ERBB4 R544W missense mutation sensitivity	OHSU Import; ERBB4 R544W missense mutation; 	preclinical	19718025						1				N/A						1	
ERBB4	2066	protein:p.R393W/; ERBB4 R393W missense mutation		Unknown	Melanoma, NOS	6367	lapatinib	208908	sensitivity	Supports	ERBB4 R393W missense mutation sensitivity	OHSU Import; ERBB4 R393W missense mutation; 	preclinical	19718025						1				N/A						1	
ERBB4	2066	protein:p.E872K/; ERBB4 E872K missense mutation		Unknown	Melanoma, NOS	6367	lapatinib	208908	sensitivity	Supports	ERBB4 E872K missense mutation sensitivity	OHSU Import; ERBB4 E872K missense mutation; 	preclinical	19718025						1				N/A						1	
RAF1	5894	protein:p.S257P/; RAF1 S257P missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumors	N/A	resistance	Supports	RAF1 S257P missense mutation resistance	OHSU Import; RAF1 S257P missense mutation; 	preclinical	23737487						1				N/A						1	
RAF1	5894	protein:p.P261T/; RAF1 P261T missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumors	N/A	resistance	Supports	RAF1 P261T missense mutation resistance	OHSU Import; RAF1 P261T missense mutation; 	preclinical	23737487						1				N/A						1	
RAF1	5894	protein:p.G361A/; RAF1 G361A missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumors	N/A	resistance	Supports	RAF1 G361A missense mutation resistance	OHSU Import; RAF1 G361A missense mutation; 	preclinical	23737487						1				N/A						1	
MYD88	4615	protein:p.L265P/; MYD88 L265P missense mutation		Unknown	Lymphoma, NOS	8838	JAK inhibitors	N/A	sensitivity	Supports	MYD88 L265P missense mutation sensitivity	OHSU Import; MYD88 L265P missense mutation; organ=Lymph Node; 	preclinical	21179087						1				N/A						1	
FGFR2	2263	protein:p.S252W/; FGFR2 S252W missense mutation		Unknown	Endometrioid carcinoma	2871	FGFR inhibitors	N/A	sensitivity	Supports	FGFR2 S252W missense mutation sensitivity	OHSU Import; FGFR2 S252W missense mutation; organ=Endometrium; 	preclinical	18552176						1				N/A						1	
FGFR2	2263	protein:p.N549K/; FGFR2 N549K missense mutation		Unknown	Endometrioid carcinoma	2871	FGFR inhibitors	N/A	sensitivity	Supports	FGFR2 N549K missense mutation sensitivity	OHSU Import; FGFR2 N549K missense mutation; organ=Endometrium; 	preclinical	18552176						1				N/A						1	
ERBB3	2065	protein:p.P262H/; ERBB3 P262H missense mutation		Unknown	Malignant neoplasm, NOS	5074	anti-HER3 mAbs	N/A	sensitivity	Supports	ERBB3 P262H missense mutation sensitivity	OHSU Import; ERBB3 P262H missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.G284R/; ERBB3 G284R missense mutation		Unknown	Malignant neoplasm, NOS	5074	anti-HER3 mAbs	N/A	sensitivity	Supports	ERBB3 G284R missense mutation sensitivity	OHSU Import; ERBB3 G284R missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.P262H/; ERBB3 P262H missense mutation		Unknown	Malignant neoplasm, NOS	5074	lapatinib	208908	sensitivity	Supports	ERBB3 P262H missense mutation sensitivity	OHSU Import; ERBB3 P262H missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.G284R/; ERBB3 G284R missense mutation		Unknown	Malignant neoplasm, NOS	5074	lapatinib	208908	sensitivity	Supports	ERBB3 G284R missense mutation sensitivity	OHSU Import; ERBB3 G284R missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.Q809R/; ERBB3 Q809R missense mutation		Unknown	Malignant neoplasm, NOS	5074	lapatinib	208908	sensitivity	Supports	ERBB3 Q809R missense mutation sensitivity	OHSU Import; ERBB3 Q809R missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.P262H/; ERBB3 P262H missense mutation		Unknown	Malignant neoplasm, NOS	5074	pertuzumab	N/A	sensitivity	Supports	ERBB3 P262H missense mutation sensitivity	OHSU Import; ERBB3 P262H missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.G284R/; ERBB3 G284R missense mutation		Unknown	Malignant neoplasm, NOS	5074	pertuzumab	N/A	sensitivity	Supports	ERBB3 G284R missense mutation sensitivity	OHSU Import; ERBB3 G284R missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.P262H/; ERBB3 P262H missense mutation		Unknown	Malignant neoplasm, NOS	5074	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	ERBB3 P262H missense mutation sensitivity	OHSU Import; ERBB3 P262H missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.G284R/; ERBB3 G284R missense mutation		Unknown	Malignant neoplasm, NOS	5074	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	ERBB3 G284R missense mutation sensitivity	OHSU Import; ERBB3 G284R missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.Q809R/; ERBB3 Q809R missense mutation		Unknown	Malignant neoplasm, NOS	5074	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	ERBB3 Q809R missense mutation sensitivity	OHSU Import; ERBB3 Q809R missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.P262H/; ERBB3 P262H missense mutation		Unknown	Malignant neoplasm, NOS	5074	trastuzumab	N/A	sensitivity	Supports	ERBB3 P262H missense mutation sensitivity	OHSU Import; ERBB3 P262H missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.G284R/; ERBB3 G284R missense mutation		Unknown	Malignant neoplasm, NOS	5074	trastuzumab	N/A	sensitivity	Supports	ERBB3 G284R missense mutation sensitivity	OHSU Import; ERBB3 G284R missense mutation; 	preclinical	23680147						1				N/A						1	
ERBB3	2065	protein:p.Q809R/; ERBB3 Q809R missense mutation		Unknown	Malignant neoplasm, NOS	5074	trastuzumab	N/A	sensitivity	Supports	ERBB3 Q809R missense mutation sensitivity	OHSU Import; ERBB3 Q809R missense mutation; 	preclinical	23680147						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:676-676;  FLT3 N676 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	crenolanib	10366136	sensitivity	Supports	FLT3 N676 missense mutation sensitivity	OHSU Import; FLT3 N676 missense mutation; organ=Bone marrow; 	preclinical	24619500						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:842-842;  FLT3 Y842 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	crenolanib	10366136	sensitivity	Supports	FLT3 Y842 missense mutation sensitivity	OHSU Import; FLT3 Y842 missense mutation; organ=Bone marrow; 	preclinical	24619500						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:591-597;  FLT3 ITD (Y591-597) mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	FLT3 inhibitors	N/A	response	Supports	FLT3 ITD (Y591-597) mutation response	OHSU Import; FLT3 ITD (Y591-597) mutation; organ=Bone marrow; 	early trials	16857985						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:835-835;  FLT3 D835 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	lestaurtinib	126565	response	Supports	FLT3 D835 missense mutation response	OHSU Import; FLT3 D835 missense mutation; organ=Bone marrow; 	case report	16857985						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:835-835;  FLT3 D835 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	midostaurin	9829523	response	Supports	FLT3 D835 missense mutation response	OHSU Import; FLT3 D835 missense mutation; organ=Bone marrow; 	case report	20733134						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:676-676;  FLT3 N676 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	PKC412	9829523	sensitivity	Supports	FLT3 N676 missense mutation sensitivity	OHSU Import; FLT3 N676 missense mutation; organ=Bone marrow; 	preclinical	24619500						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:842-842;  FLT3 Y842 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	PKC412	9829523	sensitivity	Supports	FLT3 Y842 missense mutation sensitivity	OHSU Import; FLT3 Y842 missense mutation; organ=Bone marrow; 	preclinical	24619500						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:835-835;  FLT3 D835 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	ponatinib	24826799	resistance	Supports	FLT3 D835 missense mutation resistance	OHSU Import; FLT3 D835 missense mutation; organ=Bone marrow; 	preclinical	23430109						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:842-842;  FLT3 Y842 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	ponatinib	24826799	resistance	Supports	FLT3 Y842 missense mutation resistance	OHSU Import; FLT3 Y842 missense mutation; organ=Bone marrow; 	preclinical	23430109						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:691-691;  FLT3 F691 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	quizartinib	24889392	resistance	Supports	FLT3 F691 missense mutation resistance	OHSU Import; FLT3 F691 missense mutation; organ=Bone marrow; 	preclinical	22504184						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:835-835;  FLT3 D835 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	quizartinib	24889392	resistance	Supports	FLT3 D835 missense mutation resistance	OHSU Import; FLT3 D835 missense mutation; organ=Bone marrow; 	preclinical	22504184						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:676-676;  FLT3 N676 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	quizartinib	24889392	resistance	Supports	FLT3 N676 missense mutation resistance	OHSU Import; FLT3 N676 missense mutation; organ=Bone marrow; 	preclinical	23878140						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:842-842;  FLT3 Y842 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	quizartinib	24889392	resistance	Supports	FLT3 Y842 missense mutation resistance	OHSU Import; FLT3 Y842 missense mutation; organ=Bone marrow; 	preclinical	22504184						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:591-597;  FLT3 ITD (Y591-597) mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	quizartinib	24889392	response	Supports	FLT3 ITD (Y591-597) mutation response	OHSU Import; FLT3 ITD (Y591-597) mutation; organ=Bone marrow; 	early trials	N/A						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:835-835;  FLT3 D835 missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	sorafenib	216239	resistance	Supports	FLT3 D835 missense mutation resistance	OHSU Import; FLT3 D835 missense mutation; organ=Bone marrow; 	case report	22368270						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:591-597;  FLT3 ITD (Y591-597) mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	sorafenib	216239	response	Supports	FLT3 ITD (Y591-597) mutation response	OHSU Import; FLT3 ITD (Y591-597) mutation; organ=Bone marrow; 	early trials	19389879						1				N/A						1	
FLT3	2322	transcript:CCDS31953.1;  amino_acid:591-597;  FLT3 ITD (Y591-597) mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	sorafenib + azacytidine	N/A	response	Supports	FLT3 ITD (Y591-597) mutation response	OHSU Import; FLT3 ITD (Y591-597) mutation; organ=Bone marrow; 	early trials	23613521						1				N/A						1	
ERBB2	2064	cdna:c.926G>C; protein:p.G309A/p.Gly309Ala; ERBB2 G309A missense mutation	17:37868205-37868205 (G->C)	Unknown	Ductal carcinoma	3587	lapatinib	208908	reduced sensitivity	Supports	ERBB2 G309A missense mutation reduced sensitivity	OHSU Import; ERBB2 G309A missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.2305G>T; protein:p.D769Y/p.Asp769Tyr; ERBB2 D769Y missense mutation	17:37880261-37880261 (G->T)	Unknown	Ductal carcinoma	3587	lapatinib	208908	sensitivity	Supports	ERBB2 D769Y missense mutation sensitivity	OHSU Import; ERBB2 D769Y missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.D769H/; ERBB2 D769H missense mutation		Unknown	Ductal carcinoma	3587	lapatinib	208908	reduced sensitivity	Supports	ERBB2 D769H missense mutation reduced sensitivity	OHSU Import; ERBB2 D769H missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.R896C/; ERBB2 R896C missense mutation		Unknown	Ductal carcinoma	3587	lapatinib	208908	sensitivity	Supports	ERBB2 R896C missense mutation sensitivity	OHSU Import; ERBB2 R896C missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.2329G>T; protein:p.V777L/p.Val777Leu; ERBB2 V777L missense mutation	17:37881000-37881000 (G->T)	Unknown	Ductal carcinoma	3587	lapatinib	208908	reduced sensitivity	Supports	ERBB2 V777L missense mutation reduced sensitivity	OHSU Import; ERBB2 V777L missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.2524G>A; protein:p.V842I/p.Val842Ile; ERBB2 V842I missense mutation	17:37881332-37881332 (G->A)	Unknown	Ductal carcinoma	3587	lapatinib	208908	reduced sensitivity	Supports	ERBB2 V842I missense mutation reduced sensitivity	OHSU Import; ERBB2 V842I missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.V659E/; ERBB2 V659E missense mutation		Unknown	Ductal carcinoma	3587	lapatinib	208908	response	Supports	ERBB2 V659E missense mutation response	OHSU Import; ERBB2 V659E missense mutation; organ=Breast; 	case report	23950206						1				N/A						1	
ERBB2	2064	cdna:c.2264T>C; protein:p.L755S/p.Leu755Ser; ERBB2 L755S missense mutation	17:37880220-37880220 (T->C)	Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 L755S missense mutation sensitivity	OHSU Import; ERBB2 L755S missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.926G>C; protein:p.G309A/p.Gly309Ala; ERBB2 G309A missense mutation	17:37868205-37868205 (G->C)	Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 G309A missense mutation sensitivity	OHSU Import; ERBB2 G309A missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	transcript:CCDS32642.1;  amino_acid:755-759;  ERBB2 755-759del deletion mutation		Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 755-759del deletion mutation sensitivity	OHSU Import; ERBB2 755-759del deletion mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.2305G>T; protein:p.D769Y/p.Asp769Tyr; ERBB2 D769Y missense mutation	17:37880261-37880261 (G->T)	Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 D769Y missense mutation sensitivity	OHSU Import; ERBB2 D769Y missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.D769H/; ERBB2 D769H missense mutation		Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 D769H missense mutation sensitivity	OHSU Import; ERBB2 D769H missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.R896C/; ERBB2 R896C missense mutation		Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 R896C missense mutation sensitivity	OHSU Import; ERBB2 R896C missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.2329G>T; protein:p.V777L/p.Val777Leu; ERBB2 V777L missense mutation	17:37881000-37881000 (G->T)	Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 V777L missense mutation sensitivity	OHSU Import; ERBB2 V777L missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.P780_Y781insGSP/; ERBB2 P780_Y781insGSP insertion mutation		Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 P780_Y781insGSP insertion mutation sensitivity	OHSU Import; ERBB2 P780_Y781insGSP insertion mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.2524G>A; protein:p.V842I/p.Val842Ile; ERBB2 V842I missense mutation	17:37881332-37881332 (G->A)	Unknown	Ductal carcinoma	3587	neratinib	9915743	sensitivity	Supports	ERBB2 V842I missense mutation sensitivity	OHSU Import; ERBB2 V842I missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	cdna:c.2305G>T; protein:p.D769Y/p.Asp769Tyr; ERBB2 D769Y missense mutation	17:37880261-37880261 (G->T)	Unknown	Ductal carcinoma	3587	trastuzumab	N/A	sensitivity	Supports	ERBB2 D769Y missense mutation sensitivity	OHSU Import; ERBB2 D769Y missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.D769H/; ERBB2 D769H missense mutation		Unknown	Ductal carcinoma	3587	trastuzumab	N/A	sensitivity	Supports	ERBB2 D769H missense mutation sensitivity	OHSU Import; ERBB2 D769H missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.R896C/; ERBB2 R896C missense mutation		Unknown	Ductal carcinoma	3587	trastuzumab	N/A	sensitivity	Supports	ERBB2 R896C missense mutation sensitivity	OHSU Import; ERBB2 R896C missense mutation; organ=Breast; 	preclinical	23220880						1				N/A						1	
ERBB2	2064	protein:p.G309E/; ERBB2 G309E  missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERBB2 TKIs	N/A	sensitivity	Supports	ERBB2 G309E  missense mutation sensitivity	OHSU Import; ERBB2 G309E  missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.S310F/; ERBB2 S310F missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERBB2 TKIs	N/A	sensitivity	Supports	ERBB2 S310F missense mutation sensitivity	OHSU Import; ERBB2 S310F missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.S310Y/; ERBB2 S310Y missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERBB2 TKIs	N/A	sensitivity	Supports	ERBB2 S310Y missense mutation sensitivity	OHSU Import; ERBB2 S310Y missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.C311R/; ERBB2 C311R missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERBB2 TKIs	N/A	sensitivity	Supports	ERBB2 C311R missense mutation sensitivity	OHSU Import; ERBB2 C311R missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.E321G/; ERBB2 E321G missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERBB2 TKIs	N/A	sensitivity	Supports	ERBB2 E321G missense mutation sensitivity	OHSU Import; ERBB2 E321G missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.C334S/; ERBB2 C334S missense mutation		Unknown	Malignant neoplasm, NOS	5074	ERBB2 TKIs	N/A	sensitivity	Supports	ERBB2 C334S missense mutation sensitivity	OHSU Import; ERBB2 C334S missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.G309E/; ERBB2 G309E  missense mutation		Unknown	Malignant neoplasm, NOS	5074	trastuzumab	N/A	sensitivity	Supports	ERBB2 G309E  missense mutation sensitivity	OHSU Import; ERBB2 G309E  missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.S310F/; ERBB2 S310F missense mutation		Unknown	Malignant neoplasm, NOS	5074	trastuzumab	N/A	sensitivity	Supports	ERBB2 S310F missense mutation sensitivity	OHSU Import; ERBB2 S310F missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.S310Y/; ERBB2 S310Y missense mutation		Unknown	Malignant neoplasm, NOS	5074	trastuzumab	N/A	sensitivity	Supports	ERBB2 S310Y missense mutation sensitivity	OHSU Import; ERBB2 S310Y missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	protein:p.C311R/; ERBB2 C311R missense mutation		Unknown	Malignant neoplasm, NOS	5074	trastuzumab	N/A	sensitivity	Supports	ERBB2 C311R missense mutation sensitivity	OHSU Import; ERBB2 C311R missense mutation; 	preclinical	22908275						1				N/A						1	
ERBB2	2064	transcript:CCDS32642.1;  amino_acid:775-881;  ERBB2 proximal exon 20 p.775-881 insertion mutation		Unknown	Adenocarcinoma	299	afatinib	10184653	response	Supports	ERBB2 proximal exon 20 p.775-881 insertion mutation response	OHSU Import; ERBB2 proximal exon 20 p.775-881 insertion mutation; organ=Lung; 	early trials	22325357						1				N/A						1	
ERBB2	2064	protein:p.V659E/; ERBB2 V659E missense mutation		Unknown	Adenocarcinoma	299	lapatinib	208908	response	Supports	ERBB2 V659E missense mutation response	OHSU Import; ERBB2 V659E missense mutation; organ=Lung; 	case report	23950206						1				N/A						1	
ERBB2	2064	transcript:CCDS32642.1;  amino_acid:775-881;  ERBB2 proximal exon 20 p.775-881 insertion mutation		Unknown	Adenocarcinoma	299	lapatinib	208908	sensitivity	Supports	ERBB2 proximal exon 20 p.775-881 insertion mutation sensitivity	OHSU Import; ERBB2 proximal exon 20 p.775-881 insertion mutation; organ=Lung; 	preclinical	16843263						1				N/A						1	
ERBB2	2064	transcript:CCDS32642.1;  amino_acid:775-881;  ERBB2 proximal exon 20 p.775-881 insertion mutation		Unknown	Adenocarcinoma	299	neratinib	9915743	sensitivity	Supports	ERBB2 proximal exon 20 p.775-881 insertion mutation sensitivity	OHSU Import; ERBB2 proximal exon 20 p.775-881 insertion mutation; organ=Lung; 	preclinical	16843263						1				N/A						1	
ERBB2	2064	transcript:CCDS32642.1;  amino_acid:775-881;  ERBB2 proximal exon 20 p.775-881 insertion mutation		Unknown	Adenocarcinoma	299	trastuzumab	N/A	sensitivity	Supports	ERBB2 proximal exon 20 p.775-881 insertion mutation sensitivity	OHSU Import; ERBB2 proximal exon 20 p.775-881 insertion mutation; organ=Lung; 	preclinical	16843263						1				N/A						1	
ERBB2	2064	protein:p.G776L/; ERBB2 G776L missense mutation		Unknown	Adenocarcinoma	299	trastuzumab	N/A	response	Supports	ERBB2 G776L missense mutation response	OHSU Import; ERBB2 G776L missense mutation; organ=Lung; 	case report	16775247						1				N/A						1	
ERBB2	2064	transcript:CCDS32642.1;  amino_acid:775-881;  ERBB2 proximal exon 20 p.775-881 insertion mutation		Unknown	Adenocarcinoma	299	trastuzumab	N/A	response	Supports	ERBB2 proximal exon 20 p.775-881 insertion mutation response	OHSU Import; ERBB2 proximal exon 20 p.775-881 insertion mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
ALK	238	protein:p.R1275Q /; ALK R1275Q  missense mutation		Unknown	Glioma	3070	crizotinib	11626560	sensitivity	Supports	ALK R1275Q  missense mutation sensitivity	OHSU Import; ALK R1275Q  missense mutation; organ=Brain; 	preclinical	22072639						1				N/A						1	
ALK	238	protein:p.F1174L/; ALK F1174L missense mutation		Unknown	Glioma	3070	crizotinib	11626560	reduced sensitivity	Supports	ALK F1174L missense mutation reduced sensitivity	OHSU Import; ALK F1174L missense mutation; organ=Brain; 	preclinical	22072639						1				N/A						1	
ALK	238	protein:p.G1128A/; ALK G1128A missense mutation		Unknown	Glioma	3070	crizotinib	11626560	sensitivity	Supports	ALK G1128A missense mutation sensitivity	OHSU Import; ALK G1128A missense mutation; organ=Brain; 	preclinical	22072639						1				N/A						1	
ALK	238	protein:p.I1171N/; ALK I1171N missense mutation		Unknown	Glioma	3070	crizotinib	11626560	sensitivity	Supports	ALK I1171N missense mutation sensitivity	OHSU Import; ALK I1171N missense mutation; organ=Brain; 	preclinical	22072639						1				N/A						1	
ALK	238	protein:p.R1192P/; ALK R1192P missense mutation		Unknown	Glioma	3070	crizotinib	11626560	sensitivity	Supports	ALK R1192P missense mutation sensitivity	OHSU Import; ALK R1192P missense mutation; organ=Brain; 	preclinical	22072639						1				N/A						1	
ALK	238	protein:p.F1245C/; ALK F1245C missense mutation		Unknown	Glioma	3070	crizotinib	11626560	sensitivity	Supports	ALK F1245C missense mutation sensitivity	OHSU Import; ALK F1245C missense mutation; organ=Brain; 	preclinical	22072639						1				N/A						1	
ALK	238	protein:p.L1196M/; ALK L1196M missense mutation		Unknown	Adenocarcinoma	299	ceritinib	57379345	response	Supports	ALK L1196M missense mutation response	OHSU Import; ALK L1196M missense mutation; organ=Lung; 	FDA-approved	24327273						1				N/A						1	
ALK	238	protein:p.S1206Y/; ALK  S1206Y missense mutation		Unknown	Adenocarcinoma	299	ceritinib	57379345	response	Supports	ALK  S1206Y missense mutation response	OHSU Import; ALK  S1206Y missense mutation; organ=Lung; 	FDA-approved	24670165						1				N/A						1	
ALK	238	protein:p.G1269A/; ALK G1269A missense mutation		Unknown	Adenocarcinoma	299	ceritinib	57379345	response	Supports	ALK G1269A missense mutation response	OHSU Import; ALK G1269A missense mutation; organ=Lung; 	FDA-approved	24670165						1				N/A						1	
ALK	238	protein:p.T1151_L1152insT/; ALK  1151Tins insertion mutation		Unknown	Adenocarcinoma	299	ceritinib	57379345	response	Supports	ALK  1151Tins insertion mutation response	OHSU Import; ALK  1151Tins insertion mutation; organ=Lung; 	FDA-approved	24670165						1				N/A						1	
ALK	238	protein:p.L1196M/; ALK L1196M missense mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK L1196M missense mutation resistance	OHSU Import; ALK L1196M missense mutation; organ=Lung; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.L1152R/; ALK L1152R missense mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK L1152R missense mutation resistance	OHSU Import; ALK L1152R missense mutation; organ=Lung; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.C1156Y/; ALK C1156Y missense mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK C1156Y missense mutation resistance	OHSU Import; ALK C1156Y missense mutation; organ=Lung; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.F1174L/; ALK F1174L missense mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK F1174L missense mutation resistance	OHSU Import; ALK F1174L missense mutation; organ=Lung; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.G1202R/; ALK G1202R missense mutation		Unknown	Unknown	N/A	crizotinib	11626560	resistance	Supports	ALK G1202R missense mutation resistance	OHSU Import; ALK G1202R missense mutation; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.S1206Y/; ALK  S1206Y missense mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK  S1206Y missense mutation resistance	OHSU Import; ALK  S1206Y missense mutation; organ=Lung; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.G1269A/; ALK G1269A missense mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK G1269A missense mutation resistance	OHSU Import; ALK G1269A missense mutation; organ=Lung; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.T1151_L1152insT/; ALK  1151Tins insertion mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK  1151Tins insertion mutation resistance	OHSU Import; ALK  1151Tins insertion mutation; organ=Lung; 	case report	22277784						1				N/A						1	
ALK	238	protein:p.F1174L/; ALK F1174L missense mutation		Unknown	Adenocarcinoma	299	TAE684		sensitivity	Supports	ALK F1174L missense mutation sensitivity	OHSU Import; ALK F1174L missense mutation; organ=Lung; 	preclinical	24327273						1				N/A						1	
FGFR3	2261	cdna:c.1118A>G; protein:p.Y373C/p.Tyr373Cys; FGFR3 Y373C missense mutation	4:1806099-1806099 (A->G)	Unknown	MYELOMA	0070004	bortezomib	387447	resistance	Supports	FGFR3 Y373C missense mutation resistance	OHSU Import; FGFR3 Y373C missense mutation; 	preclinical	19331127						1				N/A						1	
FGFR3	2261	transcript:CCDS3353.1;  amino_acid:650-650;  FGFR3 K650 missense mutation		Unknown	MYELOMA	0070004	bortezomib	387447	sensitivity	Supports	FGFR3 K650 missense mutation sensitivity	OHSU Import; FGFR3 K650 missense mutation; 	preclinical	19331127						1				N/A						1	
FGFR3	2261	protein:p.V555M/; FGFR3 V555M missense mutation		Unknown	MYELOMA	0070004	FGFR inhibitors	N/A	resistance	Supports	FGFR3 V555M missense mutation resistance	OHSU Import; FGFR3 V555M missense mutation; 	preclinical	22869148						1				N/A						1	
FGFR3	2261	cdna:c.1118A>G; protein:p.Y373C/p.Tyr373Cys; FGFR3 Y373C missense mutation	4:1806099-1806099 (A->G)	Unknown	MYELOMA	0070004	FGFR inhibitors	N/A	sensitivity	Supports	FGFR3 Y373C missense mutation sensitivity	OHSU Import; FGFR3 Y373C missense mutation; 	preclinical	22869148						1				N/A						1	
FGFR3	2261	transcript:CCDS3353.1;  amino_acid:650-650;  FGFR3 K650 missense mutation		Unknown	MYELOMA	0070004	FGFR inhibitors	N/A	sensitivity	Supports	FGFR3 K650 missense mutation sensitivity	OHSU Import; FGFR3 K650 missense mutation; 	preclinical	16091734						1				N/A						1	
RAD50	10111	protein:p.L1237F/; RAD50 L1237F missense mutation		Unknown	Malignant neoplasm, NOS	5074	irinotecan plus CHK1/2 inhibitor in ATM deficient tumor	N/A	response	Supports	RAD50 L1237F missense mutation response	OHSU Import; RAD50 L1237F missense mutation; 	case report	24934408						1				N/A						1	
PDGFRA	5156	cdna:c.2525A>T; protein:p.D842V/p.Asp842Val; PDGFRA  D842V missense mutation	4:55152093-55152093 (A->T)	Unknown	GIST	9253	crenolanib	10366136	sensitivity	Supports	PDGFRA  D842V missense mutation sensitivity	OHSU Import; PDGFRA  D842V missense mutation; 	preclinical	22745105						1				N/A						1	
PDGFRA	5156	cdna:c.2525A>T; protein:p.D842V/p.Asp842Val; PDGFRA  D842V missense mutation	4:55152093-55152093 (A->T)	Unknown	GIST	9253	dasatinib	3062316	sensitivity	Supports	PDGFRA  D842V missense mutation sensitivity	OHSU Import; PDGFRA  D842V missense mutation; 	preclinical	18794084						1				N/A						1	
PDGFRA	5156	cdna:c.2525A>T; protein:p.D842V/p.Asp842Val; PDGFRA  D842V missense mutation	4:55152093-55152093 (A->T)	Unknown	GIST	9253	HSP90 inhibitors	N/A	sensitivity	Supports	PDGFRA  D842V missense mutation sensitivity	OHSU Import; PDGFRA  D842V missense mutation; 	preclinical	18794084						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:552-596;  PDGFRA  exon 12 p.552-596 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	PDGFRA  exon 12 p.552-596 any mutation response	OHSU Import; PDGFRA  exon 12 p.552-596 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:631-668;  PDGFRA  exon 14 p.631-668 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	PDGFRA  exon 14 p.631-668 any mutation response	OHSU Import; PDGFRA  exon 14 p.631-668 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:814-854;  PDGFRA  exon 18 p.814-854 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	PDGFRA  exon 18 p.814-854 any mutation response	OHSU Import; PDGFRA  exon 18 p.814-854 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	cdna:c.2525A>T; protein:p.D842V/p.Asp842Val; PDGFRA  D842V missense mutation	4:55152093-55152093 (A->T)	Unknown	GIST	9253	imatinib	5291	resistance	Supports	PDGFRA  D842V missense mutation resistance	OHSU Import; PDGFRA  D842V missense mutation; 	late trials	16638875						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:552-596;  PDGFRA  exon 12 p.552-596 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	PDGFRA  exon 12 p.552-596 any mutation response	OHSU Import; PDGFRA  exon 12 p.552-596 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:631-668;  PDGFRA  exon 14 p.631-668 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	PDGFRA  exon 14 p.631-668 any mutation response	OHSU Import; PDGFRA  exon 14 p.631-668 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:814-854;  PDGFRA  exon 18 p.814-854 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	PDGFRA  exon 18 p.814-854 any mutation response	OHSU Import; PDGFRA  exon 18 p.814-854 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:552-596;  PDGFRA  exon 12 p.552-596 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	PDGFRA  exon 12 p.552-596 any mutation response	OHSU Import; PDGFRA  exon 12 p.552-596 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:631-668;  PDGFRA  exon 14 p.631-668 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	PDGFRA  exon 14 p.631-668 any mutation response	OHSU Import; PDGFRA  exon 14 p.631-668 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	transcript:CCDS3495.1;  amino_acid:814-854;  PDGFRA  exon 18 p.814-854 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	PDGFRA  exon 18 p.814-854 any mutation response	OHSU Import; PDGFRA  exon 18 p.814-854 any mutation; 	FDA-approved	N/A						1				N/A						1	
PDGFRA	5156	cdna:c.2525A>T; protein:p.D842V/p.Asp842Val; PDGFRA  D842V missense mutation	4:55152093-55152093 (A->T)	Unknown	GIST	9253	sunitinib	5329102	resistance	Supports	PDGFRA  D842V missense mutation resistance	OHSU Import; PDGFRA  D842V missense mutation; 	late trials	16638875						1				N/A						1	
PDGFRA	5156	protein:p.T674I/; PDGFRA T674I missense mutation		Unknown	Hypereosinophilic syndrome	225	imatinib	5291	resistance	Supports	PDGFRA T674I missense mutation resistance	OHSU Import; PDGFRA T674I missense mutation; organ=Bone marrow; 	case report	12660384						1				N/A						1	
PDGFRA	5156	protein:p.P577S/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	crenolanib	10366136	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.R841K/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	crenolanib	10366136	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.H845Y/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	crenolanib	10366136	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.G853D/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	crenolanib	10366136	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.V658A/; PDGFRA  V658A missense mutation		Unknown	Melanoma, NOS	6367	crenolanib	10366136	sensitivity	Supports	PDGFRA  V658A missense mutation sensitivity	OHSU Import; PDGFRA  V658A missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.P577S/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	imatinib	5291	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.R841K/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	imatinib	5291	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.H845Y/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	imatinib	5291	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.G853D/; PDGFRA P577S, R841K, H845Y, G853D missense mutation		Unknown	Melanoma, NOS	6367	imatinib	5291	sensitivity	Supports	PDGFRA P577S, R841K, H845Y, G853D missense mutation sensitivity	OHSU Import; PDGFRA P577S, R841K, H845Y, G853D missense mutation; 	preclinical	24132921						1				N/A						1	
PDGFRA	5156	protein:p.V658A/; PDGFRA  V658A missense mutation		Unknown	Melanoma, NOS	6367	imatinib	5291	resistance	Supports	PDGFRA  V658A missense mutation resistance	OHSU Import; PDGFRA  V658A missense mutation; 	preclinical	24132921						1				N/A						1	
KIT	3815	cdna:c.2466T>G; cdna:c.2466T>A; protein:p.N822K/p.Asn822Lys; KIT N822K missense mutation	4:55599340-55599340 (T->G)	Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	dasatinib	3062316	sensitivity	Supports	KIT N822K missense mutation sensitivity	OHSU Import; KIT N822K missense mutation; organ=Bone marrow; 	preclinical	23149070						1				N/A						1	
KIT	3815	cdna:c.2447A>T; protein:p.D816V/p.Asp816Val; KIT D816V missense mutation	4:55599321-55599321 (A->T)	Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	dasatinib	3062316	response	Supports	KIT D816V missense mutation response	OHSU Import; KIT D816V missense mutation; organ=Bone marrow; 	case report	18986703						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:416-422;  KIT exon 8 p.416-422 indel		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	imatinib	5291	sensitivity	Supports	KIT exon 8 p.416-422 indel sensitivity	OHSU Import; KIT exon 8 p.416-422 indel; organ=Bone marrow; 	preclinical	15618474						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:449-514;  KIT exon 9 p.449-514 any mutation		Unknown	GIST	9253	HSP90 inhibitors	N/A	sensitivity	Supports	KIT exon 9 p.449-514 any mutation sensitivity	OHSU Import; KIT exon 9 p.449-514 any mutation; 	preclinical	21737509						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592 any mutation		Unknown	GIST	9253	HSP90 inhibitors	N/A	response	Supports	KIT exon 11 p.550-592 any mutation response	OHSU Import; KIT exon 11 p.550-592 any mutation; 	early trials	22898035						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	HSP90 inhibitors	N/A	sensitivity	Supports	KIT exon 17 p.788-828 any mutation sensitivity	OHSU Import; KIT exon 17 p.788-828 any mutation; 	preclinical	21737509						1				N/A						1	
KIT	3815	protein:p.V654A/; KIT V654A missense mutation		Unknown	GIST	9253	imatinib	5291	decreased sensitivity	Supports	KIT V654A missense mutation decreased sensitivity	OHSU Import; KIT V654A missense mutation; 	preclinical	16751810						1				N/A						1	
KIT	3815	protein:p.V559I/; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	protein:p.H687Y/; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:670-670;  KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	protein:p.V654A/; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	protein:p.A829P/; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:816-816;  KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:822-822;  KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	protein:p.Y823D/; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation resistance	OHSU Import; KIT V559I, H687Y, T670, V654A, A829P, D816, N822, Y823D missense mutation; 	preclinical	17259998						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:449-514;  KIT exon 9 p.449-514 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	KIT exon 9 p.449-514 any mutation response	OHSU Import; KIT exon 9 p.449-514 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	KIT exon 11 p.550-592 any mutation response	OHSU Import; KIT exon 11 p.550-592 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:664-714;  KIT exon 14 p.664-714 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	KIT exon 14 p.664-714 any mutation response	OHSU Import; KIT exon 14 p.664-714 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	KIT exon 17 p.788-828 any mutation response	OHSU Import; KIT exon 17 p.788-828 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	protein:p.T670I/; KIT T670I missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KIT T670I missense mutation resistance	OHSU Import; KIT T670I missense mutation; 	case report	24687822						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT  exon 13 p.627-664 any mutation		Unknown	GIST	9253	imatinib	5291	response	Supports	KIT  exon 13 p.627-664 any mutation response	OHSU Import; KIT  exon 13 p.627-664 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:664-714;  KIT exon 14 p.664-714 any mutation		Unknown	GIST	9253	imatinib	5291	decreased sensitivity	Supports	KIT exon 14 p.664-714 any mutation decreased sensitivity	OHSU Import; KIT exon 14 p.664-714 any mutation; 	late trials	18955458						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	imatinib	5291	decreased sensitivity	Supports	KIT exon 17 p.788-828 any mutation decreased sensitivity	OHSU Import; KIT exon 17 p.788-828 any mutation; 	preclinical	23840364						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT  exon 13 p.627-664 any mutation		Unknown	GIST	9253	imatinib	5291	decreased sensitivity	Supports	KIT  exon 13 p.627-664 any mutation decreased sensitivity	OHSU Import; KIT  exon 13 p.627-664 any mutation; 	late trials	18955458						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:449-514;  KIT exon 9 p.449-514 any mutation		Unknown	GIST	9253	imatinib	5291	decreased sensitivity	Supports	KIT exon 9 p.449-514 any mutation decreased sensitivity	OHSU Import; KIT exon 9 p.449-514 any mutation; 	late trials	16624552						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	nilotinib	644241	response	Supports	KIT exon 17 p.788-828 any mutation response	OHSU Import; KIT exon 17 p.788-828 any mutation; 	early trials	21456006						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:449-514;  KIT exon 9 p.449-514 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	KIT exon 9 p.449-514 any mutation response	OHSU Import; KIT exon 9 p.449-514 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	KIT exon 11 p.550-592 any mutation response	OHSU Import; KIT exon 11 p.550-592 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:664-714;  KIT exon 14 p.664-714 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	KIT exon 14 p.664-714 any mutation response	OHSU Import; KIT exon 14 p.664-714 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	KIT exon 17 p.788-828 any mutation response	OHSU Import; KIT exon 17 p.788-828 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT  exon 13 p.627-664 any mutation		Unknown	GIST	9253	regorafenib	11167602	response	Supports	KIT  exon 13 p.627-664 any mutation response	OHSU Import; KIT  exon 13 p.627-664 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:449-514;  KIT exon 9 p.449-514 any mutation		Unknown	GIST	9253	sorafenib	216239	response	Supports	KIT exon 9 p.449-514 any mutation response	OHSU Import; KIT exon 9 p.449-514 any mutation; 	early trials	22270258						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592 any mutation		Unknown	GIST	9253	sorafenib	216239	response	Supports	KIT exon 11 p.550-592 any mutation response	OHSU Import; KIT exon 11 p.550-592 any mutation; 	early trials	22270258						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	sorafenib	216239	sensitivity	Supports	KIT exon 17 p.788-828 any mutation sensitivity	OHSU Import; KIT exon 17 p.788-828 any mutation; 	preclinical	23840364						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:449-514;  KIT exon 9 p.449-514 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	KIT exon 9 p.449-514 any mutation response	OHSU Import; KIT exon 9 p.449-514 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	KIT exon 11 p.550-592 any mutation response	OHSU Import; KIT exon 11 p.550-592 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:664-714;  KIT exon 14 p.664-714 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	KIT exon 14 p.664-714 any mutation response	OHSU Import; KIT exon 14 p.664-714 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	KIT exon 17 p.788-828 any mutation response	OHSU Import; KIT exon 17 p.788-828 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT  exon 13 p.627-664 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	KIT  exon 13 p.627-664 any mutation response	OHSU Import; KIT  exon 13 p.627-664 any mutation; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592 any mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	KIT exon 11 p.550-592 any mutation response	OHSU Import; KIT exon 11 p.550-592 any mutation; 	late trials	18955458						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-828;  KIT exon 17 p.788-828 any mutation		Unknown	GIST	9253	sunitinib	5329102	decreased sensitivity	Supports	KIT exon 17 p.788-828 any mutation decreased sensitivity	OHSU Import; KIT exon 17 p.788-828 any mutation; 	preclinical	23840364						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	dasatinib	3062316	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	case report	19671763						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	dasatinib	3062316	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	case report	19671763						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	imatinib	5291	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	NCCN guidelines	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	imatinib	5291	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	NCCN guidelines	N/A						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-860;  KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation		Unknown	Melanoma, NOS	6367	imatinib	5291	resistance	Supports	KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation resistance	OHSU Import; KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation; 	early trials	21642685						1				N/A						1	
KIT	3815	cdna:c.2458G>T; protein:p.D820Y/p.Asp820Tyr; KIT D820Y missense mutation	4:55599332-55599332 (G->T)	Unknown	Melanoma, NOS	6367	imatinib	5291	response	Supports	KIT D820Y missense mutation response	OHSU Import; KIT D820Y missense mutation; 	case report	23775962						1				N/A						1	
KIT	3815	KIT amplification copy number gain		Unknown	Melanoma, NOS	6367	imatinib	5291	no response	Supports	KIT amplification copy number gain no response	OHSU Import; KIT amplification copy number gain; 	early trials	23775962						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	imatinib	5291	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	late trials	18421059						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	imatinib	5291	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	late trials	18421059						1				N/A						1	
KIT	3815	KIT amplification copy number gain		Unknown	Melanoma, NOS	6367	imatinib	5291	response	Supports	KIT amplification copy number gain response	OHSU Import; KIT amplification copy number gain; 	early trials	21642685						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	nilotinib	644241	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	case report	22068222						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	nilotinib	644241	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	case report	22068222						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:788-860;  KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation		Unknown	Melanoma, NOS	6367	sorafenib	216239	response	Supports	KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation response	OHSU Import; KIT exon 17 p.788-828, exon 18 p.829-860 missense mutation; 	case report	20372153						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	sorafenib	216239	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	case report	18936790						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	sorafenib	216239	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	case report	18936790						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:550-592;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	sunitinib	5329102	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	late trials	18421059						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:627-664;  KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  		Unknown	Melanoma, NOS	6367	sunitinib	5329102	response	Supports	KIT exon 11 p.550-592, exon 13 p.627-664   any mutation   response	OHSU Import; KIT exon 11 p.550-592, exon 13 p.627-664   any mutation  ; 	late trials	18421059						1				N/A						1	
KIT	3815	KIT amplification copy number gain		Unknown	Melanoma, NOS	6367	sunitinib	5329102	response	Supports	KIT amplification copy number gain response	OHSU Import; KIT amplification copy number gain; 	early trials	22261812						1				N/A						1	
KIT	3815	cdna:c.2447A>T; protein:p.D816V/p.Asp816Val; KIT  D816V missense mutation	4:55599321-55599321 (A->T)	Unknown	Mastocytosis	350	dasatinib	3062316	response	Supports	KIT  D816V missense mutation response	OHSU Import; KIT  D816V missense mutation; organ=Bone marrow; 	early trials	18559612						1				N/A						1	
KIT	3815	protein:p.Y553N/; KIT Y553N missense mutation		Unknown	Thymic carcinoma	3284	imatinib	5291	response	Supports	KIT Y553N missense mutation response	OHSU Import; KIT Y553N missense mutation; organ=Thymus; 	case report	21969494						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:560-560;  KIT V560del deletion mutation		Unknown	Thymic carcinoma	3284	imatinib	5291	response	Supports	KIT V560del deletion mutation response	OHSU Import; KIT V560del deletion mutation; organ=Thymus; 	case report	15201427						1				N/A						1	
KIT	3815	protein:p.D820E/; KIT D820E missense mutation		Unknown	Thymic carcinoma	3284	sorafenib	216239	response	Supports	KIT D820E missense mutation response	OHSU Import; KIT D820E missense mutation; organ=Thymus; 	case report	19461405						1				N/A						1	
KIT	3815	transcript:CCDS3496.1;  amino_acid:577-578;  KIT del577-578_579 deletion mutation		Unknown	Thymic carcinoma	3284	sorafenib	216239	response	Supports	KIT del577-578_579 deletion mutation response	OHSU Import; KIT del577-578_579 deletion mutation; organ=Thymus; 	case report	20970876						1				N/A						1	
KIT	3815	protein:p.H697Y/; KIT H697Y missense mutation		Unknown	Thymic carcinoma	3284	sunitinib	5329102	sensitivity	Supports	KIT H697Y missense mutation sensitivity	OHSU Import; KIT H697Y missense mutation; organ=Thymus; 	preclinical	19861435						1				N/A						1	
KIT	3815	protein:p.Y553N/; KIT Y553N missense mutation		Unknown	Thymic carcinoma	3284	sunitinib	5329102	response	Supports	KIT Y553N missense mutation response	OHSU Import; KIT Y553N missense mutation; organ=Thymus; 	case report	23375402						1				N/A						1	
KDR	3791	cdna:c.3193G>A; protein:p.A1065T/p.Ala1065Thr; KDR A1065T missense mutation	4:55955969-55955969 (C->T)	Unknown	Malignant neoplasm, NOS	5074	VEGFR inhibitors	N/A	sensitivity	Supports	KDR A1065T missense mutation sensitivity	OHSU Import; KDR A1065T missense mutation; 	preclinical	24569783						1				N/A						1	
ABL1	25	cdna:c.944C>T; protein:p.T315I/p.Thr315Ile; ABL1 T315I missense mutation	9:133748283-133748283 (C->T)	Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	AURK inhibitors + BCR-ABL1 inhibitors	N/A	response	Supports	ABL1 T315I missense mutation response	OHSU Import; ABL1 T315I missense mutation; 	case report	22772060						1				N/A						1	
ABL1	25	protein:p.F359V/; ABL1 F359V/C/I missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	dasatinib	3062316	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F359C/; ABL1 F359V/C/I missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	dasatinib	3062316	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F359I/; ABL1 F359V/C/I missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	dasatinib	3062316	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.Y253H/; ABL1 Y253H missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	dasatinib	3062316	response	Supports	ABL1 Y253H missense mutation response	OHSU Import; ABL1 Y253H missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.E255K/; ABL1 E255K/V missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	dasatinib	3062316	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.E255V/; ABL1 E255K/V missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	dasatinib	3062316	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.T315A/; ABL1 T315A missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	nilotinib	644241	response	Supports	ABL1 T315A missense mutation response	OHSU Import; ABL1 T315A missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317L/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317V/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317I/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317C/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.V299L/; ABL1 V299L missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	nilotinib	644241	response	Supports	ABL1 V299L missense mutation response	OHSU Import; ABL1 V299L missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.T315A/; ABL1 T315A missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 T315A missense mutation response	OHSU Import; ABL1 T315A missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	cdna:c.944C>T; protein:p.T315I/p.Thr315Ile; ABL1 T315I missense mutation	9:133748283-133748283 (C->T)	Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 T315I missense mutation response	OHSU Import; ABL1 T315I missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317L/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317V/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317I/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F317C/; ABL1 F317L/V/I/C missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F359V/; ABL1 F359V/C/I missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F359C/; ABL1 F359V/C/I missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.F359I/; ABL1 F359V/C/I missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.Y253H/; ABL1 Y253H missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 Y253H missense mutation response	OHSU Import; ABL1 Y253H missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.E255K/; ABL1 E255K/V missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.E255V/; ABL1 E255K/V missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.V299L/; ABL1 V299L missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	ABL1 V299L missense mutation response	OHSU Import; ABL1 V299L missense mutation; 	NCCN guidelines	N/A						1				N/A						1	
ABL1	25	protein:p.T315A/; ABL1 T315A missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 T315A missense mutation response	OHSU Import; ABL1 T315A missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317L/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317V/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317I/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317C/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359V/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359C/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359I/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.Y253H/; ABL1 Y253H missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 Y253H missense mutation response	OHSU Import; ABL1 Y253H missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.E255K/; ABL1 E255K/V missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.E255V/; ABL1 E255K/V missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359V/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	dasatinib	3062316	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359C/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	dasatinib	3062316	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359I/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	dasatinib	3062316	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.Y253H/; ABL1 Y253H missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	dasatinib	3062316	response	Supports	ABL1 Y253H missense mutation response	OHSU Import; ABL1 Y253H missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.E255K/; ABL1 E255K/V missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	dasatinib	3062316	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.E255V/; ABL1 E255K/V missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	dasatinib	3062316	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.T315A/; ABL1 T315A missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	nilotinib	644241	response	Supports	ABL1 T315A missense mutation response	OHSU Import; ABL1 T315A missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317L/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317V/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317I/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317C/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	nilotinib	644241	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.V299L/; ABL1 V299L missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	nilotinib	644241	response	Supports	ABL1 V299L missense mutation response	OHSU Import; ABL1 V299L missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.T315A/; ABL1 T315A missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 T315A missense mutation response	OHSU Import; ABL1 T315A missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	cdna:c.944C>T; protein:p.T315I/p.Thr315Ile; ABL1 T315I missense mutation	9:133748283-133748283 (C->T)	Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 T315I missense mutation response	OHSU Import; ABL1 T315I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317L/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317V/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317I/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F317C/; ABL1 F317L/V/I/C missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 F317L/V/I/C missense mutation response	OHSU Import; ABL1 F317L/V/I/C missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359V/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359C/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.F359I/; ABL1 F359V/C/I missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 F359V/C/I missense mutation response	OHSU Import; ABL1 F359V/C/I missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.Y253H/; ABL1 Y253H missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 Y253H missense mutation response	OHSU Import; ABL1 Y253H missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.E255K/; ABL1 E255K/V missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.E255V/; ABL1 E255K/V missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 E255K/V missense mutation response	OHSU Import; ABL1 E255K/V missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ABL1	25	protein:p.V299L/; ABL1 V299L missense mutation		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	ABL1 V299L missense mutation response	OHSU Import; ABL1 V299L missense mutation; organ=Bone marrow; 	NCCN guidelines	21562040						1				N/A						1	
ARAF	369	protein:p.S214C/; ARAF S214C missense mutation		Unknown	Adenocarcinoma	299	sorafenib	216239	response	Supports	ARAF S214C missense mutation response	OHSU Import; ARAF S214C missense mutation; organ=Lung; 	case report	24569458						1				N/A						1	
IL7R	3575	protein:p.S185C/; IL7R  237-255_indel or S185C mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	mTOR inhibitors	N/A	sensitivity	Supports	IL7R  237-255_indel or S185C mutation sensitivity	OHSU Import; IL7R  237-255_indel or S185C mutation; 	preclinical	22955920						1				N/A						1	
IL7R	3575	transcript:CCDS3911.1;  amino_acid:237-255;  IL7R  237-255_indel or S185C mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	mTOR inhibitors	N/A	sensitivity	Supports	IL7R  237-255_indel or S185C mutation sensitivity	OHSU Import; IL7R  237-255_indel or S185C mutation; 	preclinical	22955920						1				N/A						1	
IL7R	3575	protein:p.S185C/; IL7R  237-255_indel or S185C mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ruxolitinib	25126798	sensitivity	Supports	IL7R  237-255_indel or S185C mutation sensitivity	OHSU Import; IL7R  237-255_indel or S185C mutation; 	preclinical	22897847						1				N/A						1	
IL7R	3575	transcript:CCDS3911.1;  amino_acid:237-255;  IL7R  237-255_indel or S185C mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ruxolitinib	25126798	sensitivity	Supports	IL7R  237-255_indel or S185C mutation sensitivity	OHSU Import; IL7R  237-255_indel or S185C mutation; 	preclinical	22897847						1				N/A						1	
CSF3R	1441	protein:p.Q741X /; CSF3R Q741X  missense mutation		Unknown	Chronic neutrophilic leukaemia	2475	dasatinib	3062316	sensitivity	Supports	CSF3R Q741X  missense mutation sensitivity	OHSU Import; CSF3R Q741X  missense mutation; organ=Bone marrow; 	preclinical	23656643						1				N/A						1	
CSF3R	1441	protein:p.Y752X/; CSF3R Y752X missense mutation		Unknown	Chronic neutrophilic leukaemia	2475	dasatinib	3062316	sensitivity	Supports	CSF3R Y752X missense mutation sensitivity	OHSU Import; CSF3R Y752X missense mutation; organ=Bone marrow; 	preclinical	23656643						1				N/A						1	
CSF3R	1441	protein:p.W791X/; CSF3R W791X missense mutation		Unknown	Chronic neutrophilic leukaemia	2475	dasatinib	3062316	sensitivity	Supports	CSF3R W791X missense mutation sensitivity	OHSU Import; CSF3R W791X missense mutation; organ=Bone marrow; 	preclinical	23656643						1				N/A						1	
CSF3R	1441	protein:p.D771fs/; CSF3R D771fs missense mutation		Unknown	Chronic neutrophilic leukaemia	2475	dasatinib	3062316	sensitivity	Supports	CSF3R D771fs missense mutation sensitivity	OHSU Import; CSF3R D771fs missense mutation; organ=Bone marrow; 	preclinical	23656643						1				N/A						1	
CSF3R	1441	protein:p.S783fs/; CSF3R S783fs missense mutation		Unknown	Chronic neutrophilic leukaemia	2475	dasatinib	3062316	sensitivity	Supports	CSF3R S783fs missense mutation sensitivity	OHSU Import; CSF3R S783fs missense mutation; organ=Bone marrow; 	preclinical	23656643						1				N/A						1	
CSF3R	1441	protein:p.T615A/; CSF3R T615A missense mutation		Unknown	Chronic neutrophilic leukaemia	2475	ruxolitinib	25126798	sensitivity	Supports	CSF3R T615A missense mutation sensitivity	OHSU Import; CSF3R T615A missense mutation; organ=Bone marrow; 	preclinical	23656643						1				N/A						1	
CSF3R	1441	cdna:c.1853C>T; protein:p.T618I/p.Thr618Ile; CSF3R T618I missense mutation	1:36933434-36933434 (G->A)	Unknown	Chronic neutrophilic leukaemia	2475	ruxolitinib	25126798	response	Supports	CSF3R T618I missense mutation response	OHSU Import; CSF3R T618I missense mutation; organ=Bone marrow; 	case report	23656643						1				N/A						1	
PLCG2	5336	protein:p.R665W/; PLCG2 R665W, L845F missense mutation		Unknown	Chronic lymphocytic leukaemia/small lymphocytic lymphoma	8144	ibrutinib	24821094	resistance	Supports	PLCG2 R665W, L845F missense mutation resistance	OHSU Import; PLCG2 R665W, L845F missense mutation; organ=Lymph Node; 	early trials	24869598						1				N/A						1	
PLCG2	5336	protein:p.L845F/; PLCG2 R665W, L845F missense mutation		Unknown	Chronic lymphocytic leukaemia/small lymphocytic lymphoma	8144	ibrutinib	24821094	resistance	Supports	PLCG2 R665W, L845F missense mutation resistance	OHSU Import; PLCG2 R665W, L845F missense mutation; organ=Lymph Node; 	early trials	24869598						1				N/A						1	
CSF1R	1436	protein:p.Y571D/; CSF1R Y571D missense mutation		Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	imatinib	5291	sensitivity	Supports	CSF1R Y571D missense mutation sensitivity	OHSU Import; CSF1R Y571D missense mutation; organ=Bone marrow; 	preclinical	18971950						1				N/A						1	
MET	4233	cdna:c.3274G>A; protein:p.V1092I/p.Val1092Ile; MET V1092I missense mutation	7:116417457-116417457 (G->A)	Unknown	Malignant neoplasm, NOS	5074	crizotinib	11626560	sensitivity	Supports	MET V1092I missense mutation sensitivity	OHSU Import; MET V1092I missense mutation; 	preclinical	17483355						1				N/A						1	
MET	4233	protein:p.H1094R/; MET H1094R missense mutation		Unknown	Malignant neoplasm, NOS	5074	crizotinib	11626560	sensitivity	Supports	MET H1094R missense mutation sensitivity	OHSU Import; MET H1094R missense mutation; 	preclinical	17483355						1				N/A						1	
MET	4233	protein:p.M1250I/; MET M1250I missense mutation		Unknown	Malignant neoplasm, NOS	5074	crizotinib	11626560	sensitivity	Supports	MET M1250I missense mutation sensitivity	OHSU Import; MET M1250I missense mutation; 	preclinical	17483355						1				N/A						1	
MET	4233	protein:p.R988C/; MET R988C missense mutation		Unknown	Malignant neoplasm, NOS	5074	crizotinib	11626560	sensitivity	Supports	MET R988C missense mutation sensitivity	OHSU Import; MET R988C missense mutation; 	preclinical	17483355						1				N/A						1	
MET	4233	protein:p.T1010I/; MET T1010I missense mutation		Unknown	Malignant neoplasm, NOS	5074	crizotinib	11626560	sensitivity	Supports	MET T1010I missense mutation sensitivity	OHSU Import; MET T1010I missense mutation; 	preclinical	17483355						1				N/A						1	
MET	4233	protein:p.Y1230C/; MET Y1230C missense mutation		Unknown	Malignant neoplasm, NOS	5074	crizotinib	11626560	reduced sensitivity	Supports	MET Y1230C missense mutation reduced sensitivity	OHSU Import; MET Y1230C missense mutation; 	preclinical	17483355						1				N/A						1	
MET	4233	protein:p.Y1235D/; MET Y1235D missense mutation		Unknown	Malignant neoplasm, NOS	5074	crizotinib	11626560	reduced sensitivity	Supports	MET Y1235D missense mutation reduced sensitivity	OHSU Import; MET Y1235D missense mutation; 	preclinical	17483355						1				N/A						1	
MET	4233	protein:p.H1112L/; MET H1112L missense mutation		Unknown	Malignant neoplasm, NOS	5074	MET inhibitors	N/A	sensitivity	Supports	MET H1112L missense mutation sensitivity	OHSU Import; MET H1112L missense mutation; 	preclinical	N/A						1				N/A						1	
MET	4233	protein:p.M1268T/; MET M1268T missense mutation		Unknown	Clear cell carcinoma	7267	MET inhibitors	N/A	response	Supports	MET M1268T missense mutation response	OHSU Import; MET M1268T missense mutation; organ=Kidney; 	case report	23610116						1				N/A						1	
MET	4233	protein:p.H1094R/; MET H1094R missense mutation		Unknown	Clear cell carcinoma	7267	MET inhibitors	N/A	response	Supports	MET H1094R missense mutation response	OHSU Import; MET H1094R missense mutation; organ=Kidney; 	early trials	23213094						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:2245-2536;  NOTCH1 PEST domain p.2245-2536 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors	N/A	response	Supports	NOTCH1 PEST domain p.2245-2536 mutation response	OHSU Import; NOTCH1 PEST domain p.2245-2536 mutation; 	early trials	N/A						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:1529-1723;  NOTCH1 HD p.1529-1723 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors	N/A	response	Supports	NOTCH1 HD p.1529-1723 mutation response	OHSU Import; NOTCH1 HD p.1529-1723 mutation; 	early trials	N/A						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:2245-2536;  NOTCH1 PEST domain p.2245-2536 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors	N/A	sensitivity	Supports	NOTCH1 PEST domain p.2245-2536 mutation sensitivity	OHSU Import; NOTCH1 PEST domain p.2245-2536 mutation; 	preclinical	15472075						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:1529-1723;  NOTCH1 HD p.1529-1723 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors	N/A	sensitivity	Supports	NOTCH1 HD p.1529-1723 mutation sensitivity	OHSU Import; NOTCH1 HD p.1529-1723 mutation; 	preclinical	15472075						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:2245-2536;  NOTCH1 PEST domain p.2245-2536 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors + CDK4 inhibitors	N/A	sensitivity	Supports	NOTCH1 PEST domain p.2245-2536 mutation sensitivity	OHSU Import; NOTCH1 PEST domain p.2245-2536 mutation; 	preclinical	19318552						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:1529-1723;  NOTCH1 HD p.1529-1723 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors + CDK4 inhibitors	N/A	sensitivity	Supports	NOTCH1 HD p.1529-1723 mutation sensitivity	OHSU Import; NOTCH1 HD p.1529-1723 mutation; 	preclinical	19318552						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:2245-2536;  NOTCH1 PEST domain p.2245-2536 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors + mTOR inhibitors	N/A	sensitivity	Supports	NOTCH1 PEST domain p.2245-2536 mutation sensitivity	OHSU Import; NOTCH1 PEST domain p.2245-2536 mutation; 	preclinical	19246562						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:1529-1723;  NOTCH1 HD p.1529-1723 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors + mTOR inhibitors	N/A	sensitivity	Supports	NOTCH1 HD p.1529-1723 mutation sensitivity	OHSU Import; NOTCH1 HD p.1529-1723 mutation; 	preclinical	19246562						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:2245-2536;  NOTCH1 PEST domain p.2245-2536 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	steroids	N/A	response	Supports	NOTCH1 PEST domain p.2245-2536 mutation response	OHSU Import; NOTCH1 PEST domain p.2245-2536 mutation; 	late trials	20861909						1				N/A						1	
NOTCH1	4851	transcript:CCDS43905.1;  amino_acid:1529-1723;  NOTCH1 HD p.1529-1723 mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	steroids	N/A	response	Supports	NOTCH1 HD p.1529-1723 mutation response	OHSU Import; NOTCH1 HD p.1529-1723 mutation; 	late trials	20861909						1				N/A						1	
FGFR4	2264	protein:p.N535K/; FGFR4 K535 missense mutation		Unknown	Rhabdomyosarcoma, NOS	3250	FGFR inhibitors	N/A	sensitivity	Supports	FGFR4 K535 missense mutation sensitivity	OHSU Import; FGFR4 K535 missense mutation; organ=Soft tissue; 	preclinical	19809159						1				N/A						1	
FGFR4	2264	protein:p.V550E/; FGFR4 E550 missense mutation		Unknown	Rhabdomyosarcoma, NOS	3250	FGFR inhibitors	N/A	sensitivity	Supports	FGFR4 E550 missense mutation sensitivity	OHSU Import; FGFR4 E550 missense mutation; organ=Soft tissue; 	preclinical	19809159						1				N/A						1	
STK11	6794	protein:p.D194E/; STK11 D194E missense mutation		Unknown	Adenocarcinoma	299	everolimus	6442177	response	Supports	STK11 D194E missense mutation response	OHSU Import; STK11 D194E missense mutation; organ=Pancreas; 	case report	21189378						1				N/A						1	
MPL	4352	protein:p.W515F/; MPL W515F missense mutation		Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	JAK inhibitors	N/A	sensitivity	Supports	MPL W515F missense mutation sensitivity	OHSU Import; MPL W515F missense mutation; organ=Bone marrow; 	preclinical	16834459						1				N/A						1	
ROS1	6098	protein:p.G2032R/; ROS1 G2032R missense mutation		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ROS1 G2032R missense mutation resistance	OHSU Import; ROS1 G2032R missense mutation; organ=Lung; 	case report	23724914						1				N/A						1	
ESR1	2099	protein:p.E380Q/; ESR1 E380Q missense mutation		Unknown	Ductal carcinoma	3587	anti-estrogens	N/A	resistance	Supports	ESR1 E380Q missense mutation resistance	OHSU Import; ESR1 E380Q missense mutation; organ=Breast; 	early trials	24185510						1				N/A						1	
ESR1	2099	transcript:CCDS5234.1;  amino_acid:537-537;  ESR1 codon 537 missense mutation		Unknown	Ductal carcinoma	3587	anti-estrogens	N/A	resistance	Supports	ESR1 codon 537 missense mutation resistance	OHSU Import; ESR1 codon 537 missense mutation; organ=Breast; 	early trials	24185510						1				N/A						1	
ESR1	2099	transcript:CCDS5234.1;  amino_acid:538-538;  ESR1 codon 538 missense mutation		Unknown	Ductal carcinoma	3587	anti-estrogens	N/A	resistance	Supports	ESR1 codon 538 missense mutation resistance	OHSU Import; ESR1 codon 538 missense mutation; organ=Breast; 	early trials	24185510						1				N/A						1	
ESR1	2099	transcript:CCDS5234.1;  amino_acid:536-536;  ESR1 L536 missense mutation		Unknown	Ductal carcinoma	3587	anti-estrogens	N/A	resistance	Supports	ESR1 L536 missense mutation resistance	OHSU Import; ESR1 L536 missense mutation; organ=Breast; 	early trials	24185510						1				N/A						1	
ESR1	2099	protein:p.P535H/; ESR1 P535H missense mutation		Unknown	Ductal carcinoma	3587	anti-estrogens	N/A	resistance	Supports	ESR1 P535H missense mutation resistance	OHSU Import; ESR1 P535H missense mutation; organ=Breast; 	early trials	24185512						1				N/A						1	
RAC1	5879	cdna:c.85C>T; protein:p.P29S/p.Pro29Ser; RAC1 P29S missense mutation	7:6426892-6426892 (C->T)	Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumors	N/A	resistance	Supports	RAC1 P29S missense mutation resistance	OHSU Import; RAC1 P29S missense mutation; 	case report	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:30-336;  EGFR exon 2-7 p.30-336 deletion mutation		Unknown	Glioma	3070	EGFR TKIs	N/A	no response	Supports	EGFR exon 2-7 p.30-336 deletion mutation no response	OHSU Import; EGFR exon 2-7 p.30-336 deletion mutation; organ=Brain; 	early trials	19204207						1				N/A						1	
EGFR	1956	protein:p.A289V/; EGFR A289V missense mutation		Unknown	Glioma	3070	erlotinib	176870	sensitivity	Supports	EGFR A289V missense mutation sensitivity	OHSU Import; EGFR A289V missense mutation; organ=Brain; 	preclinical	17177598						1				N/A						1	
EGFR	1956	cdna:c.323G>A; protein:p.R108K/p.Arg108Lys; EGFR R108K missense mutation	7:55211080-55211080 (G->A)	Unknown	Glioma	3070	erlotinib	176870	sensitivity	Supports	EGFR R108K missense mutation sensitivity	OHSU Import; EGFR R108K missense mutation; organ=Brain; 	preclinical	17177598						1				N/A						1	
EGFR	1956	protein:p.A289V/; EGFR G598V missense mutation		Unknown	Glioma	3070	erlotinib	176870	sensitivity	Supports	EGFR G598V missense mutation sensitivity	OHSU Import; EGFR G598V missense mutation; organ=Brain; 	preclinical	17177598						1				N/A						1	
EGFR	1956	protein:p.T263P/; EGFR T263P missense mutation		Unknown	Glioma	3070	erlotinib	176870	sensitivity	Supports	EGFR T263P missense mutation sensitivity	OHSU Import; EGFR T263P missense mutation; organ=Brain; 	preclinical	17177598						1				N/A						1	
EGFR	1956	protein:p.S492R/; EGFR S492R missense mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	EGFR S492R missense mutation resistance	OHSU Import; EGFR S492R missense mutation; organ=Colon; 	case report	22270724						1				N/A						1	
EGFR	1956	protein:p.S492R/; EGFR S492R missense mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	response	Supports	EGFR S492R missense mutation response	OHSU Import; EGFR S492R missense mutation; organ=Colon; 	case report	22270724						1				N/A						1	
EGFR	1956	protein:p.E690K/; EGFR E690K missense mutation		Unknown	Endometrioid carcinoma	2871	lapatinib	208908	response	Supports	EGFR E690K missense mutation response	OHSU Import; EGFR E690K missense mutation; organ=Endometrium; 	case report	22885469						1				N/A						1	
EGFR	1956	protein:p.P546S/; EGFR P546S missense mutation		Unknown	Squamous cell carcinoma	1749	cetuximab	N/A	response	Supports	EGFR P546S missense mutation response	OHSU Import; EGFR P546S missense mutation; organ=Oropharynx; 	case report	23578570						1				N/A						1	
EGFR	1956	protein:p.P753S/; EGFR P753S missense mutation		Unknown	Squamous cell carcinoma	1749	cetuximab plus sirolimus	N/A	response	Supports	EGFR P753S missense mutation response	OHSU Import; EGFR P753S missense mutation; organ=Oropharynx; 	case report	24934779						1				N/A						1	
EGFR	1956	cdna:c.2527G>A; protein:p.V843I/p.Val843Ile; EGFR V843I missense mutation	7:55259469-55259469 (G->A)	Unknown	Squamous cell carcinoma	1749	gefitinib	123631	no response	Supports	EGFR V843I missense mutation no response	OHSU Import; EGFR V843I missense mutation; organ=Oropharynx; 	case report	21274259						1				N/A						1	
EGFR	1956	protein:p.L747-P753delinsS/; EGFR delL747-P753insS indel		Unknown	Squamous cell carcinoma	1749	gefitinib	123631	no response	Supports	EGFR delL747-P753insS indel no response	OHSU Import; EGFR delL747-P753insS indel; organ=Oropharynx; 	case report	21274259						1				N/A						1	
EGFR	1956	cdna:c.2573T>G; protein:p.L858R/p.Leu858Arg; EGFR L858R missense mutation	7:55259515-55259515 (T->G)	Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR L858R missense mutation response	OHSU Import; EGFR L858R missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2582T>A; protein:p.L861Q/p.Leu861Gln; EGFR L861Q missense mutation	7:55259524-55259524 (T->A)	Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR L861Q missense mutation response	OHSU Import; EGFR L861Q missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.G719A/; EGFR G719A missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR G719A missense mutation response	OHSU Import; EGFR G719A missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2155G>A; protein:p.G719S/p.Gly719Ser; EGFR G719S missense mutation	7:55241707-55241707 (G->A)	Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR G719S missense mutation response	OHSU Import; EGFR G719S missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.G719C/; EGFR G719C missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR G719C missense mutation response	OHSU Import; EGFR G719C missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.G719D/; EGFR G719D missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR G719D missense mutation response	OHSU Import; EGFR G719D missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.L747S/; EGFR L747S missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR L747S missense mutation response	OHSU Import; EGFR L747S missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2303_2304TT; cdna:c.2303G>T; protein:p.S768I/p.Ser768Ile; EGFR S768I missense mutation	7:55249005-55249006 (GC->TT)	Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR S768I missense mutation response	OHSU Import; EGFR S768I missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.L861P/; EGFR L861P missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR L861P missense mutation response	OHSU Import; EGFR L861P missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.L861R/; EGFR L861R missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR L861R missense mutation response	OHSU Import; EGFR L861R missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2369C>T; protein:p.T790M/p.Thr790Met; EGFR T790M missense mutation	7:55249071-55249071 (C->T)	Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	resistance	Supports	EGFR T790M missense mutation resistance	OHSU Import; EGFR T790M missense mutation; organ=Lung; 	NCCN/ CAP guidelines	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 insertion mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR exon 19 p.729-761 insertion mutation response	OHSU Import; EGFR exon 19 p.729-761 insertion mutation; organ=Lung; 	FDA-approved	22190593						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 deletion mutation		Unknown	Adenosquamous carcinoma	4830	afatinib	10184653	response	Supports	EGFR exon 19 p.729-761 deletion mutation response	OHSU Import; EGFR exon 19 p.729-761 deletion mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2369C>T; protein:p.T790M/p.Thr790Met; EGFR T790M missense mutation	7:55249071-55249071 (C->T)	Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR T790M missense mutation response	OHSU Import; EGFR T790M missense mutation; organ=Lung; 	early trials	25074459						1				N/A						1	
EGFR	1956	cdna:c.2573T>G; protein:p.L858R/p.Leu858Arg; EGFR L858R missense mutation	7:55259515-55259515 (T->G)	Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR L858R missense mutation response	OHSU Import; EGFR L858R missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2582T>A; protein:p.L861Q/p.Leu861Gln; EGFR L861Q missense mutation	7:55259524-55259524 (T->A)	Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR L861Q missense mutation response	OHSU Import; EGFR L861Q missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.G719A/; EGFR G719A missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR G719A missense mutation response	OHSU Import; EGFR G719A missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2155G>A; protein:p.G719S/p.Gly719Ser; EGFR G719S missense mutation	7:55241707-55241707 (G->A)	Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR G719S missense mutation response	OHSU Import; EGFR G719S missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.G719C/; EGFR G719C missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR G719C missense mutation response	OHSU Import; EGFR G719C missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.G719D/; EGFR G719D missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR G719D missense mutation response	OHSU Import; EGFR G719D missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.L747S/; EGFR L747S missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR L747S missense mutation response	OHSU Import; EGFR L747S missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2303_2304TT; cdna:c.2303G>T; protein:p.S768I/p.Ser768Ile; EGFR S768I missense mutation	7:55249005-55249006 (GC->TT)	Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR S768I missense mutation response	OHSU Import; EGFR S768I missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.L861P/; EGFR L861P missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR L861P missense mutation response	OHSU Import; EGFR L861P missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.L861R/; EGFR L861R missense mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR L861R missense mutation response	OHSU Import; EGFR L861R missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 insertion mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR exon 19 p.729-761 insertion mutation response	OHSU Import; EGFR exon 19 p.729-761 insertion mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 deletion mutation		Unknown	Adenosquamous carcinoma	4830	afatinib + cetuximab	N/A	response	Supports	EGFR exon 19 p.729-761 deletion mutation response	OHSU Import; EGFR exon 19 p.729-761 deletion mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2573T>G; protein:p.L858R/p.Leu858Arg; EGFR L858R missense mutation	7:55259515-55259515 (T->G)	Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR L858R missense mutation response	OHSU Import; EGFR L858R missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2582T>A; protein:p.L861Q/p.Leu861Gln; EGFR L861Q missense mutation	7:55259524-55259524 (T->A)	Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR L861Q missense mutation response	OHSU Import; EGFR L861Q missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.G719A/; EGFR G719A missense mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR G719A missense mutation response	OHSU Import; EGFR G719A missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2155G>A; protein:p.G719S/p.Gly719Ser; EGFR G719S missense mutation	7:55241707-55241707 (G->A)	Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR G719S missense mutation response	OHSU Import; EGFR G719S missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.G719C/; EGFR G719C missense mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR G719C missense mutation response	OHSU Import; EGFR G719C missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.G719D/; EGFR G719D missense mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR G719D missense mutation response	OHSU Import; EGFR G719D missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.L747S/; EGFR L747S missense mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR L747S missense mutation response	OHSU Import; EGFR L747S missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2303_2304TT; cdna:c.2303G>T; protein:p.S768I/p.Ser768Ile; EGFR S768I missense mutation	7:55249005-55249006 (GC->TT)	Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR S768I missense mutation response	OHSU Import; EGFR S768I missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.L861P/; EGFR L861P missense mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR L861P missense mutation response	OHSU Import; EGFR L861P missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	protein:p.L861R/; EGFR L861R missense mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR L861R missense mutation response	OHSU Import; EGFR L861R missense mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	cdna:c.2369C>T; protein:p.T790M/p.Thr790Met; EGFR T790M missense mutation	7:55249071-55249071 (C->T)	Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	resistance	Supports	EGFR T790M missense mutation resistance	OHSU Import; EGFR T790M missense mutation; organ=Lung; 	NCCN/ CAP guidelines	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 insertion mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR exon 19 p.729-761 insertion mutation response	OHSU Import; EGFR exon 19 p.729-761 insertion mutation; organ=Lung; 	FDA-approved	22190593						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 deletion mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR exon 19 p.729-761 deletion mutation response	OHSU Import; EGFR exon 19 p.729-761 deletion mutation; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:763-764;  EGFR exon 20 p.763-764 insertion mutation		Unknown	Adenosquamous carcinoma	4830	erlotinib	176870	response	Supports	EGFR exon 20 p.763-764 insertion mutation response	OHSU Import; EGFR exon 20 p.763-764 insertion mutation; organ=Lung; 	case report	23969006						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:762-823;  EGFR exon 20 p.762-823 insertion mutation		Unknown	Adenosquamous carcinoma	4830	EGFR TKIs	N/A	decreased sensitivity	Supports	EGFR exon 20 p.762-823 insertion mutation decreased sensitivity	OHSU Import; EGFR exon 20 p.762-823 insertion mutation; organ=Lung; 	late trials	21764376						1				N/A						1	
EGFR	1956	cdna:c.2369C>T; protein:p.T790M/p.Thr790Met; EGFR T790M missense mutation	7:55249071-55249071 (C->T)	Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR T790M missense mutation response	OHSU Import; EGFR T790M missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2573T>G; protein:p.L858R/p.Leu858Arg; EGFR L858R missense mutation	7:55259515-55259515 (T->G)	Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR L858R missense mutation response	OHSU Import; EGFR L858R missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2582T>A; protein:p.L861Q/p.Leu861Gln; EGFR L861Q missense mutation	7:55259524-55259524 (T->A)	Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR L861Q missense mutation response	OHSU Import; EGFR L861Q missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.G719A/; EGFR G719A missense mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR G719A missense mutation response	OHSU Import; EGFR G719A missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2155G>A; protein:p.G719S/p.Gly719Ser; EGFR G719S missense mutation	7:55241707-55241707 (G->A)	Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR G719S missense mutation response	OHSU Import; EGFR G719S missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.G719C/; EGFR G719C missense mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR G719C missense mutation response	OHSU Import; EGFR G719C missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.G719D/; EGFR G719D missense mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR G719D missense mutation response	OHSU Import; EGFR G719D missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.L747S/; EGFR L747S missense mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR L747S missense mutation response	OHSU Import; EGFR L747S missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2303_2304TT; cdna:c.2303G>T; protein:p.S768I/p.Ser768Ile; EGFR S768I missense mutation	7:55249005-55249006 (GC->TT)	Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR S768I missense mutation response	OHSU Import; EGFR S768I missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.L861P/; EGFR L861P missense mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR L861P missense mutation response	OHSU Import; EGFR L861P missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	protein:p.L861R/; EGFR L861R missense mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR L861R missense mutation response	OHSU Import; EGFR L861R missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 insertion mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR exon 19 p.729-761 insertion mutation response	OHSU Import; EGFR exon 19 p.729-761 insertion mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 deletion mutation		Unknown	Adenosquamous carcinoma	4830	HSP90 inhibitors	N/A	response	Supports	EGFR exon 19 p.729-761 deletion mutation response	OHSU Import; EGFR exon 19 p.729-761 deletion mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2369C>T; protein:p.T790M/p.Thr790Met; EGFR T790M missense mutation	7:55249071-55249071 (C->T)	Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR T790M missense mutation response	OHSU Import; EGFR T790M missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
EGFR	1956	cdna:c.2573T>G; protein:p.L858R/p.Leu858Arg; EGFR L858R missense mutation	7:55259515-55259515 (T->G)	Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR L858R missense mutation response	OHSU Import; EGFR L858R missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	cdna:c.2582T>A; protein:p.L861Q/p.Leu861Gln; EGFR L861Q missense mutation	7:55259524-55259524 (T->A)	Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR L861Q missense mutation response	OHSU Import; EGFR L861Q missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	protein:p.G719A/; EGFR G719A missense mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR G719A missense mutation response	OHSU Import; EGFR G719A missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	cdna:c.2155G>A; protein:p.G719S/p.Gly719Ser; EGFR G719S missense mutation	7:55241707-55241707 (G->A)	Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR G719S missense mutation response	OHSU Import; EGFR G719S missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	protein:p.G719C/; EGFR G719C missense mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR G719C missense mutation response	OHSU Import; EGFR G719C missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	protein:p.G719D/; EGFR G719D missense mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR G719D missense mutation response	OHSU Import; EGFR G719D missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	protein:p.L747S/; EGFR L747S missense mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR L747S missense mutation response	OHSU Import; EGFR L747S missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	cdna:c.2303_2304TT; cdna:c.2303G>T; protein:p.S768I/p.Ser768Ile; EGFR S768I missense mutation	7:55249005-55249006 (GC->TT)	Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR S768I missense mutation response	OHSU Import; EGFR S768I missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	protein:p.L861P/; EGFR L861P missense mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR L861P missense mutation response	OHSU Import; EGFR L861P missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	protein:p.L861R/; EGFR L861R missense mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR L861R missense mutation response	OHSU Import; EGFR L861R missense mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 insertion mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR exon 19 p.729-761 insertion mutation response	OHSU Import; EGFR exon 19 p.729-761 insertion mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 deletion mutation		Unknown	Adenosquamous carcinoma	4830	irreversible EGFR TKIs	N/A	response	Supports	EGFR exon 19 p.729-761 deletion mutation response	OHSU Import; EGFR exon 19 p.729-761 deletion mutation; organ=Lung; 	late trials	22753918						1				N/A						1	
EGFR	1956	cdna:c.2573T>G; protein:p.L858R/p.Leu858Arg; EGFR L858R missense mutation	7:55259515-55259515 (T->G)	Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR L858R missense mutation sensitivity	OHSU Import; EGFR L858R missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	cdna:c.2582T>A; protein:p.L861Q/p.Leu861Gln; EGFR L861Q missense mutation	7:55259524-55259524 (T->A)	Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR L861Q missense mutation sensitivity	OHSU Import; EGFR L861Q missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	protein:p.G719A/; EGFR G719A missense mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR G719A missense mutation sensitivity	OHSU Import; EGFR G719A missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	cdna:c.2155G>A; protein:p.G719S/p.Gly719Ser; EGFR G719S missense mutation	7:55241707-55241707 (G->A)	Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR G719S missense mutation sensitivity	OHSU Import; EGFR G719S missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	protein:p.G719C/; EGFR G719C missense mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR G719C missense mutation sensitivity	OHSU Import; EGFR G719C missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	protein:p.G719D/; EGFR G719D missense mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR G719D missense mutation sensitivity	OHSU Import; EGFR G719D missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	protein:p.L747S/; EGFR L747S missense mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR L747S missense mutation sensitivity	OHSU Import; EGFR L747S missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	cdna:c.2303_2304TT; cdna:c.2303G>T; protein:p.S768I/p.Ser768Ile; EGFR S768I missense mutation	7:55249005-55249006 (GC->TT)	Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR S768I missense mutation sensitivity	OHSU Import; EGFR S768I missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	protein:p.L861P/; EGFR L861P missense mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR L861P missense mutation sensitivity	OHSU Import; EGFR L861P missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	protein:p.L861R/; EGFR L861R missense mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR L861R missense mutation sensitivity	OHSU Import; EGFR L861R missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	cdna:c.2369C>T; protein:p.T790M/p.Thr790Met; EGFR T790M missense mutation	7:55249071-55249071 (C->T)	Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR T790M missense mutation sensitivity	OHSU Import; EGFR T790M missense mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 insertion mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR exon 19 p.729-761 insertion mutation sensitivity	OHSU Import; EGFR exon 19 p.729-761 insertion mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EGFR	1956	transcript:CCDS5514.1;  amino_acid:729-761;  EGFR exon 19 p.729-761 deletion mutation		Unknown	Adenosquamous carcinoma	4830	MEK inhibitors	N/A	sensitivity	Supports	EGFR exon 19 p.729-761 deletion mutation sensitivity	OHSU Import; EGFR exon 19 p.729-761 deletion mutation; organ=Lung; 	preclinical	23102728						1				N/A						1	
EZH2	2146	transcript:CCDS56516.1;  amino_acid:641-641;  EZH2 Y641 missense mutation		Unknown	Lymphoma, NOS	8838	EZH2 inhibitor	68210102	sensitivity	Supports	EZH2 Y641 missense mutation sensitivity	OHSU Import; EZH2 Y641 missense mutation; organ=Lymph Node; 	preclinical	23023262						1				N/A						1	
EZH2	2146	transcript:CCDS56516.1;  amino_acid:677-677;  EZH2 A677 missense mutation		Unknown	Lymphoma, NOS	8838	EZH2 inhibitor	68210102	sensitivity	Supports	EZH2 A677 missense mutation sensitivity	OHSU Import; EZH2 A677 missense mutation; organ=Lymph Node; 	preclinical	23023262						1				N/A						1	
SMO	6608	protein:p.D473H/; SMO D473H missense mutation		Unknown	Medulloblastoma	0050902	vismodegib	24776445	resistance	Supports	SMO D473H missense mutation resistance	OHSU Import; SMO D473H missense mutation; organ=Brain; 	case report	19726788						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Hairy cell leukaemia	711	vemurafenib	42611257	response	Supports	BRAF V600E missense mutation response	OHSU Import; BRAF V600E missense mutation; organ=Bone marrow; 	case report	22621641						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Astrocytoma	3069	BRAF inhibitors	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Brain; 	preclinical	22038996						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	BRAF inhibitors + EGFR inhibitors	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Colon; 	preclinical	22281684						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:600-600;  BRAF  V600 (other than E) missense mutation		Unknown	Adenocarcinoma	299	BRAF inhibitors + MEK inhibitors	N/A	response	Supports	BRAF  V600 (other than E) missense mutation response	OHSU Import; BRAF  V600 (other than E) missense mutation; organ=Colon; 	early trials	N/A						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	BRAF inhibitors + PI3K pathway inhibitors	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Colon; 	preclinical	23251002						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	dabrafenib	44462760	response	Supports	BRAF V600E missense mutation response	OHSU Import; BRAF V600E missense mutation; organ=Colon; 	early trials	22608338						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	BRAF V600E missense mutation resistance	OHSU Import; BRAF V600E missense mutation; organ=Colon; 	late trials	20619739						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:600-600;  BRAF  V600 (other than E) missense mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	BRAF  V600 (other than E) missense mutation resistance	OHSU Import; BRAF  V600 (other than E) missense mutation; organ=Colon; 	late trials	20619739						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:600-600;  BRAF  V600 (other than E) missense mutation		Unknown	Adenocarcinoma	299	mTOR inhibitors + BH3 mimetics	N/A	sensitivity	Supports	BRAF  V600 (other than E) missense mutation sensitivity	OHSU Import; BRAF  V600 (other than E) missense mutation; organ=Colon; 	preclinical	24163374						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	mTOR inhibitors + BH3 mimetics	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Colon; 	preclinical	24163374						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	BRAF V600E missense mutation resistance	OHSU Import; BRAF V600E missense mutation; organ=Colon; 	late trials	20619739						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:600-600;  BRAF  V600 (other than E) missense mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	BRAF  V600 (other than E) missense mutation resistance	OHSU Import; BRAF  V600 (other than E) missense mutation; organ=Colon; 	late trials	20619739						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	proteosome inhibitors	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Colon; 	preclinical	24107445						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	GIST	9253	dabrafenib	44462760	response	Supports	BRAF V600E missense mutation response	OHSU Import; BRAF V600E missense mutation; 	case report	22608338						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	BRAF inhibitors +/- MEK inhibitors	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Lung; 	preclinical	19010912						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	dabrafenib	44462760	response	Supports	BRAF V600E missense mutation response	OHSU Import; BRAF V600E missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
BRAF	673	protein:p.Y472C/; BRAF Y472C missense mutation		Unknown	Adenocarcinoma	299	dasatinib	3062316	response	Supports	BRAF Y472C missense mutation response	OHSU Import; BRAF Y472C missense mutation; organ=Lung; 	case report	22649091						1				N/A						1	
BRAF	673	cdna:c.1397G>T; protein:p.G466V/p.Gly466Val; BRAF G466V missense mutation	7:140481411-140481411 (C->A)	Unknown	Adenocarcinoma	299	dasatinib	3062316	sensitivity	Supports	BRAF G466V missense mutation sensitivity	OHSU Import; BRAF G466V missense mutation; organ=Lung; 	preclinical	22649091						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	EGFR TKIs	N/A	resistance	Supports	BRAF V600E missense mutation resistance	OHSU Import; BRAF V600E missense mutation; organ=Lung; 	case report	22773810						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Adenocarcinoma	299	vemurafenib	42611257	response	Supports	BRAF V600E missense mutation response	OHSU Import; BRAF V600E missense mutation; organ=Lung; 	case report	22743296						1				N/A						1	
BRAF	673	protein:p.V600R/; BRAF  V600R missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	response	Supports	BRAF  V600R missense mutation response	OHSU Import; BRAF  V600R missense mutation; 	early trials	23237741						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; 	early trials	N/A						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:597-597;  BRAF  L597 missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	response	Supports	BRAF  L597 missense mutation response	OHSU Import; BRAF  L597 missense mutation; 	case report	23715574						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	BRAF inhibitors + CDK2/4 inhibitors	N/A	sensitivity	Supports	BRAF  V600E missense mutation sensitivity	OHSU Import; BRAF  V600E missense mutation; 	preclinical	22997239						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	BRAF inhibitors + HSP90 inhibitors	N/A	sensitivity	Supports	BRAF  V600E missense mutation sensitivity	OHSU Import; BRAF  V600E missense mutation; 	preclinical	22351686						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	BRAF inhibitors + PI3K pathway inhibitors	N/A	sensitivity	Supports	BRAF  V600E missense mutation sensitivity	OHSU Import; BRAF  V600E missense mutation; 	preclinical	21156289						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	dabrafenib	44462760	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; 	FDA-approved	N/A						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	dabrafenib + trametinib	N/A	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; 	FDA-approved	N/A						1				N/A						1	
BRAF	673	cdna:c.1798_1799AA; protein:p.V600K/; BRAF  V600K missense mutation	7:140453136-140453137 (AC->TT)	Unknown	Melanoma, NOS	6367	dabrafenib + trametinib	N/A	response	Supports	BRAF  V600K missense mutation response	OHSU Import; BRAF  V600K missense mutation; 	FDA-approved	N/A						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	ERK inhibitors	N/A	sensitivity	Supports	BRAF  V600E missense mutation sensitivity	OHSU Import; BRAF  V600E missense mutation; 	preclinical	22997239						1				N/A						1	
BRAF	673	protein:p.K601R/; BRAF  K601R missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	BRAF  K601R missense mutation response	OHSU Import; BRAF  K601R missense mutation; 	case report	23248257						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:597-597;  BRAF  L597 missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	BRAF  L597 missense mutation response	OHSU Import; BRAF  L597 missense mutation; 	case report	22798288						1				N/A						1	
BRAF	673	protein:p.V600R/; BRAF  V600R missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	BRAF  V600R missense mutation response	OHSU Import; BRAF  V600R missense mutation; 	case report	23248257						1				N/A						1	
BRAF	673	protein:p.K601R/; BRAF  K601R missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	BRAF  K601R missense mutation response	OHSU Import; BRAF  K601R missense mutation; 	case report	23248257						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:597-597;  BRAF  L597 missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	BRAF  L597 missense mutation response	OHSU Import; BRAF  L597 missense mutation; 	case report	22798288						1				N/A						1	
BRAF	673	protein:p.V600R/; BRAF  V600R missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	BRAF  V600R missense mutation response	OHSU Import; BRAF  V600R missense mutation; 	case report	23248257						1				N/A						1	
BRAF	673	cdna:c.1781A>G; protein:p.D594G/p.Asp594Gly; BRAF  D594G missense mutation	7:140453154-140453154 (T->C)	Unknown	Melanoma, NOS	6367	sorafenib	216239	sensitivity	Supports	BRAF  D594G missense mutation sensitivity	OHSU Import; BRAF  D594G missense mutation; 	preclinical	18794803						1				N/A						1	
BRAF	673	protein:p.G469E/; BRAF  G469E  missense mutation		Unknown	Melanoma, NOS	6367	sorafenib	216239	sensitivity	Supports	BRAF  G469E  missense mutation sensitivity	OHSU Import; BRAF  G469E  missense mutation; 	preclinical	18794803						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	trametinib	11707110	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; 	FDA-approved	N/A						1				N/A						1	
BRAF	673	cdna:c.1798_1799AA; protein:p.V600K/; BRAF  V600K missense mutation	7:140453136-140453137 (AC->TT)	Unknown	Melanoma, NOS	6367	trametinib	11707110	response	Supports	BRAF  V600K missense mutation response	OHSU Import; BRAF  V600K missense mutation; 	FDA-approved	N/A						1				N/A						1	
BRAF	673	transcript:CCDS5863.1;  amino_acid:597-597;  BRAF  L597 missense mutation		Unknown	Melanoma, NOS	6367	trametinib	11707110	response	Supports	BRAF  L597 missense mutation response	OHSU Import; BRAF  L597 missense mutation; 	case report	22798288						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Melanoma, NOS	6367	vemurafenib	42611257	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; 	FDA-approved	N/A						1				N/A						1	
BRAF	673	cdna:c.1798_1799AA; protein:p.V600K/; BRAF  V600K missense mutation	7:140453136-140453137 (AC->TT)	Unknown	Melanoma, NOS	6367	vemurafenib	42611257	response	Supports	BRAF  V600K missense mutation response	OHSU Import; BRAF  V600K missense mutation; 	late trials	22356324						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	MYELOMA	0070004	vemurafenib	42611257	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; 	case report	23612012						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Serous carcinoma, high grade	3230	BRAF inhibitors	N/A	response	Supports	BRAF V600E missense mutation response	OHSU Import; BRAF V600E missense mutation; organ=Ovary; 	case report	22608338						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E mutation	7:140453135-140453136 (CA->TT)	Unknown	Serous carcinoma, high grade	3230	dabrafenib	44462760	response	Supports	BRAF V600E mutation response	OHSU Import; BRAF V600E mutation; organ=Ovary; 	case report	22608338						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Serous carcinoma, high grade	3230	MEK inhibitors	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Ovary; 	preclinical	19018267						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Serous carcinoma, high grade	3230	MEK inhibitors	N/A	sensitivity	Supports	BRAF V600E missense mutation sensitivity	OHSU Import; BRAF V600E missense mutation; organ=Ovary; 	preclinical	19018267						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Papillary thyroid carcinoma	3969	BRAF inhibitors + MEK inhibitors	N/A	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; organ=Thyroid; 	early trials	N/A						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Papillary thyroid carcinoma	3969	dabrafenib	44462760	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; organ=Thyroid; 	early trials	20818844						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Papillary thyroid carcinoma	3969	MEK inhibitors	N/A	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; organ=Thyroid; 	early trials	22241789						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Papillary thyroid carcinoma	3969	MEK inhibitors	N/A	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; organ=Thyroid; 	early trials	23406027						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Papillary thyroid carcinoma	3969	MEK inhibitors	N/A	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; organ=Thyroid; 	early trials	22241789						1				N/A						1	
BRAF	673	cdna:c.1799_1800AA; cdna:c.1799T>A; protein:p.V600E/p.Val600Glu; BRAF  V600E missense mutation	7:140453135-140453136 (CA->TT)	Unknown	Papillary thyroid carcinoma	3969	vemurafenib	42611257	response	Supports	BRAF  V600E missense mutation response	OHSU Import; BRAF  V600E missense mutation; organ=Thyroid; 	early trials	20818844						1				N/A						1	
EZH2	2146	protein:p.Y646F/; EZH2 Y646F missense mutation		Unknown	Lymphoma, NOS	8838	EZH2 inhibitor	68210102	sensitivity	Supports	EZH2 Y646F missense mutation sensitivity	OHSU Import; EZH2 Y646F missense mutation; organ=Lymph Node; 	preclinical	24563539						1				N/A						1	
JAK2	3717	transcript:CCDS6457.1;  amino_acid:683-683;  JAK2 R683 missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ruxolitinib	25126798	sensitivity	Supports	JAK2 R683 missense mutation sensitivity	OHSU Import; JAK2 R683 missense mutation; 	preclinical	18805579						1				N/A						1	
JAK2	3717	cdna:c.1849G>T; protein:p.V617F/p.Val617Phe; JAK2 V617F missense mutation	9:5073770-5073770 (G->T)	Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	JAK inhibitors	N/A	response	Supports	JAK2 V617F missense mutation response	OHSU Import; JAK2 V617F missense mutation; organ=Bone marrow; 	preclinical	22829971						1				N/A						1	
JAK2	3717	cdna:c.1849G>T; protein:p.V617F/p.Val617Phe; JAK2 V617F missense mutation	9:5073770-5073770 (G->T)	Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	ruxolitinib	25126798	response	Supports	JAK2 V617F missense mutation response	OHSU Import; JAK2 V617F missense mutation; organ=Bone marrow; 	early trials	22422826						1				N/A						1	
JAK2	3717	cdna:c.1849G>T; protein:p.V617F/p.Val617Phe; JAK2 V617F missense mutation	9:5073770-5073770 (G->T)	Unknown	Myelofibrosis	4971	ruxolitinib	25126798	response	Supports	JAK2 V617F missense mutation response	OHSU Import; JAK2 V617F missense mutation; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
GNAQ	2776	transcript:CCDS6658.1;  amino_acid:209-209;  GNAQ Q209 missense mutation		Unknown	Melanoma, NOS	6367	PI3K pathway inhibitors + MEK inhibitors	N/A	response	Supports	GNAQ Q209 missense mutation response	OHSU Import; GNAQ Q209 missense mutation; 	preclinical	22733540						1				N/A						1	
GNAQ	2776	transcript:CCDS6658.1;  amino_acid:209-209;  GNAQ Q209 missense mutation		Unknown	Melanoma, NOS	6367	PKC inhibitor	N/A	sensitivity	Supports	GNAQ Q209 missense mutation sensitivity	OHSU Import; GNAQ Q209 missense mutation; 	preclinical	22253748						1				N/A						1	
GNAQ	2776	transcript:CCDS6658.1;  amino_acid:209-209;  GNAQ Q209 missense mutation		Unknown	Melanoma, NOS	6367	selumetinib	10127622	response	Supports	GNAQ Q209 missense mutation response	OHSU Import; GNAQ Q209 missense mutation; 	early trials	N/A						1				N/A						1	
RET	5979	protein:p.C634W/; RET C634W missense mutation		Unknown	Papillary thyroid carcinoma	3969	cabozantinib	25102847	sensitivity	Supports	RET C634W missense mutation sensitivity	OHSU Import; RET C634W missense mutation; organ=Thyroid; 	preclinical	21470995						1				N/A						1	
RET	5979	cdna:c.2753T>C; protein:p.M918T/p.Met918Thr; RET M918T missense mutation	10:43617416-43617416 (T->C)	Unknown	Papillary thyroid carcinoma	3969	cabozantinib	25102847	sensitivity	Supports	RET M918T missense mutation sensitivity	OHSU Import; RET M918T missense mutation; organ=Thyroid; 	preclinical	21470995						1				N/A						1	
RET	5979	protein:p.C634W/; RET C634W missense mutation		Unknown	Papillary thyroid carcinoma	3969	RET inhibitors	N/A	sensitivity	Supports	RET C634W missense mutation sensitivity	OHSU Import; RET C634W missense mutation; organ=Thyroid; 	preclinical	23056499						1				N/A						1	
RET	5979	cdna:c.2753T>C; protein:p.M918T/p.Met918Thr; RET M918T missense mutation	10:43617416-43617416 (T->C)	Unknown	Papillary thyroid carcinoma	3969	RET inhibitors	N/A	sensitivity	Supports	RET M918T missense mutation sensitivity	OHSU Import; RET M918T missense mutation; organ=Thyroid; 	preclinical	23056499						1				N/A						1	
RET	5979	protein:p.C634W/; RET C634W missense mutation		Unknown	Papillary thyroid carcinoma	3969	sunitinib	5329102	sensitivity	Supports	RET C634W missense mutation sensitivity	OHSU Import; RET C634W missense mutation; organ=Thyroid; 	preclinical	21470995						1				N/A						1	
RET	5979	cdna:c.2753T>C; protein:p.M918T/p.Met918Thr; RET M918T missense mutation	10:43617416-43617416 (T->C)	Unknown	Papillary thyroid carcinoma	3969	sunitinib	5329102	sensitivity	Supports	RET M918T missense mutation sensitivity	OHSU Import; RET M918T missense mutation; organ=Thyroid; 	preclinical	21470995						1				N/A						1	
RET	5979	transcript:CCDS7200.1;  amino_acid:618-618;  RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation response	OHSU Import; RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	transcript:CCDS7200.1;  amino_acid:620-620;  RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation response	OHSU Import; RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	transcript:CCDS7200.1;  amino_acid:634-634;  RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation response	OHSU Import; RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	transcript:CCDS7200.1;  amino_acid:768-768;  RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation response	OHSU Import; RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	transcript:CCDS7200.1;  amino_acid:791-791;  RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation response	OHSU Import; RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	transcript:CCDS7200.1;  amino_acid:891-891;  RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation response	OHSU Import; RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	transcript:CCDS7200.1;  amino_acid:918-918;  RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation response	OHSU Import; RET codon 618, 620, 634, 768, 791, 891, 918 missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	protein:p.C634W/; RET C634W missense mutation		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET C634W missense mutation response	OHSU Import; RET C634W missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
RET	5979	cdna:c.2753T>C; protein:p.M918T/p.Met918Thr; RET M918T missense mutation	10:43617416-43617416 (T->C)	Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	response	Supports	RET M918T missense mutation response	OHSU Import; RET M918T missense mutation; organ=Thyroid; 	FDA-approved	20065189						1				N/A						1	
FGFR2	2263	protein:p.V565I/; FGFR2 V565I missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 V565I missense mutation resistance	OHSU Import; FGFR2 V565I missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.M536I/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation resistance	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.M538I/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation resistance	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.I548V/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation resistance	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	transcript:CCDS7620.2;  amino_acid:550-550;  FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation resistance	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.E566G/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation resistance	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.L618M/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation resistance	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.K660E /; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	dovitinib	9886808	resistance	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation resistance	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.V565I/; FGFR2 V565I missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	resistance	Supports	FGFR2 V565I missense mutation resistance	OHSU Import; FGFR2 V565I missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.M536I/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	sensitivity	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation sensitivity	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.M538I/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	sensitivity	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation sensitivity	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.I548V/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	sensitivity	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation sensitivity	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	transcript:CCDS7620.2;  amino_acid:550-550;  FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	sensitivity	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation sensitivity	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.E566G/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	sensitivity	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation sensitivity	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.L618M/; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	sensitivity	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation sensitivity	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	gemcitabine + MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	early trials	23583440						1				N/A						1	
FGFR2	2263	protein:p.K660E /; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation		Unknown	Endometrioid carcinoma	2871	ponatinib	24826799	sensitivity	Supports	FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation sensitivity	OHSU Import; FGFR2 M536I, M538I, I548V, N550, E566G, L618M, K660E  missense mutation; organ=Endometrium; 	preclinical	23908597						1				N/A						1	
FGFR2	2263	protein:p.P253R/; FGFR2 P253R missense mutation		Unknown	Squamous cell carcinoma	1749	pazopanib	10113978	response	Supports	FGFR2 P253R missense mutation response	OHSU Import; FGFR2 P253R missense mutation; organ=Oropharynx; 	case report	23786770						1				N/A						1	
FGFR2	2263	protein:p.K660N/; FGFR2 K660N missense mutation		Unknown	Adenosquamous carcinoma	4830	FGFR inhibitors	N/A	sensitivity	Supports	FGFR2 K660N missense mutation sensitivity	OHSU Import; FGFR2 K660N missense mutation; organ=Lung; 	preclinical	25035393						1				N/A						1	
FGFR2	2263	protein:p.W290C/; FGFR2 W290C missense mutation		Unknown	Squamous cell carcinoma	1749	FGFR inhibitors	N/A	sensitivity	Supports	FGFR2 W290C missense mutation sensitivity	OHSU Import; FGFR2 W290C missense mutation; organ=Lung; 	preclinical	23786770						1				N/A						1	
FGFR2	2263	protein:p.S320C/; FGFR2 S320C missense mutation		Unknown	Squamous cell carcinoma	1749	FGFR inhibitors	N/A	sensitivity	Supports	FGFR2 S320C missense mutation sensitivity	OHSU Import; FGFR2 S320C missense mutation; organ=Lung; 	preclinical	23786770						1				N/A						1	
HRAS	3265	transcript:CCDS7698.1;  amino_acid:12-12;  HRAS codon 12 missense mutation		Unknown	Squamous cell carcinoma	1749	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	HRAS codon 12 missense mutation sensitivity	OHSU Import; HRAS codon 12 missense mutation; organ=Cervix; 	preclinical	15950068						1				N/A						1	
HRAS	3265	transcript:CCDS7698.1;  amino_acid:12-12;  HRAS codon 12 missense mutation		Unknown	Squamous cell carcinoma	1749	mTOR inhibitors	N/A	sensitivity	Supports	HRAS codon 12 missense mutation sensitivity	OHSU Import; HRAS codon 12 missense mutation; organ=Cervix; 	preclinical	22345164						1				N/A						1	
HRAS	3265	transcript:CCDS7698.1;  amino_acid:12-12;  HRAS codon 12 missense mutation		Unknown	Squamous cell carcinoma	1749	mTOR inhibitors	N/A	sensitivity	Supports	HRAS codon 12 missense mutation sensitivity	OHSU Import; HRAS codon 12 missense mutation; organ=Cervix; 	preclinical	22345164						1				N/A						1	
CBL	867	cdna:c.1111T>C; protein:p.Y371H/p.Tyr371His; CBL Y371H missense mutation	11:119148891-119148891 (T->C)	Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	dasatinib	3062316	sensitivity	Supports	CBL Y371H missense mutation sensitivity	OHSU Import; CBL Y371H missense mutation; organ=Bone marrow; 	preclinical	23696637						1				N/A						1	
CBL	867	cdna:c.1150T>C; protein:p.C384R/p.Cys384Arg; CBL C384R missense mutation	11:119148930-119148930 (T->C)	Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	dasatinib	3062316	sensitivity	Supports	CBL C384R missense mutation sensitivity	OHSU Import; CBL C384R missense mutation; organ=Bone marrow; 	preclinical	23696637						1				N/A						1	
CBL	867	cdna:c.1111T>C; protein:p.Y371H/p.Tyr371His; CBL Y371H missense mutation	11:119148891-119148891 (T->C)	Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	JAK inhibitors	N/A	sensitivity	Supports	CBL Y371H missense mutation sensitivity	OHSU Import; CBL Y371H missense mutation; organ=Bone marrow; 	preclinical	23696637						1				N/A						1	
CBL	867	cdna:c.1150T>C; protein:p.C384R/p.Cys384Arg; CBL C384R missense mutation	11:119148930-119148930 (T->C)	Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	JAK inhibitors	N/A	sensitivity	Supports	CBL C384R missense mutation sensitivity	OHSU Import; CBL C384R missense mutation; organ=Bone marrow; 	preclinical	23696637						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-12;  KRAS codon 12 missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12 missense mutation sensitivity	OHSU Import; KRAS codon 12 missense mutation; 	preclinical	18701506						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-12;  KRAS codon 12 missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12 missense mutation sensitivity	OHSU Import; KRAS codon 12 missense mutation; 	preclinical	18701506						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Cholangiocarcinoma	4947	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Bile duct; 	early trials	23391555						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Cholangiocarcinoma	4947	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Bile duct; 	early trials	23391555						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Cholangiocarcinoma	4947	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Bile duct; 	early trials	23391555						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Cholangiocarcinoma	4947	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Bile duct; 	early trials	23391555						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Squamous cell carcinoma	1749	MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Cervix; 	preclinical	22169769						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Squamous cell carcinoma	1749	MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Cervix; 	preclinical	22169769						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Squamous cell carcinoma	1749	MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Cervix; 	preclinical	22169769						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Squamous cell carcinoma	1749	MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Cervix; 	preclinical	22169769						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	anti-EGFR mAbs + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	24553387						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	anti-EGFR mAbs + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	24553387						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	FDA-rejected	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	FDA-rejected	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:146-146;  KRAS codon 146 missense mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	KRAS codon 146 missense mutation resistance	OHSU Import; KRAS codon 146 missense mutation; organ=Colon; 	late trials	20619739						1				N/A						1	
KRAS	3845	cdna:c.38G>A; protein:p.G13D/p.Gly13Asp; KRAS G13D missense mutation	12:25398281-25398281 (C->T)	Unknown	Adenocarcinoma	299	cetuximab	N/A	response	Supports	KRAS G13D missense mutation response	OHSU Import; KRAS G13D missense mutation; organ=Colon; 	late trials	20978259						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	ERK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	23614898						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	ERK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	23614898						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + BCL-XL inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	23245996						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + BCL-XL inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	23245996						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + IGF1R inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	24045180						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + IGF1R inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	24045180						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:146-146;  KRAS codon 146 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + PI3K pathway inhibitors	N/A	sensitivity	Supports	KRAS codon 146 missense mutation sensitivity	OHSU Import; KRAS codon 146 missense mutation; organ=Colon; 	preclinical	22392911						1				N/A						1	
KRAS	3845	cdna:c.38G>A; protein:p.G13D/p.Gly13Asp; KRAS G13D missense mutation	12:25398281-25398281 (C->T)	Unknown	Adenocarcinoma	299	MEK inhibitors + PI3K pathway inhibitors	N/A	sensitivity	Supports	KRAS G13D missense mutation sensitivity	OHSU Import; KRAS G13D missense mutation; organ=Colon; 	preclinical	22392911						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + PI3K pathway inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	22392911						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + PI3K pathway inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	22392911						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	mTOR inhibitors + BH3 mimetics	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	24163374						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	mTOR inhibitors + BH3 mimetics	N/A	sensitivity	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	preclinical	24163374						1				N/A						1	
KRAS	3845	cdna:c.38G>A; protein:p.G13D/p.Gly13Asp; KRAS G13D missense mutation	12:25398281-25398281 (C->T)	Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	KRAS G13D missense mutation resistance	OHSU Import; KRAS G13D missense mutation; organ=Colon; 	FDA-rejected	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	FDA-rejected	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13 (nonG13D), 61 missense mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	KRAS codon 12, 13 (nonG13D), 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13 (nonG13D), 61 missense mutation; organ=Colon; 	FDA-rejected	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:146-146;  KRAS codon 146 missense mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	KRAS codon 146 missense mutation resistance	OHSU Import; KRAS codon 146 missense mutation; organ=Colon; 	late trials	20619739						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors	N/A	resistance	Supports	KRAS codon 12, 13, 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Endometrium; 	preclinical	22662154						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors	N/A	resistance	Supports	KRAS codon 12, 13, 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Endometrium; 	preclinical	22662154						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Endometrium; 	preclinical	21984976						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Endometrium; 	preclinical	21984976						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13 missense mutation		Unknown	Adenocarcinoma	299	anti-EGFR mAbs	N/A	resistance	Supports	KRAS codon 12, 13 missense mutation resistance	OHSU Import; KRAS codon 12, 13 missense mutation; organ=Stomach; 	preclinical	22290393						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-12;  KRAS codon 12 missense mutation		Unknown	GIST	9253	imatinib	5291	resistance	Supports	KRAS codon 12 missense mutation resistance	OHSU Import; KRAS codon 12 missense mutation; 	case report	24687822						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	BET inhibitors in LKB1 wt	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	23129625						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	BET inhibitors in LKB1 wt	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	23129625						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	CDK4/6 inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	20609353						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	CDK4/6 inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	20609353						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	EGFR TKIs	N/A	resistance	Supports	KRAS codon 12, 13, 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	NCCN guidelines	20921461						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	EGFR TKIs	N/A	resistance	Supports	KRAS codon 12, 13, 61 missense mutation resistance	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	NCCN guidelines	20921461						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	HSP90 inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	21907929						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	HSP90 inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	21907929						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	JAK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	24444711						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	JAK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	24444711						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	19029981						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Lung; 	preclinical	19029981						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	MYELOMA	0070004	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; 	preclinical	22985491						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	MYELOMA	0070004	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; 	preclinical	22985491						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS  codon 12, 13, 61 missense mutation		Unknown	Serous carcinoma, high grade	3230	MEK inhibitors	N/A	sensitivity	Supports	KRAS  codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS  codon 12, 13, 61 missense mutation; organ=Ovary; 	preclinical	19018267						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS  codon 12, 13, 61 missense mutation		Unknown	Serous carcinoma, high grade	3230	MEK inhibitors	N/A	sensitivity	Supports	KRAS  codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS  codon 12, 13, 61 missense mutation; organ=Ovary; 	preclinical	19018267						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS  codon 12, 13, 61 missense mutation		Unknown	Serous carcinoma, high grade	3230	MEK inhibitors	N/A	sensitivity	Supports	KRAS  codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS  codon 12, 13, 61 missense mutation; organ=Ovary; 	preclinical	19018267						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS  codon 12, 13, 61 missense mutation		Unknown	Serous carcinoma, high grade	3230	MEK inhibitors	N/A	sensitivity	Supports	KRAS  codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS  codon 12, 13, 61 missense mutation; organ=Ovary; 	preclinical	19018267						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS  codon 12, 13, 61 missense mutation		Unknown	Serous carcinoma, high grade	3230	PI3K pathway inhibitors + MEK inhibitors	N/A	response	Supports	KRAS  codon 12, 13, 61 missense mutation response	OHSU Import; KRAS  codon 12, 13, 61 missense mutation; organ=Ovary; 	early trials	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS  codon 12, 13, 61 missense mutation		Unknown	Serous carcinoma, high grade	3230	PI3K pathway inhibitors + MEK inhibitors	N/A	response	Supports	KRAS  codon 12, 13, 61 missense mutation response	OHSU Import; KRAS  codon 12, 13, 61 missense mutation; organ=Ovary; 	early trials	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	dasatinib	3062316	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; 	FDA-approved	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	gemcitabine + MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	early trials	23583440						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	case report	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	case report	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	case report	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	response	Supports	KRAS codon 12, 13, 61 missense mutation response	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	case report	N/A						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:12-13;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors + MEK inhibitor	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	preclinical	22952903						1				N/A						1	
KRAS	3845	transcript:CCDS8702.1;  amino_acid:61-61;  KRAS codon 12, 13, 61 missense mutation		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors + MEK inhibitor	N/A	sensitivity	Supports	KRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; KRAS codon 12, 13, 61 missense mutation; organ=Pancreas; 	preclinical	22952903						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-13;  NRAS codon 12, 13, 61 missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 13, 61 missense mutation; 	preclinical	18701506						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 13, 61 missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 13, 61 missense mutation; 	preclinical	18701506						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-13;  NRAS codon 12, 13, 61 missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 13, 61 missense mutation; 	preclinical	18701506						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 13, 61 missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 13, 61 missense mutation; 	preclinical	18701506						1				N/A						1	
NRAS	4893	cdna:c.34G>T; protein:p.G12C/p.Gly12Cys; NRAS G12C missense mutation	1:115258748-115258748 (C->A)	Unknown	Malignant neoplasm, NOS	5074	ERK inhibitors	N/A	sensitivity	Supports	NRAS G12C missense mutation sensitivity	OHSU Import; NRAS G12C missense mutation; 	preclinical	23614898						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-12;  NRAS codon 12, 61  missense mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	NRAS codon 12, 61  missense mutation resistance	OHSU Import; NRAS codon 12, 61  missense mutation; organ=Colon; 	NCCN guidelines	20619739						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 61  missense mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	NRAS codon 12, 61  missense mutation resistance	OHSU Import; NRAS codon 12, 61  missense mutation; organ=Colon; 	NCCN guidelines	20619739						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-12;  NRAS codon 12, 61  missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors +/- PI3K pathway inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 61  missense mutation sensitivity	OHSU Import; NRAS codon 12, 61  missense mutation; organ=Colon; 	preclinical	22392911						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 61  missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors +/- PI3K pathway inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 61  missense mutation sensitivity	OHSU Import; NRAS codon 12, 61  missense mutation; organ=Colon; 	preclinical	22392911						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-12;  NRAS codon 12, 61  missense mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	NRAS codon 12, 61  missense mutation resistance	OHSU Import; NRAS codon 12, 61  missense mutation; organ=Colon; 	NCCN guidelines	20619739						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 61  missense mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	resistance	Supports	NRAS codon 12, 61  missense mutation resistance	OHSU Import; NRAS codon 12, 61  missense mutation; organ=Colon; 	NCCN guidelines	20619739						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-12;  NRAS codon 12, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 61 missense mutation; organ=Lung; 	preclinical	23515407						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 61 missense mutation; organ=Lung; 	preclinical	23515407						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-12;  NRAS codon 12, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 61 missense mutation; organ=Lung; 	preclinical	23515407						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 61 missense mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 61 missense mutation; organ=Lung; 	preclinical	23515407						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	NRAS Q61 missense mutation resistance	OHSU Import; NRAS Q61 missense mutation; 	case report	23569304						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	ERK inhibitors	N/A	sensitivity	Supports	NRAS Q61 missense mutation sensitivity	OHSU Import; NRAS Q61 missense mutation; 	preclinical	23614898						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	HSP90 inhibitors	N/A	sensitivity	Supports	NRAS Q61 missense mutation sensitivity	OHSU Import; NRAS Q61 missense mutation; 	preclinical	23538902						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	NRAS Q61 missense mutation response	OHSU Import; NRAS Q61 missense mutation; 	late trials	23414587						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	NRAS Q61 missense mutation response	OHSU Import; NRAS Q61 missense mutation; 	early trials	18390968						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	binimetinib + LEE011	N/A	response	Supports	NRAS Q61 missense mutation response	OHSU Import; NRAS Q61 missense mutation; 	early trials	N/A						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	NRAS Q61 missense mutation response	OHSU Import; NRAS Q61 missense mutation; 	late trials	23414587						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS Q61 missense mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	response	Supports	NRAS Q61 missense mutation response	OHSU Import; NRAS Q61 missense mutation; 	early trials	18390968						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:12-13;  NRAS codon 12, 13, 61 missense mutation		Unknown	MYELOMA	0070004	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 13, 61 missense mutation; 	preclinical	22985491						1				N/A						1	
NRAS	4893	transcript:CCDS877.1;  amino_acid:61-61;  NRAS codon 12, 13, 61 missense mutation		Unknown	MYELOMA	0070004	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	NRAS codon 12, 13, 61 missense mutation sensitivity	OHSU Import; NRAS codon 12, 13, 61 missense mutation; 	preclinical	22985491						1				N/A						1	
AKT1	207	cdna:c.49G>A; protein:p.E17K/p.Glu17Lys; AKT1 E17K missense mutation	14:105246551-105246551 (C->T)	Unknown	Ductal carcinoma	3587	allosteric AKT inhibitors	N/A	sensitivity	Supports	AKT1 E17K missense mutation sensitivity	OHSU Import; AKT1 E17K missense mutation; organ=Breast; 	preclinical	17611497						1				N/A						1	
AKT1	207	cdna:c.49G>A; protein:p.E17K/p.Glu17Lys; AKT1 E17K missense mutation	14:105246551-105246551 (C->T)	Unknown	Malignant neoplasm, NOS	5074	AKT inhibitors	N/A	sensitivity	Supports	AKT1 E17K missense mutation sensitivity	OHSU Import; AKT1 E17K missense mutation; 	preclinical	17611497						1				N/A						1	
AKT1	207	protein:p.Q79K/; AKT1 Q79K missense mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	AKT1 Q79K missense mutation resistance	OHSU Import; AKT1 Q79K missense mutation; 	preclinical	24265152						1				N/A						1	
AKT1	207	cdna:c.49G>A; protein:p.E17K/p.Glu17Lys; AKT1 E17K missense mutation	14:105246551-105246551 (C->T)	Unknown	Serous carcinoma, high grade	3230	AKT inhibitors	N/A	response	Supports	AKT1 E17K missense mutation response	OHSU Import; AKT1 E17K missense mutation; organ=Ovary; 	case report	N/A						1				N/A						1	
PDGFRA	5156	PDGFRA rearrangement fusion gene		Unknown	Chronic eosinophilic leukaemia, NOS	9502	imatinib	5291	response	Supports	PDGFRA rearrangement fusion gene response	OHSU Import; PDGFRA rearrangement fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
SYK	6850	SYK amplification copy number gain		Unknown	Mantle cell lymphoma	0050746	SYK inhibitors	N/A	sensitivity	Supports	SYK amplification copy number gain sensitivity	OHSU Import; SYK amplification copy number gain; organ=Lymph Node; 	preclinical	16409295						1				N/A						1	
NOTCH1	4851	NOTCH1 any mutation 		Unknown	Mantle cell lymphoma	0050746	Gamma secretase inhibitors	N/A	sensitivity	Supports	NOTCH1 any mutation  sensitivity	OHSU Import; NOTCH1 any mutation ; organ=Lymph Node; 	preclinical	22210878						1				N/A						1	
CRLF2	64109	CRLF2 rearrangement fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	BET inhibitors	N/A	sensitivity	Supports	CRLF2 rearrangement fusion gene sensitivity	OHSU Import; CRLF2 rearrangement fusion gene; 	preclinical	22904298						1				N/A						1	
NOTCH1	4851	NOTCH1 rearrangement fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	Gamma secretase inhibitors	N/A	sensitivity	Supports	NOTCH1 rearrangement fusion gene sensitivity	OHSU Import; NOTCH1 rearrangement fusion gene; 	preclinical	16688224						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	imatinib	5291	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; 	FDA-approved	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	nilotinib	644241	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; 	NCCN guidelines	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ponatinib	24826799	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; 	FDA-approved	N/A						1				N/A						1	
BCR	613	BCR JAK2 fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ruxolitinib	25126798	sensitivity	Supports	BCR JAK2 fusion gene sensitivity	OHSU Import; BCR JAK2 fusion gene; 	preclinical	22897847						1				N/A						1	
JAK1	3716	JAK1 S646F missense mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ruxolitinib	25126798	sensitivity	Supports	JAK1 S646F missense mutation sensitivity	OHSU Import; JAK1 S646F missense mutation; 	preclinical	22955920						1				N/A						1	
JAK2	3717	JAK2 rearrangement fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	ruxolitinib	25126798	sensitivity	Supports	JAK2 rearrangement fusion gene sensitivity	OHSU Import; JAK2 rearrangement fusion gene; 	preclinical	22875628						1				N/A						1	
FBXW7	55294	FBXW7 any mutation		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	steroids	N/A	response	Supports	FBXW7 any mutation response	OHSU Import; FBXW7 any mutation; 	late trials	20861909						1				N/A						1	
CRLF2	64109	CRLF2 rearrangement fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	mTOR inhibitors	N/A	sensitivity	Supports	CRLF2 rearrangement fusion gene sensitivity	OHSU Import; CRLF2 rearrangement fusion gene; 	preclinical	N/A						1				N/A						1	
CRLF2	64109	CRLF2 rearrangement fusion gene		Unknown	ACUTE LYMPHOCYTIC LEUKEMIA	9952	mTOR inhibitors	N/A	sensitivity	Supports	CRLF2 rearrangement fusion gene sensitivity	OHSU Import; CRLF2 rearrangement fusion gene; 	preclinical	N/A						1				N/A						1	
NPM1	4869	NPM1 any mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	ATRA		response	Supports	NPM1 any mutation response	OHSU Import; NPM1 any mutation; organ=Bone marrow; 	late trials	19059939						1				N/A						1	
PML	5371	PML RARA fusion gene		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	ATRA + arsenic trioxide	N/A	response	Supports	PML RARA fusion gene response	OHSU Import; PML RARA fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
MLL	-1	MLL  rearrangement fusion gene		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	BET inhibitors	N/A	sensitivity	Supports	MLL  rearrangement fusion gene sensitivity	OHSU Import; MLL  rearrangement fusion gene; organ=Bone marrow; 	preclinical	21964340						1				N/A						1	
DNMT3A	1788	DNMT3A any mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	daunorubicin	30323	response	Supports	DNMT3A any mutation response	OHSU Import; DNMT3A any mutation; organ=Bone marrow; 	FDA-approved	22417203						1				N/A						1	
MLL	-1	MLL  rearrangement fusion gene		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	daunorubicin	30323	response	Supports	MLL  rearrangement fusion gene response	OHSU Import; MLL  rearrangement fusion gene; organ=Bone marrow; 	FDA-approved	22417203						1				N/A						1	
NPM1	4869	NPM1 any mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	daunorubicin	30323	response	Supports	NPM1 any mutation response	OHSU Import; NPM1 any mutation; organ=Bone marrow; 	FDA-approved	22417203						1				N/A						1	
MLL	-1	MLL  rearrangement fusion gene		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	DOT1L inhibitors	N/A	sensitivity	Supports	MLL  rearrangement fusion gene sensitivity	OHSU Import; MLL  rearrangement fusion gene; organ=Bone marrow; 	preclinical	21741596						1				N/A						1	
MLL	-1	MLL  rearrangement fusion gene		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	HDAC inhibitors	N/A	sensitivity	Supports	MLL  rearrangement fusion gene sensitivity	OHSU Import; MLL  rearrangement fusion gene; organ=Bone marrow; 	preclinical	22015773						1				N/A						1	
IDH2	3418	IDH2 R172K missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	IDH inhibitors	N/A	response	Supports	IDH2 R172K missense mutation response	OHSU Import; IDH2 R172K missense mutation; organ=Bone marrow; 	early trials	N/A						1				N/A						1	
KRAS	3845	KRAS any mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	MEK inhibitors	N/A	sensitivity	Supports	KRAS any mutation sensitivity	OHSU Import; KRAS any mutation; organ=Bone marrow; 	preclinical	22507781						1				N/A						1	
NRAS	4893	NRAS any mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	MEK inhibitors	N/A	sensitivity	Supports	NRAS any mutation sensitivity	OHSU Import; NRAS any mutation; organ=Bone marrow; 	preclinical	22507781						1				N/A						1	
HRAS	3265	HRAS any missense mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	MEK inhibitors +/- mTOR inhibitors	N/A	sensitivity	Supports	HRAS any missense mutation sensitivity	OHSU Import; HRAS any missense mutation; organ=Bone marrow; 	preclinical	22399013						1				N/A						1	
KRAS	3845	KRAS any mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	MEK inhibitors	N/A	sensitivity	Supports	KRAS any mutation sensitivity	OHSU Import; KRAS any mutation; organ=Bone marrow; 	preclinical	22507781						1				N/A						1	
NRAS	4893	NRAS any mutation		Unknown	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	9119	MEK inhibitors	N/A	sensitivity	Supports	NRAS any mutation sensitivity	OHSU Import; NRAS any mutation; organ=Bone marrow; 	preclinical	22507781						1				N/A						1	
TSC1	7248	TSC1 any mutation		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	TSC1 any mutation sensitivity	OHSU Import; TSC1 any mutation; organ=Soft tissue; 	early trials	20048174						1				N/A						1	
TSC2	7249	TSC2 any  mutation   		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	TSC2 any  mutation    sensitivity	OHSU Import; TSC2 any  mutation   ; organ=Soft tissue; 	early trials	20048174						1				N/A						1	
TSC1	7248	TSC1 any mutation		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	TSC1 any mutation sensitivity	OHSU Import; TSC1 any mutation; organ=Soft tissue; 	early trials	20048174						1				N/A						1	
TSC2	7249	TSC2 any  mutation   		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	TSC2 any  mutation    sensitivity	OHSU Import; TSC2 any  mutation   ; organ=Soft tissue; 	early trials	20048174						1				N/A						1	
PTCH1	5727	PTCH1 any mutation  		Unknown	Basal cell carcinoma	2513	vismodegib	24776445	sensitivity	Supports	PTCH1 any mutation   sensitivity	OHSU Import; PTCH1 any mutation  ; organ=Skin; 	FDA-approved	19726761						1				N/A						1	
FGFR2	2263	FGFR2 rearrangement fusion gene		Unknown	Cholangiocarcinoma	4947	FGFR inhibitors	N/A	sensitivity	Supports	FGFR2 rearrangement fusion gene sensitivity	OHSU Import; FGFR2 rearrangement fusion gene; organ=Bile duct; 	preclinical	23558953						1				N/A						1	
ERCC2	2068	ERCC2 any mutation		Unknown	Urothelial carcinoma	6166	cisplatin	N/A	response	Supports	ERCC2 any mutation response	OHSU Import; ERCC2 any mutation; organ=Bladder; 	early trials	25096233						1				N/A						1	
PIK3R1	5295	PIK3R1 any  mutation		Unknown	Glioma	3070	AKT inhibitors	N/A	sensitivity	Supports	PIK3R1 any  mutation sensitivity	OHSU Import; PIK3R1 any  mutation; organ=Brain; 	preclinical	23166678						1				N/A						1	
CDKN2A	1029	CDKN2A any mutation		Unknown	Glioma	3070	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2A any mutation sensitivity	OHSU Import; CDKN2A any mutation; organ=Brain; 	preclinical	22586120						1				N/A						1	
CDKN2A	1029	CDKN2A any copy number loss		Unknown	Glioma	3070	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2A any copy number loss sensitivity	OHSU Import; CDKN2A any copy number loss; organ=Brain; 	preclinical	22586120						1				N/A						1	
CDKN2B	1030	CDKN2B any mutation		Unknown	Glioma	3070	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2B any mutation sensitivity	OHSU Import; CDKN2B any mutation; organ=Brain; 	preclinical	22711607						1				N/A						1	
CDKN2B	1030	CDKN2B any copy number loss		Unknown	Glioma	3070	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2B any copy number loss sensitivity	OHSU Import; CDKN2B any copy number loss; organ=Brain; 	preclinical	22711607						1				N/A						1	
CDKN2C	1031	CDKN2C any mutation		Unknown	Glioma	3070	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2C any mutation sensitivity	OHSU Import; CDKN2C any mutation; organ=Brain; 	preclinical	22711607						1				N/A						1	
CDKN2C	1031	CDKN2C any copy number loss		Unknown	Glioma	3070	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2C any copy number loss sensitivity	OHSU Import; CDKN2C any copy number loss; organ=Brain; 	preclinical	22711607						1				N/A						1	
MET	4233	MET amplification copy number gain		Unknown	Glioma	3070	crizotinib	11626560	response	Supports	MET amplification copy number gain response	OHSU Import; MET amplification copy number gain; organ=Brain; 	case report	22162573						1				N/A						1	
EGFR	1956	EGFR amplification copy number gain		Unknown	Glioma	3070	EGFR TKIs	N/A	no response	Supports	EGFR amplification copy number gain no response	OHSU Import; EGFR amplification copy number gain; organ=Brain; 	early trials	16278407						1				N/A						1	
FGFR3	2261	FGFR3 rearrangement fusion gene		Unknown	Glioma	3070	FGFR inhibitors	N/A	sensitivity	Supports	FGFR3 rearrangement fusion gene sensitivity	OHSU Import; FGFR3 rearrangement fusion gene; organ=Brain; 	early trials	N/A						1				N/A						1	
STAG2	10735	STAG2 any mutation		Unknown	Glioma	3070	PARP inhibitors	N/A	sensitivity	Supports	STAG2 any mutation sensitivity	OHSU Import; STAG2 any mutation; organ=Brain; 	preclinical	24356817						1				N/A						1	
PDGFRA	5156	PDGFRA amplification copy number gain		Unknown	Glioma	3070	PDGFR inhibitors	N/A	no sensitivity	Supports	PDGFRA amplification copy number gain no sensitivity	OHSU Import; PDGFRA amplification copy number gain; organ=Brain; 	preclinical	23544171						1				N/A						1	
PIK3CA	5290	PIK3CA  any mutation		Unknown	Glioma	3070	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA  any mutation sensitivity	OHSU Import; PIK3CA  any mutation; organ=Brain; 	preclinical	19671762						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Glioma	3070	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Brain; 	preclinical	17804702						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Glioma	3070	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Brain; 	preclinical	17804702						1				N/A						1	
ATM	472	ATM any mutation		Unknown	Glioma	3070	temozolomide	5394	sensitivity	Supports	ATM any mutation sensitivity	OHSU Import; ATM any mutation; organ=Brain; 	preclinical	23960094						1				N/A						1	
ATR	545	ATR any mutation		Unknown	Glioma	3070	temozolomide	5394	sensitivity	Supports	ATR any mutation sensitivity	OHSU Import; ATR any mutation; organ=Brain; 	preclinical	23960094						1				N/A						1	
MGMT	4255	MGMT any promoter methylation		Unknown	Glioma	3070	temozolomide	5394	increased benefit	Supports	MGMT any promoter methylation increased benefit	OHSU Import; MGMT any promoter methylation; organ=Brain; 	late trials	15758010						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Glioma	3070	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Brain; 	preclinical	19573811						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Glioma	3070	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Brain; 	preclinical	19573811						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Glioma	3070	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Brain; 	preclinical	19573811						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Glioma	3070	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Brain; 	preclinical	19573811						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	ado-trastuzumab emtansine	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	FDA-approved	N/A						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	afatinib	10184653	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	late trials	20142587						1				N/A						1	
TOP2A	7153	TOP2A amplification copy number gain		Unknown	Ductal carcinoma	3587	anthracyclines	N/A	sensitivity	Supports	TOP2A amplification copy number gain sensitivity	OHSU Import; TOP2A amplification copy number gain; organ=Breast; 	late trials	22864769						1				N/A						1	
ESR1	2099	ESR1 YAP1 fusion gene		Unknown	Ductal carcinoma	3587	anti-estrogens	N/A	resistance	Supports	ESR1 YAP1 fusion gene resistance	OHSU Import; ESR1 YAP1 fusion gene; organ=Breast; 	preclinical	24055055						1				N/A						1	
GATA3	2625	GATA3 any mutation		Unknown	Ductal carcinoma	3587	aromatase inhhibitors	N/A	sensitivity	Supports	GATA3 any mutation sensitivity	OHSU Import; GATA3 any mutation; organ=Breast; 	preclinical	24758297						1				N/A						1	
MAGI3	260425	MAGI3 AKT3 fusion gene		Unknown	Ductal carcinoma	3587	ATP-competitive AKT inhibitors	N/A	sensitivity	Supports	MAGI3 AKT3 fusion gene sensitivity	OHSU Import; MAGI3 AKT3 fusion gene; organ=Breast; 	preclinical	22722202						1				N/A						1	
FGF3	2248	FGF3 amplification copy number gain		Unknown	Ductal carcinoma	3587	dovitinib	9886808	response	Supports	FGF3 amplification copy number gain response	OHSU Import; FGF3 amplification copy number gain; organ=Breast; 	early trials	23658459						1				N/A						1	
FGF4	2249	FGF4 amplification copy number gain		Unknown	Ductal carcinoma	3587	dovitinib	9886808	response	Supports	FGF4 amplification copy number gain response	OHSU Import; FGF4 amplification copy number gain; organ=Breast; 	early trials	23658459						1				N/A						1	
FGFR1	2260	FGFR1 amplification copy number gain		Unknown	Ductal carcinoma	3587	FGFR inhibitors	N/A	response	Supports	FGFR1 amplification copy number gain response	OHSU Import; FGFR1 amplification copy number gain; organ=Breast; 	early trials	N/A						1				N/A						1	
FGFR2	2263	FGFR2 amplification copy number gain		Unknown	Ductal carcinoma	3587	FGFR inhibitors	N/A	response	Supports	FGFR2 amplification copy number gain response	OHSU Import; FGFR2 amplification copy number gain; organ=Breast; 	case report	N/A						1				N/A						1	
NOTCH1	4851	NOTCH1 rearrangement fusion gene		Unknown	Ductal carcinoma	3587	Gamma secretase inhibitors	N/A	sensitivity	Supports	NOTCH1 rearrangement fusion gene sensitivity	OHSU Import; NOTCH1 rearrangement fusion gene; organ=Breast; 	preclinical	22101766						1				N/A						1	
NOTCH2	4853	NOTCH2 rearrangement fusion gene		Unknown	Ductal carcinoma	3587	Gamma secretase inhibitors	N/A	sensitivity	Supports	NOTCH2 rearrangement fusion gene sensitivity	OHSU Import; NOTCH2 rearrangement fusion gene; organ=Breast; 	preclinical	22101766						1				N/A						1	
NTRK3	4916	NTRK3 rearrangement fusion gene		Unknown	Ductal carcinoma	3587	IGF1R inhibitors	N/A	sensitivity	Supports	NTRK3 rearrangement fusion gene sensitivity	OHSU Import; NTRK3 rearrangement fusion gene; organ=Breast; 	preclinical	21148487						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	lapatinib	208908	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	FDA-approved	N/A						1				N/A						1	
NTRK3	4916	NTRK3 rearrangement fusion gene		Unknown	Ductal carcinoma	3587	midostaurin	9829523	sensitivity	Supports	NTRK3 rearrangement fusion gene sensitivity	OHSU Import; NTRK3 rearrangement fusion gene; organ=Breast; 	preclinical	21148487						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	neratinib	9915743	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	late trials	20142587						1				N/A						1	
BRCA1	672	BRCA1 any mutation 		Unknown	Ductal carcinoma	3587	PARP inhibitors	N/A	sensitivity	Supports	BRCA1 any mutation  sensitivity	OHSU Import; BRCA1 any mutation ; organ=Breast; 	early trials	20609467						1				N/A						1	
BRCA2	675	BRCA2 any mutation 		Unknown	Ductal carcinoma	3587	PARP inhibitors	N/A	sensitivity	Supports	BRCA2 any mutation  sensitivity	OHSU Import; BRCA2 any mutation ; organ=Breast; 	early trials	20609467						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	pertuzumab	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	FDA-approved	N/A						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Ductal carcinoma	3587	PI3K alpha inhibitors	N/A	response	Supports	PIK3CA any  mutation response	OHSU Import; PIK3CA any  mutation; organ=Breast; 	early trials	N/A						1				N/A						1	
INPP4B	8821	INPP4B any mutation		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	sensitivity	Supports	INPP4B any mutation sensitivity	OHSU Import; INPP4B any mutation; organ=Breast; 	preclinical	23551093						1				N/A						1	
INPP4B	8821	INPP4B any copy number loss		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	sensitivity	Supports	INPP4B any copy number loss sensitivity	OHSU Import; INPP4B any copy number loss; organ=Breast; 	preclinical	23551093						1				N/A						1	
NTRK3	4916	NTRK3 rearrangement fusion gene		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	sensitivity	Supports	NTRK3 rearrangement fusion gene sensitivity	OHSU Import; NTRK3 rearrangement fusion gene; organ=Breast; 	preclinical	21148487						1				N/A						1	
PDPK1	5170	PDPK1 amplification copy number gain		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	sensitivity	Supports	PDPK1 amplification copy number gain sensitivity	OHSU Import; PDPK1 amplification copy number gain; organ=Breast; 	preclinical	19602588						1				N/A						1	
PIK3CA	5290	PIK3CA amplification copy number gain		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	resistance	Supports	PIK3CA amplification copy number gain resistance	OHSU Import; PIK3CA amplification copy number gain; organ=Breast; 	preclinical	24366379						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Breast; 	preclinical	22932669						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Breast; 	preclinical	22932669						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	response	Supports	PIK3CA any  mutation response	OHSU Import; PIK3CA any  mutation; organ=Breast; 	early trials	22271473						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Ductal carcinoma	3587	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA any  mutation sensitivity	OHSU Import; PIK3CA any  mutation; organ=Breast; 	preclinical	18829560						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	trastuzumab	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	FDA-approved	N/A						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	trastuzumab + everolimus + chemotherapy	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	early trials	20975068						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	trastuzumab + HSP90 inhibitors	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	early trials	21558407						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Ductal carcinoma	3587	trastuzumab + PI3K pathway inhibitors	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Breast; 	early trials	N/A						1				N/A						1	
HGF	3082	HGF amplification copy number gain		Unknown	Ductal carcinoma	3587	trastuzumab	N/A	resistance	Supports	HGF amplification copy number gain resistance	OHSU Import; HGF amplification copy number gain; organ=Breast; 	early trials	22850551						1				N/A						1	
MET	4233	MET amplification copy number gain		Unknown	Ductal carcinoma	3587	trastuzumab	N/A	resistance	Supports	MET amplification copy number gain resistance	OHSU Import; MET amplification copy number gain; organ=Breast; 	early trials	22850551						1				N/A						1	
FBXW7	55294	FBXW7 any mutation		Unknown	Malignant neoplasm, NOS	5074	anti-tubulin agents	N/A	resistance	Supports	FBXW7 any mutation resistance	OHSU Import; FBXW7 any mutation; 	preclinical	21368834						1				N/A						1	
FBXW7	55294	FBXW7 any copy number loss		Unknown	Malignant neoplasm, NOS	5074	anti-tubulin agents	N/A	resistance	Supports	FBXW7 any copy number loss resistance	OHSU Import; FBXW7 any copy number loss; 	preclinical	21368834						1				N/A						1	
MCL1	4170	MCL1 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	anti-tubulin agents	N/A	resistance	Supports	MCL1 amplification copy number gain resistance	OHSU Import; MCL1 amplification copy number gain; 	preclinical	21368834						1				N/A						1	
AURKA	6790	AURKA amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	AURK inhibitors	N/A	sensitivity	Supports	AURKA amplification copy number gain sensitivity	OHSU Import; AURKA amplification copy number gain; 	preclinical	22302096						1				N/A						1	
CCNE1	898	CCNE1 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	CDK2 inhibitors	N/A	sensitivity	Supports	CCNE1 amplification copy number gain sensitivity	OHSU Import; CCNE1 amplification copy number gain; 	preclinical	22471707						1				N/A						1	
CDKN2C	1031	CDKN2C any mutation		Unknown	Malignant neoplasm, NOS	5074	CDK2 inhibitors	N/A	sensitivity	Supports	CDKN2C any mutation sensitivity	OHSU Import; CDKN2C any mutation; 	preclinical	22471707						1				N/A						1	
CDKN2C	1031	CDKN2C any copy number loss		Unknown	Malignant neoplasm, NOS	5074	CDK2 inhibitors	N/A	sensitivity	Supports	CDKN2C any copy number loss sensitivity	OHSU Import; CDKN2C any copy number loss; 	preclinical	22471707						1				N/A						1	
CDKN1A	1026	CDKN1A any mutation		Unknown	Malignant neoplasm, NOS	5074	CDK2/4 inhibitors	N/A	sensitivity	Supports	CDKN1A any mutation sensitivity	OHSU Import; CDKN1A any mutation; 	preclinical	22471707						1				N/A						1	
CDKN1A	1026	CDKN1A any copy number loss		Unknown	Malignant neoplasm, NOS	5074	CDK2/4 inhibitors	N/A	sensitivity	Supports	CDKN1A any copy number loss sensitivity	OHSU Import; CDKN1A any copy number loss; 	preclinical	22471707						1				N/A						1	
CDKN1B	1027	CDKN1B any mutation		Unknown	Malignant neoplasm, NOS	5074	CDK2/4 inhibitors	N/A	sensitivity	Supports	CDKN1B any mutation sensitivity	OHSU Import; CDKN1B any mutation; 	preclinical	22471707						1				N/A						1	
CDKN1B	1027	CDKN1B any copy number loss		Unknown	Malignant neoplasm, NOS	5074	CDK2/4 inhibitors	N/A	sensitivity	Supports	CDKN1B any copy number loss sensitivity	OHSU Import; CDKN1B any copy number loss; 	preclinical	22471707						1				N/A						1	
CCND1	595	CCND1 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CCND1 amplification copy number gain sensitivity	OHSU Import; CCND1 amplification copy number gain; 	preclinical	22471707						1				N/A						1	
CCND2	894	CCND2 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CCND2 amplification copy number gain sensitivity	OHSU Import; CCND2 amplification copy number gain; 	preclinical	22471707						1				N/A						1	
CCND3	896	CCND3 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CCND3 amplification copy number gain sensitivity	OHSU Import; CCND3 amplification copy number gain; 	preclinical	22471707						1				N/A						1	
CDKN2A	1029	CDKN2A any mutation		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2A any mutation sensitivity	OHSU Import; CDKN2A any mutation; 	preclinical	22471707						1				N/A						1	
CDKN2A	1029	CDKN2A any copy number loss		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2A any copy number loss sensitivity	OHSU Import; CDKN2A any copy number loss; 	preclinical	22471707						1				N/A						1	
CDKN2B	1030	CDKN2B any mutation		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2B any mutation sensitivity	OHSU Import; CDKN2B any mutation; 	preclinical	22471707						1				N/A						1	
CDKN2B	1030	CDKN2B any copy number loss		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDKN2B any copy number loss sensitivity	OHSU Import; CDKN2B any copy number loss; 	preclinical	22471707						1				N/A						1	
CDK6	1021	CDK6 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDK6 amplification copy number gain sensitivity	OHSU Import; CDK6 amplification copy number gain; 	preclinical	22471707						1				N/A						1	
EPHA2	1969	EPHA2 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	dasatinib	3062316	sensitivity	Supports	EPHA2 amplification copy number gain sensitivity	OHSU Import; EPHA2 amplification copy number gain; 	preclinical	18047674						1				N/A						1	
ATM	472	ATM any mutation		Unknown	Malignant neoplasm, NOS	5074	DNA-PK inhibitors	N/A	sensitivity	Supports	ATM any mutation sensitivity	OHSU Import; ATM any mutation; 	preclinical	23761041						1				N/A						1	
ATM	472	ATM any copy number loss		Unknown	Malignant neoplasm, NOS	5074	DNA-PK inhibitors	N/A	sensitivity	Supports	ATM any copy number loss sensitivity	OHSU Import; ATM any copy number loss; 	preclinical	23761041						1				N/A						1	
MSH3	4437	MSH3 any mutation		Unknown	Malignant neoplasm, NOS	5074	DNA-PK inhibitors	N/A	sensitivity	Supports	MSH3 any mutation sensitivity	OHSU Import; MSH3 any mutation; 	preclinical	24556366						1				N/A						1	
EPHA3	2042	EPHA3 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	EPHA3 inhibitors	N/A	sensitivity	Supports	EPHA3 amplification copy number gain sensitivity	OHSU Import; EPHA3 amplification copy number gain; 	preclinical	25125683						1				N/A						1	
ATM	472	ATM any mutation		Unknown	Malignant neoplasm, NOS	5074	PARP inhibitors	N/A	sensitivity	Supports	ATM any mutation sensitivity	OHSU Import; ATM any mutation; 	preclinical	21300883						1				N/A						1	
ATM	472	ATM any copy number loss		Unknown	Malignant neoplasm, NOS	5074	PARP inhibitors	N/A	sensitivity	Supports	ATM any copy number loss sensitivity	OHSU Import; ATM any copy number loss; 	preclinical	21300883						1				N/A						1	
ATR	545	ATR any mutation		Unknown	Malignant neoplasm, NOS	5074	PARP inhibitors	N/A	sensitivity	Supports	ATR any mutation sensitivity	OHSU Import; ATR any mutation; 	preclinical	23548269						1				N/A						1	
ATR	545	ATR any copy number loss		Unknown	Malignant neoplasm, NOS	5074	PARP inhibitors	N/A	sensitivity	Supports	ATR any copy number loss sensitivity	OHSU Import; ATR any copy number loss; 	preclinical	23548269						1				N/A						1	
BAP1	8314	BAP1 any mutation		Unknown	Malignant neoplasm, NOS	5074	PARP inhibitors	N/A	sensitivity	Supports	BAP1 any mutation sensitivity	OHSU Import; BAP1 any mutation; 	preclinical	22683710						1				N/A						1	
BAP1	8314	BAP1 any copy number loss		Unknown	Malignant neoplasm, NOS	5074	PARP inhibitors	N/A	sensitivity	Supports	BAP1 any copy number loss sensitivity	OHSU Import; BAP1 any copy number loss; 	preclinical	22683710						1				N/A						1	
CD274	29126	CD274 amplification copy number gain		Unknown	Malignant neoplasm, NOS	5074	PDL1 inhibitors	N/A	sensitivity	Supports	CD274 amplification copy number gain sensitivity	OHSU Import; CD274 amplification copy number gain; 	preclinical	25079317						1				N/A						1	
PTEN	5728	PTEN  any mutation  		Unknown	Malignant neoplasm, NOS	5074	PI3K beta inhibitors	N/A	sensitivity	Supports	PTEN  any mutation   sensitivity	OHSU Import; PTEN  any mutation  ; 	preclinical	N/A						1				N/A						1	
PTEN	5728	PTEN  any copy number loss		Unknown	Malignant neoplasm, NOS	5074	PI3K beta inhibitors	N/A	sensitivity	Supports	PTEN  any copy number loss sensitivity	OHSU Import; PTEN  any copy number loss; 	preclinical	N/A						1				N/A						1	
PTEN	5728	PTEN  any mutation  		Unknown	Malignant neoplasm, NOS	5074	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN  any mutation   sensitivity	OHSU Import; PTEN  any mutation  ; 	preclinical	21673091						1				N/A						1	
PTEN	5728	PTEN  any copy number loss		Unknown	Malignant neoplasm, NOS	5074	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN  any copy number loss sensitivity	OHSU Import; PTEN  any copy number loss; 	preclinical	21673091						1				N/A						1	
PTEN	5728	PTEN any  mutation		Unknown	Malignant neoplasm, NOS	5074	sirolimus	5284616	sensitivity	Supports	PTEN any  mutation sensitivity	OHSU Import; PTEN any  mutation; 	early trials	N/A						1				N/A						1	
BRCA1	672	BRCA1 any mutation		Unknown	Malignant neoplasm, NOS	5074	wee1 inhibitors	N/A	response	Supports	BRCA1 any mutation response	OHSU Import; BRCA1 any mutation; 	case report	N/A						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Malignant neoplasm, NOS	5074	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; 	preclinical	19541609						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Malignant neoplasm, NOS	5074	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; 	preclinical	19541609						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Malignant neoplasm, NOS	5074	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; 	preclinical	19541609						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Malignant neoplasm, NOS	5074	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; 	preclinical	19541609						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Squamous cell carcinoma	1749	PI3K pathway inhibitors	N/A	response	Supports	PIK3CA any  mutation response	OHSU Import; PIK3CA any  mutation; organ=Cervix; 	early trials	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	chronic myeloid leukemia (CML)	8552	bosutinib	5328940	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	chronic myeloid leukemia (CML)	8552	dasatinib	3062316	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	chronic myeloid leukemia (CML)	8552	imatinib	5291	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	chronic myeloid leukemia (CML)	8552	nilotinib	644241	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
BCR	613	BCR ABL1 fusion gene		Unknown	chronic myeloid leukemia (CML)	8552	ponatinib	24826799	response	Supports	BCR ABL1 fusion gene response	OHSU Import; BCR ABL1 fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
PRKCH	5583	PRKCH amplification copy number gain		Unknown	chronic myeloid leukemia (CML)	8552	trametinib	11707110	sensitivity	Supports	PRKCH amplification copy number gain sensitivity	OHSU Import; PRKCH amplification copy number gain; organ=Bone marrow; 	preclinical	25186176						1				N/A						1	
MLH1	4292	MLH1 any mutation		Unknown	Adenocarcinoma	299	5FU-based adjuvant therapy	N/A	detrimental effect	Supports	MLH1 any mutation detrimental effect	OHSU Import; MLH1 any mutation; organ=Colon; 	late trials	20498393						1				N/A						1	
MSH1	-1	MSH1 any mutation		Unknown	Adenocarcinoma	299	5FU-based adjuvant therapy	N/A	detrimental effect	Supports	MSH1 any mutation detrimental effect	OHSU Import; MSH1 any mutation; organ=Colon; 	late trials	20498393						1				N/A						1	
MSH2	4436	MSH2 any mutation		Unknown	Adenocarcinoma	299	5FU-based adjuvant therapy	N/A	detrimental effect	Supports	MSH2 any mutation detrimental effect	OHSU Import; MSH2 any mutation; organ=Colon; 	late trials	20498393						1				N/A						1	
MSH3	4437	MSH3 any mutation		Unknown	Adenocarcinoma	299	5FU-based adjuvant therapy	N/A	detrimental effect	Supports	MSH3 any mutation detrimental effect	OHSU Import; MSH3 any mutation; organ=Colon; 	late trials	20498393						1				N/A						1	
MSH6	2956	MSH6 any mutation		Unknown	Adenocarcinoma	299	5FU-based adjuvant therapy	N/A	detrimental effect	Supports	MSH6 any mutation detrimental effect	OHSU Import; MSH6 any mutation; organ=Colon; 	late trials	20498393						1				N/A						1	
PMS2	5395	PMS2 any mutation		Unknown	Adenocarcinoma	299	5FU-based adjuvant therapy	N/A	detrimental effect	Supports	PMS2 any mutation detrimental effect	OHSU Import; PMS2 any mutation; organ=Colon; 	late trials	20498393						1				N/A						1	
EGFR	1956	EGFR amplification copy number gain		Unknown	Adenocarcinoma	299	anti-EGFR mAbs	N/A	response	Supports	EGFR amplification copy number gain response	OHSU Import; EGFR amplification copy number gain; organ=Colon; 	late trials	17664472						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Adenocarcinoma	299	anti-EGFR mAbs	N/A	resistance	Supports	ERBB2 amplification copy number gain resistance	OHSU Import; ERBB2 amplification copy number gain; organ=Colon; 	early trials	22586653						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Adenocarcinoma	299	anti-EGFR mAbs	N/A	resistance	Supports	PTEN any mutation   resistance	OHSU Import; PTEN any mutation  ; organ=Colon; 	late trials	19398573						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Adenocarcinoma	299	anti-EGFR mAbs	N/A	resistance	Supports	PTEN any copy number loss resistance	OHSU Import; PTEN any copy number loss; organ=Colon; 	late trials	19398573						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Adenocarcinoma	299	anti-EGFR mAbs + anti-HER2 mAbs	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Colon; 	preclinical	22586653						1				N/A						1	
PIK3CA	5290	PIK3CA any   mutation		Unknown	Adenocarcinoma	299	aspirin in adjuvant setting	N/A	response	Supports	PIK3CA any   mutation response	OHSU Import; PIK3CA any   mutation; organ=Colon; 	late trials	23094721						1				N/A						1	
KRAS	3845	KRAS wild type no mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	response	Supports	KRAS wild type no mutation response	OHSU Import; KRAS wild type no mutation; organ=Colon; 	FDA-approved	N/A						1				N/A						1	
PIK3CA	5290	PIK3CA any   mutation		Unknown	Adenocarcinoma	299	cetuximab	N/A	resistance	Supports	PIK3CA any   mutation resistance	OHSU Import; PIK3CA any   mutation; organ=Colon; 	late trials	19223544						1				N/A						1	
NTRK1	4914	NTRK1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	TRK inhibitors	N/A	response	Supports	NTRK1 rearrangement fusion gene response	OHSU Import; NTRK1 rearrangement fusion gene; organ=Colon; 	case report	N/A						1				N/A						1	
KRAS	3845	KRAS wild type no mutation		Unknown	Adenocarcinoma	299	panitumumab	N/A	response	Supports	KRAS wild type no mutation response	OHSU Import; KRAS wild type no mutation; organ=Colon; 	FDA-approved	N/A						1				N/A						1	
PIK3CA	5290	PIK3CA any   mutation		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA any   mutation sensitivity	OHSU Import; PIK3CA any   mutation; organ=Colon; 	preclinical	22392911						1				N/A						1	
APC	324	APC any mutation		Unknown	Adenocarcinoma	299	tankyrase inhibitors	N/A	sensitivity	Supports	APC any mutation sensitivity	OHSU Import; APC any mutation; organ=Colon; 	preclinical	22440753						1				N/A						1	
CTNNB1	1499	CTNNB1 any mutation		Unknown	Adenocarcinoma	299	tankyrase inhibitors	N/A	resistance	Supports	CTNNB1 any mutation resistance	OHSU Import; CTNNB1 any mutation; organ=Colon; 	preclinical	23539443						1				N/A						1	
COL1A1	1277	COL1A1 PDGFRB fusion gene		Unknown	Dermatofibrosarcoma protuberans	3507	imatinib	5291	response	Supports	COL1A1 PDGFRB fusion gene response	OHSU Import; COL1A1 PDGFRB fusion gene; organ=Skin; 	FDA-approved	N/A						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Endometrioid carcinoma	2871	PARP inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Endometrium; 	case report	20944090						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Endometrioid carcinoma	2871	PARP inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Endometrium; 	case report	20944090						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Endometrioid carcinoma	2871	PARP inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Endometrium; 	preclinical	24222661						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Endometrioid carcinoma	2871	PARP inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Endometrium; 	preclinical	24222661						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors	N/A	response	Supports	PIK3CA any  mutation response	OHSU Import; PIK3CA any  mutation; organ=Endometrium; 	early trials	N/A						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA any  mutation sensitivity	OHSU Import; PIK3CA any  mutation; organ=Endometrium; 	preclinical	22662154						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Endometrium; 	preclinical	22662154						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Endometrioid carcinoma	2871	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Endometrium; 	preclinical	22662154						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Endometrioid carcinoma	2871	trastuzumab	N/A	no response	Supports	ERBB2 amplification copy number gain no response	OHSU Import; ERBB2 amplification copy number gain; organ=Endometrium; 	early trials	19840887						1				N/A						1	
PIK3R1	5295	PIK3R1 any mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	sensitivity	Supports	PIK3R1 any mutation sensitivity	OHSU Import; PIK3R1 any mutation; organ=Endometrium; 	preclinical	19962665						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	no response	Supports	PIK3CA any  mutation no response	OHSU Import; PIK3CA any  mutation; organ=Endometrium; 	early trials	N/A						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	no response	Supports	PTEN any mutation   no response	OHSU Import; PTEN any mutation  ; organ=Endometrium; 	early trials	21788564						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	no response	Supports	PTEN any copy number loss no response	OHSU Import; PTEN any copy number loss; organ=Endometrium; 	early trials	21788564						1				N/A						1	
PIK3R1	5295	PIK3R1 any mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	sensitivity	Supports	PIK3R1 any mutation sensitivity	OHSU Import; PIK3R1 any mutation; organ=Endometrium; 	preclinical	19962665						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	no response	Supports	PIK3CA any  mutation no response	OHSU Import; PIK3CA any  mutation; organ=Endometrium; 	early trials	N/A						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	no response	Supports	PTEN any mutation   no response	OHSU Import; PTEN any mutation  ; organ=Endometrium; 	early trials	21788564						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Endometrioid carcinoma	2871	mTOR inhibitors	N/A	no response	Supports	PTEN any copy number loss no response	OHSU Import; PTEN any copy number loss; organ=Endometrium; 	early trials	21788564						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Adenocarcinoma	299	afatinib	10184653	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Stomach; 	case report	N/A						1				N/A						1	
FGFR2	2263	FGFR2 amplification copy number gain		Unknown	Adenocarcinoma	299	FGFR inhibitors	N/A	sensitivity	Supports	FGFR2 amplification copy number gain sensitivity	OHSU Import; FGFR2 amplification copy number gain; organ=Stomach; 	preclinical	23493349						1				N/A						1	
MET	4233	MET amplification copy number gain		Unknown	Adenocarcinoma	299	lapatinib	208908	resistance	Supports	MET amplification copy number gain resistance	OHSU Import; MET amplification copy number gain; organ=Stomach; 	preclinical	22238368						1				N/A						1	
MET	4233	MET amplification copy number gain		Unknown	Adenocarcinoma	299	MET inhibitors	N/A	response	Supports	MET amplification copy number gain response	OHSU Import; MET amplification copy number gain; organ=Stomach; 	case report	22042947						1				N/A						1	
MET	4233	MET amplification copy number gain		Unknown	Adenocarcinoma	299	MET inhibitors	N/A	sensitivity	Supports	MET amplification copy number gain sensitivity	OHSU Import; MET amplification copy number gain; organ=Stomach; 	preclinical	22729845						1				N/A						1	
PIK3CA	5290	PIK3CA any mutation		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA any mutation sensitivity	OHSU Import; PIK3CA any mutation; organ=Stomach; 	preclinical	22336586						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Adenocarcinoma	299	trastuzumab	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Stomach; 	FDA-approved	N/A						1				N/A						1	
KIT	3815	KIT  wild type no mutation		Unknown	GIST	9253	dasatinib	3062316	sensitivity	Supports	KIT  wild type no mutation sensitivity	OHSU Import; KIT  wild type no mutation; 	preclinical	16397263						1				N/A						1	
PDGFRA	5156	PDGFRA  wild type no mutation		Unknown	GIST	9253	dasatinib	3062316	sensitivity	Supports	PDGFRA  wild type no mutation sensitivity	OHSU Import; PDGFRA  wild type no mutation; 	preclinical	16397263						1				N/A						1	
KIT	3815	KIT  wild type no mutation		Unknown	GIST	9253	imatinib	5291	decreased sensitivity	Supports	KIT  wild type no mutation decreased sensitivity	OHSU Import; KIT  wild type no mutation; 	late trials	18955458						1				N/A						1	
PDGFRA	5156	PDGFRA  wild type no mutation		Unknown	GIST	9253	imatinib	5291	decreased sensitivity	Supports	PDGFRA  wild type no mutation decreased sensitivity	OHSU Import; PDGFRA  wild type no mutation; 	late trials	14645423						1				N/A						1	
KIT	3815	KIT  wild type no mutation		Unknown	GIST	9253	sorafenib	216239	response	Supports	KIT  wild type no mutation response	OHSU Import; KIT  wild type no mutation; 	early trials	N/A						1				N/A						1	
PDGFRA	5156	PDGFRA  wild type no mutation		Unknown	GIST	9253	sorafenib	216239	response	Supports	PDGFRA  wild type no mutation response	OHSU Import; PDGFRA  wild type no mutation; 	early trials	N/A						1				N/A						1	
KIT	3815	KIT  wild type no mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	KIT  wild type no mutation response	OHSU Import; KIT  wild type no mutation; 	late trials	18955458						1				N/A						1	
PDGFRA	5156	PDGFRA  wild type no mutation		Unknown	GIST	9253	sunitinib	5329102	response	Supports	PDGFRA  wild type no mutation response	OHSU Import; PDGFRA  wild type no mutation; 	late trials	18955458						1				N/A						1	
FGFR1	2260	FGFR1  amplification copy number gain		Unknown	Squamous cell carcinoma	1749	FGFR inhibitors	N/A	sensitivity	Supports	FGFR1  amplification copy number gain sensitivity	OHSU Import; FGFR1  amplification copy number gain; organ=Oropharynx; 	preclinical	23418312						1				N/A						1	
EGFR	1956	EGFR amplification copy number gain		Unknown	Squamous cell carcinoma	1749	gefitinib	123631	no response	Supports	EGFR amplification copy number gain no response	OHSU Import; EGFR amplification copy number gain; organ=Oropharynx; 	early trials	21274259						1				N/A						1	
PIK3CA	5290	PIK3CA any mutation		Unknown	Squamous cell carcinoma	1749	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA any mutation sensitivity	OHSU Import; PIK3CA any mutation; organ=Oropharynx; 	preclinical	23200321						1				N/A						1	
PIK3CB	5291	PIK3CB any mutation		Unknown	Squamous cell carcinoma	1749	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CB any mutation sensitivity	OHSU Import; PIK3CB any mutation; organ=Oropharynx; 	preclinical	23619167						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Squamous cell carcinoma	1749	trastuzumab	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Oropharynx; 	case report	21380780						1				N/A						1	
VEGFA	7422	VEGFA amplification copy number gain		Unknown	Hepatocellular carcinoma	684	sorafenib	216239	sensitivity	Supports	VEGFA amplification copy number gain sensitivity	OHSU Import; VEGFA amplification copy number gain; organ=Liver; 	early trials	24687604						1				N/A						1	
PDGFRA	5156	PDGFRA rearrangement fusion gene		Unknown	Hypereosinophilic syndrome	225	imatinib	5291	response	Supports	PDGFRA rearrangement fusion gene response	OHSU Import; PDGFRA rearrangement fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Inflammatory myofibroblastic tumor	0050905	crizotinib	11626560	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Soft tissue; 	case report	20979472						1				N/A						1	
ROS1	6098	ROS1 rearrangement fusion gene		Unknown	Inflammatory myofibroblastic tumor	0050905	crizotinib	11626560	response	Supports	ROS1 rearrangement fusion gene response	OHSU Import; ROS1 rearrangement fusion gene; organ=Soft tissue; 	case report	24875859						1				N/A						1	
CDK4	1019	CDK4 amplification copy number gain		Unknown	Liposarcoma	3382	CDK4/6 inhibitors	N/A	sensitivity	Supports	CDK4 amplification copy number gain sensitivity	OHSU Import; CDK4 amplification copy number gain; organ=Soft tissue; 	early trials	23569312						1				N/A						1	
FRS2	10818	FRS2 amplification copy number gain		Unknown	Liposarcoma	3382	FGFR inhibitors	N/A	sensitivity	Supports	FRS2 amplification copy number gain sensitivity	OHSU Import; FRS2 amplification copy number gain; organ=Soft tissue; 	preclinical	23393200						1				N/A						1	
MDM2	4193	MDM2 amplification copy number gain		Unknown	Liposarcoma	3382	MDM2 inhibitors	N/A	response	Supports	MDM2 amplification copy number gain response	OHSU Import; MDM2 amplification copy number gain; organ=Soft tissue; 	early trials	23084521						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Adenocarcinoma	299	IGF1R inhibitors	N/A	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Lung; 	case report	25173427						1				N/A						1	
RET	5979	RET rearrangement fusion gene		Unknown	Adenocarcinoma	299	cabozantinib	25102847	response	Supports	RET rearrangement fusion gene response	OHSU Import; RET rearrangement fusion gene; organ=Lung; 	early trials	23533264						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Adenocarcinoma	299	ceritinib	57379345	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Adenocarcinoma	299	crizotinib	11626560	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Lung; 	FDA-approved	N/A						1				N/A						1	
ALK	238	ALK amplification copy number gain		Unknown	Adenocarcinoma	299	crizotinib	11626560	resistance	Supports	ALK amplification copy number gain resistance	OHSU Import; ALK amplification copy number gain; organ=Lung; 	case report	22277784						1				N/A						1	
MET	4233	MET amplification copy number gain		Unknown	Adenocarcinoma	299	crizotinib	11626560	response	Supports	MET amplification copy number gain response	OHSU Import; MET amplification copy number gain; organ=Lung; 	early trials	N/A						1				N/A						1	
NTRK1	4914	NTRK1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	crizotinib	11626560	response	Supports	NTRK1 rearrangement fusion gene response	OHSU Import; NTRK1 rearrangement fusion gene; organ=Lung; 	case report	N/A						1				N/A						1	
ROS1	6098	ROS1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	crizotinib	11626560	response	Supports	ROS1 rearrangement fusion gene response	OHSU Import; ROS1 rearrangement fusion gene; organ=Lung; 	early trials	N/A						1				N/A						1	
BRAF	673	BRAF  G469A  missense mutation		Unknown	Adenocarcinoma	299	EGFR TKIs	N/A	resistance	Supports	BRAF  G469A  missense mutation resistance	OHSU Import; BRAF  G469A  missense mutation; organ=Lung; 	case report	22773810						1				N/A						1	
CRKL	1399	CRKL amplification copy number gain		Unknown	Adenocarcinoma	299	EGFR TKIs	N/A	resistance	Supports	CRKL amplification copy number gain resistance	OHSU Import; CRKL amplification copy number gain; organ=Lung; 	preclinical	22586683						1				N/A						1	
BRAF	673	BRAF  G469A  missense mutation		Unknown	Adenocarcinoma	299	EGFR TKIs + MEK inhibitors	N/A	sensitivity	Supports	BRAF  G469A  missense mutation sensitivity	OHSU Import; BRAF  G469A  missense mutation; organ=Lung; 	preclinical	22773810						1				N/A						1	
IGF1R	3480	IGF1R amplification copy number gain		Unknown	Adenocarcinoma	299	erlotinib	176870	resistance	Supports	IGF1R amplification copy number gain resistance	OHSU Import; IGF1R amplification copy number gain; organ=Lung; 	preclinical	24458568						1				N/A						1	
ROS1	6098	ROS1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	HSP90 inhibitors	N/A	sensitivity	Supports	ROS1 rearrangement fusion gene sensitivity	OHSU Import; ROS1 rearrangement fusion gene; organ=Lung; 	preclinical	23533265						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Adenocarcinoma	299	HSP90 inhibitors	N/A	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Lung; 	early trials	N/A						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; organ=Lung; 	preclinical	19165201						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; organ=Lung; 	preclinical	19165201						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Adenocarcinoma	299	MEK inhibitors + docetaxel in KRAS mutant	N/A	resistance	Supports	STK11 any mutation resistance	OHSU Import; STK11 any mutation; organ=Lung; 	preclinical	22425996						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Adenocarcinoma	299	MEK inhibitors + docetaxel in KRAS mutant	N/A	resistance	Supports	STK11 any copy number loss resistance	OHSU Import; STK11 any copy number loss; organ=Lung; 	preclinical	22425996						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; organ=Lung; 	preclinical	19165201						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; organ=Lung; 	preclinical	19165201						1				N/A						1	
ERBB2	2064	ERBB2 pending missense mutation		Unknown	Adenocarcinoma	299	neratinib + temsirolimus	N/A	response	Supports	ERBB2 pending missense mutation response	OHSU Import; ERBB2 pending missense mutation; organ=Lung; 	early trials	N/A						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Adenocarcinoma	299	ALK inhibitors	N/A	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Lung; 	early trials	23639470						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Adenocarcinoma	299	phenformin	8249	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; organ=Lung; 	preclinical	23352126						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Adenocarcinoma	299	phenformin	8249	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; organ=Lung; 	preclinical	23352126						1				N/A						1	
RET	5979	RET rearrangement fusion gene		Unknown	Adenocarcinoma	299	RET inhibitors	N/A	sensitivity	Supports	RET rearrangement fusion gene sensitivity	OHSU Import; RET rearrangement fusion gene; organ=Lung; 	preclinical	22327622						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Adenocarcinoma	299	SRC inhibitors	N/A	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; organ=Lung; 	preclinical	20541700						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Adenocarcinoma	299	SRC inhibitors	N/A	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; organ=Lung; 	preclinical	20541700						1				N/A						1	
NTRK1	4914	NTRK1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	TRK inhibitors	N/A	sensitivity	Supports	NTRK1 rearrangement fusion gene sensitivity	OHSU Import; NTRK1 rearrangement fusion gene; organ=Lung; 	preclinical	24162815						1				N/A						1	
RET	5979	RET rearrangement fusion gene		Unknown	Adenocarcinoma	299	vandetanib	3081361	response	Supports	RET rearrangement fusion gene response	OHSU Import; RET rearrangement fusion gene; organ=Lung; 	early trials	23533264						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Adenocarcinoma	299	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; organ=Lung; 	preclinical	19165201						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Adenocarcinoma	299	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; organ=Lung; 	preclinical	19165201						1				N/A						1	
STK11	6794	STK11 any mutation		Unknown	Adenocarcinoma	299	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any mutation sensitivity	OHSU Import; STK11 any mutation; organ=Lung; 	preclinical	19165201						1				N/A						1	
STK11	6794	STK11 any copy number loss		Unknown	Adenocarcinoma	299	mTOR inhibitors	N/A	sensitivity	Supports	STK11 any copy number loss sensitivity	OHSU Import; STK11 any copy number loss; organ=Lung; 	preclinical	19165201						1				N/A						1	
ERCC1	2067	ERCC1 any mutation		Unknown	Adenosquamous carcinoma	4830	cisplatin	N/A	sensitivity	Supports	ERCC1 any mutation sensitivity	OHSU Import; ERCC1 any mutation; organ=Lung; 	preclinical	23275151						1				N/A						1	
ERCC1	2067	ERCC1 any copy number loss		Unknown	Adenosquamous carcinoma	4830	cisplatin	N/A	sensitivity	Supports	ERCC1 any copy number loss sensitivity	OHSU Import; ERCC1 any copy number loss; organ=Lung; 	preclinical	23275151						1				N/A						1	
ERCC1	2067	ERCC1 any mutation		Unknown	Adenosquamous carcinoma	4830	PARP inhibitors	N/A	sensitivity	Supports	ERCC1 any mutation sensitivity	OHSU Import; ERCC1 any mutation; organ=Lung; 	preclinical	23934192						1				N/A						1	
ERCC1	2067	ERCC1 any copy number loss		Unknown	Adenosquamous carcinoma	4830	PARP inhibitors	N/A	sensitivity	Supports	ERCC1 any copy number loss sensitivity	OHSU Import; ERCC1 any copy number loss; organ=Lung; 	preclinical	23934192						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Adenosquamous carcinoma	4830	PI3K pathway inhibitors	N/A	response	Supports	PIK3CA any  mutation response	OHSU Import; PIK3CA any  mutation; organ=Lung; 	case report	N/A						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Adenosquamous carcinoma	4830	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Lung; 	preclinical	23136191						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Adenosquamous carcinoma	4830	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Lung; 	preclinical	23136191						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Adenosquamous carcinoma	4830	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA any  mutation sensitivity	OHSU Import; PIK3CA any  mutation; organ=Lung; 	preclinical	23136191						1				N/A						1	
FGFR1	2260	FGFR1 amplification copy number gain		Unknown	Squamous cell carcinoma	1749	FGFR inhibitors	N/A	response	Supports	FGFR1 amplification copy number gain response	OHSU Import; FGFR1 amplification copy number gain; organ=Lung; 	early trials	N/A						1				N/A						1	
TSC2	7249	TSC2 any mutation		Unknown	Lymphangioleiomyomatosis	3319	SRC inhibitors	N/A	sensitivity	Supports	TSC2 any mutation sensitivity	OHSU Import; TSC2 any mutation; organ=Soft tissue; 	preclinical	N/A						1				N/A						1	
TSC2	7249	TSC2 any copy number loss		Unknown	Lymphangioleiomyomatosis	3319	SRC inhibitors	N/A	sensitivity	Supports	TSC2 any copy number loss sensitivity	OHSU Import; TSC2 any copy number loss; organ=Soft tissue; 	preclinical	N/A						1				N/A						1	
BCL2	596	BCL2 amplification copy number gain		Unknown	Lymphoma, NOS	8838	BCL2 inhibitors	N/A	sensitivity	Supports	BCL2 amplification copy number gain sensitivity	OHSU Import; BCL2 amplification copy number gain; organ=Lymph Node; 	preclinical	22649144						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Lymphoma, NOS	8838	crizotinib	11626560	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Lymph Node; 	early trials	24491302						1				N/A						1	
SOCS1	8651	SOCS1 any mutation 		Unknown	Lymphoma, NOS	8838	JAK inhibitors	N/A	sensitivity	Supports	SOCS1 any mutation  sensitivity	OHSU Import; SOCS1 any mutation ; organ=Lymph Node; 	preclinical	22025331						1				N/A						1	
PDGFRA	5156	PDGFRA rearrangement fusion gene		Unknown	MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS	518	imatinib	5291	response	Supports	PDGFRA rearrangement fusion gene response	OHSU Import; PDGFRA rearrangement fusion gene; organ=Bone marrow; 	FDA-approved	N/A						1				N/A						1	
MITF	4286	MITF amplification copy number gain		Unknown	Melanoma, NOS	6367	BRAF inhibitors	N/A	resistance	Supports	MITF amplification copy number gain resistance	OHSU Import; MITF amplification copy number gain; 	case report	24265153						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	resistance	Supports	PTEN any mutation   resistance	OHSU Import; PTEN any mutation  ; 	preclinical	21317224						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	resistance	Supports	PTEN any copy number loss resistance	OHSU Import; PTEN any copy number loss; 	preclinical	21317224						1				N/A						1	
RB1	5925	RB1 any mutation  		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	resistance	Supports	RB1 any mutation   resistance	OHSU Import; RB1 any mutation  ; 	preclinical	21725359						1				N/A						1	
RB1	5925	RB1 any copy number loss		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	resistance	Supports	RB1 any copy number loss resistance	OHSU Import; RB1 any copy number loss; 	preclinical	21725359						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	resistance	Supports	NF1 any mutation resistance	OHSU Import; NF1 any mutation; 	preclinical	23288408						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Melanoma, NOS	6367	BRAF inhibitors in BRAF mutant tumor	N/A	resistance	Supports	NF1 any copy number loss resistance	OHSU Import; NF1 any copy number loss; 	preclinical	23288408						1				N/A						1	
CCND1	595	CCND1 amplification copy number gain		Unknown	Melanoma, NOS	6367	CDK4/6 inhibitors	N/A	response	Supports	CCND1 amplification copy number gain response	OHSU Import; CCND1 amplification copy number gain; 	case report	N/A						1				N/A						1	
CDKN2A	1029	CDKN2A any mutation		Unknown	Melanoma, NOS	6367	CDK4/6 inhibitors	N/A	response	Supports	CDKN2A any mutation response	OHSU Import; CDKN2A any mutation; 	case report	N/A						1				N/A						1	
CDKN2A	1029	CDKN2A any copy number loss		Unknown	Melanoma, NOS	6367	CDK4/6 inhibitors	N/A	response	Supports	CDKN2A any copy number loss response	OHSU Import; CDKN2A any copy number loss; 	case report	N/A						1				N/A						1	
BAP1	8314	BAP1 any mutation		Unknown	Melanoma, NOS	6367	HDAC inhibitors	N/A	sensitivity	Supports	BAP1 any mutation sensitivity	OHSU Import; BAP1 any mutation; 	preclinical	22038994						1				N/A						1	
BAP1	8314	BAP1 any copy number loss		Unknown	Melanoma, NOS	6367	HDAC inhibitors	N/A	sensitivity	Supports	BAP1 any copy number loss sensitivity	OHSU Import; BAP1 any copy number loss; 	preclinical	22038994						1				N/A						1	
BRAF	673	BRAF rearrangement fusion gene		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	sensitivity	Supports	BRAF rearrangement fusion gene sensitivity	OHSU Import; BRAF rearrangement fusion gene; 	preclinical	24345920						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	PTEN any mutation   resistance	OHSU Import; PTEN any mutation  ; 	preclinical	23039341						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	PTEN any copy number loss resistance	OHSU Import; PTEN any copy number loss; 	preclinical	23039341						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	NF1 any mutation resistance	OHSU Import; NF1 any mutation; 	case report	23288408						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	resistance	Supports	NF1 any copy number loss resistance	OHSU Import; NF1 any copy number loss; 	case report	23288408						1				N/A						1	
BRAF	673	BRAF rearrangement fusion gene		Unknown	Melanoma, NOS	6367	MEK inhibitors	N/A	sensitivity	Supports	BRAF rearrangement fusion gene sensitivity	OHSU Import; BRAF rearrangement fusion gene; 	preclinical	24345920						1				N/A						1	
PAK1	5058	PAK1 amplification copy number gain		Unknown	Melanoma, NOS	6367	PAK inhibitors	N/A	sensitivity	Supports	PAK1 amplification copy number gain sensitivity	OHSU Import; PAK1 amplification copy number gain; 	preclinical	23535073						1				N/A						1	
BRAF	673	BRAF rearrangement fusion gene		Unknown	Melanoma, NOS	6367	sorafenib	216239	sensitivity	Supports	BRAF rearrangement fusion gene sensitivity	OHSU Import; BRAF rearrangement fusion gene; 	preclinical	238900088						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Melanoma, NOS	6367	trametinib	11707110	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; 	preclinical	24576830						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Melanoma, NOS	6367	trametinib	11707110	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; 	preclinical	24576830						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Melanoma, NOS	6367	trametinib	11707110	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; 	preclinical	24576830						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Melanoma, NOS	6367	trametinib	11707110	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; 	preclinical	24576830						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Meningioma	3565	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any mutation sensitivity	OHSU Import; NF2 any mutation; organ=Meninges; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	Meningioma	3565	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any copy number loss sensitivity	OHSU Import; NF2 any copy number loss; organ=Meninges; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Meningioma	3565	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any mutation sensitivity	OHSU Import; NF2 any mutation; organ=Meninges; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	Meningioma	3565	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any copy number loss sensitivity	OHSU Import; NF2 any copy number loss; organ=Meninges; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Schwannoma	3192	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any mutation sensitivity	OHSU Import; NF2 any mutation; organ=Peripheral nerve; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	Schwannoma	3192	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any copy number loss sensitivity	OHSU Import; NF2 any copy number loss; organ=Peripheral nerve; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Schwannoma	3192	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any mutation sensitivity	OHSU Import; NF2 any mutation; organ=Peripheral nerve; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	Schwannoma	3192	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any copy number loss sensitivity	OHSU Import; NF2 any copy number loss; organ=Peripheral nerve; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any mutation sensitivity	OHSU Import; NF2 any mutation; organ=Soft tissue; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any copy number loss sensitivity	OHSU Import; NF2 any copy number loss; organ=Soft tissue; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any mutation sensitivity	OHSU Import; NF2 any mutation; organ=Soft tissue; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	PEComa	2643	mTOR inhibitors	N/A	sensitivity	Supports	NF2 any copy number loss sensitivity	OHSU Import; NF2 any copy number loss; organ=Soft tissue; 	preclinical	19451225						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Malignant mesothelioma	1790	FAK inhibitors	N/A	response	Supports	NF2 any mutation response	OHSU Import; NF2 any mutation; organ=Pleura; 	early trials	N/A						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	Malignant mesothelioma	1790	FAK inhibitors	N/A	response	Supports	NF2 any copy number loss response	OHSU Import; NF2 any copy number loss; organ=Pleura; 	early trials	N/A						1				N/A						1	
SH2B3	10019	SH2B3 any mutation		Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	JAK inhibitors	N/A	sensitivity	Supports	SH2B3 any mutation sensitivity	OHSU Import; SH2B3 any mutation; organ=Bone marrow; 	preclinical	20404132						1				N/A						1	
SH2B3	10019	SH2B3 any copy number loss		Unknown	MYELOPROLIFERATIVE NEOPLASMS	4960	JAK inhibitors	N/A	sensitivity	Supports	SH2B3 any copy number loss sensitivity	OHSU Import; SH2B3 any copy number loss; organ=Bone marrow; 	preclinical	20404132						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Malignant peripheral nerve sheath tumor	5940	MEK inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Soft tissue; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Malignant peripheral nerve sheath tumor	5940	MEK inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Soft tissue; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Malignant peripheral nerve sheath tumor	5940	MEK inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Soft tissue; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Malignant peripheral nerve sheath tumor	5940	MEK inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Soft tissue; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Malignant peripheral nerve sheath tumor	5940	mTOR inhibitors + HSP90 inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Soft tissue; 	preclinical	21907929						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Malignant peripheral nerve sheath tumor	5940	mTOR inhibitors + HSP90 inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Soft tissue; 	preclinical	21907929						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Malignant peripheral nerve sheath tumor	5940	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Soft tissue; 	preclinical	18483311						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Malignant peripheral nerve sheath tumor	5940	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Soft tissue; 	preclinical	18483311						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Malignant peripheral nerve sheath tumor	5940	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Soft tissue; 	preclinical	18483311						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Malignant peripheral nerve sheath tumor	5940	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Soft tissue; 	preclinical	18483311						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Leukemia, NOS	8692	MEK inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Bone marrow; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Leukemia, NOS	8692	MEK inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Bone marrow; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Leukemia, NOS	8692	MEK inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Bone marrow; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Leukemia, NOS	8692	MEK inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Bone marrow; 	preclinical	23221341						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Leukemia, NOS	8692	mTOR inhibitors + HSP90 inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Bone marrow; 	preclinical	21907929						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Leukemia, NOS	8692	mTOR inhibitors + HSP90 inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Bone marrow; 	preclinical	21907929						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Leukemia, NOS	8692	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Bone marrow; 	preclinical	18483311						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Leukemia, NOS	8692	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Bone marrow; 	preclinical	18483311						1				N/A						1	
NF1	4763	NF1 any mutation		Unknown	Leukemia, NOS	8692	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any mutation sensitivity	OHSU Import; NF1 any mutation; organ=Bone marrow; 	preclinical	18483311						1				N/A						1	
NF1	4763	NF1 any copy number loss		Unknown	Leukemia, NOS	8692	mTOR inhibitors	N/A	sensitivity	Supports	NF1 any copy number loss sensitivity	OHSU Import; NF1 any copy number loss; organ=Bone marrow; 	preclinical	18483311						1				N/A						1	
MYCN	4613	MYCN amplification copy number gain		Unknown	MYELOMA	0070004	BET inhibitors	N/A	sensitivity	Supports	MYCN amplification copy number gain sensitivity	OHSU Import; MYCN amplification copy number gain; 	preclinical	21889194						1				N/A						1	
MYC	4609	MYC amplification copy number gain		Unknown	Neuroblastoma	769	BET inhibitors	N/A	sensitivity	Supports	MYC amplification copy number gain sensitivity	OHSU Import; MYC amplification copy number gain; organ=Sympathetic nerve; 	preclinical	23430699						1				N/A						1	
MYCN	4613	MYCN amplification copy number gain		Unknown	Neuroblastoma	769	BET inhibitors	N/A	sensitivity	Supports	MYCN amplification copy number gain sensitivity	OHSU Import; MYCN amplification copy number gain; organ=Sympathetic nerve; 	preclinical	23430699						1				N/A						1	
BRD4	23476	BRD4 NUT fusion gene		Unknown	NUT midline carcinoma	14131	BET inhibitors	N/A	sensitivity	Supports	BRD4 NUT fusion gene sensitivity	OHSU Import; BRD4 NUT fusion gene; 	preclinical	20871596						1				N/A						1	
LRP1B	53353	LRP1B  any mutation		Unknown	Serous carcinoma, high grade	3230	liposomal doxorubicin	N/A	resistance	Supports	LRP1B  any mutation resistance	OHSU Import; LRP1B  any mutation; organ=Ovary; 	early trials	22896685						1				N/A						1	
LRP1B	53353	LRP1B  any copy number loss		Unknown	Serous carcinoma, high grade	3230	liposomal doxorubicin	N/A	resistance	Supports	LRP1B  any copy number loss resistance	OHSU Import; LRP1B  any copy number loss; organ=Ovary; 	early trials	22896685						1				N/A						1	
BRCA1	672	BRCA1 any mutation 		Unknown	Serous carcinoma, high grade	3230	PARP inhibitors	N/A	response	Supports	BRCA1 any mutation  response	OHSU Import; BRCA1 any mutation ; organ=Ovary; 	late trials	20406929						1				N/A						1	
BRCA1	672	BRCA1 deletion copy number loss		Unknown	Serous carcinoma, high grade	3230	PARP inhibitors	N/A	sensitivity	Supports	BRCA1 deletion copy number loss sensitivity	OHSU Import; BRCA1 deletion copy number loss; organ=Ovary; 	preclinical	22392482						1				N/A						1	
BRCA2	675	BRCA2 any mutation		Unknown	Serous carcinoma, high grade	3230	PARP inhibitors	N/A	response	Supports	BRCA2 any mutation response	OHSU Import; BRCA2 any mutation; organ=Ovary; 	late trials	20406929						1				N/A						1	
BRCA2	675	BRCA2 deletion copy number loss		Unknown	Serous carcinoma, high grade	3230	PARP inhibitors	N/A	sensitivity	Supports	BRCA2 deletion copy number loss sensitivity	OHSU Import; BRCA2 deletion copy number loss; organ=Ovary; 	preclinical	22392482						1				N/A						1	
BRCA1	672	BRCA1 any mutation 		Unknown	Serous carcinoma, high grade	3230	PARP inhibitors + chemotherapy	N/A	response	Supports	BRCA1 any mutation  response	OHSU Import; BRCA1 any mutation ; organ=Ovary; 	early trials	N/A						1				N/A						1	
BRCA2	675	BRCA2 any mutation		Unknown	Serous carcinoma, high grade	3230	PARP inhibitors + chemotherapy	N/A	response	Supports	BRCA2 any mutation response	OHSU Import; BRCA2 any mutation; organ=Ovary; 	early trials	N/A						1				N/A						1	
PIK3CA	5290	PIK3CA any  mutation		Unknown	Serous carcinoma, high grade	3230	PI3K pathway inhibitors	N/A	response	Supports	PIK3CA any  mutation response	OHSU Import; PIK3CA any  mutation; organ=Ovary; 	early trials	N/A						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Serous carcinoma, high grade	3230	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Ovary; 	preclinical	21632463						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Serous carcinoma, high grade	3230	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Ovary; 	preclinical	21632463						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Serous carcinoma, high grade	3230	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Ovary; 	preclinical	21632463						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Serous carcinoma, high grade	3230	PI3K pathway inhibitors + MEK inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Ovary; 	preclinical	21632463						1				N/A						1	
BRCA1	672	BRCA1 any mutation 		Unknown	Serous carcinoma, high grade	3230	platinum agents	N/A	response	Supports	BRCA1 any mutation  response	OHSU Import; BRCA1 any mutation ; organ=Ovary; 	late trials	22406760						1				N/A						1	
BRCA2	675	BRCA2 any mutation		Unknown	Serous carcinoma, high grade	3230	platinum agents	N/A	response	Supports	BRCA2 any mutation response	OHSU Import; BRCA2 any mutation; organ=Ovary; 	late trials	22406760						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Serous carcinoma, high grade	3230	trastuzumab	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Ovary; 	early trials	12525520						1				N/A						1	
ERBB2	2064	ERBB2 amplification copy number gain		Unknown	Serous carcinoma, high grade	3230	trastuzumab	N/A	response	Supports	ERBB2 amplification copy number gain response	OHSU Import; ERBB2 amplification copy number gain; organ=Ovary; 	case report	20003286						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Adenocarcinoma	299	AKT inhibitors	N/A	response	Supports	PTEN any mutation   response	OHSU Import; PTEN any mutation  ; organ=Pancreas; 	case report	22025163						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Adenocarcinoma	299	AKT inhibitors	N/A	response	Supports	PTEN any copy number loss response	OHSU Import; PTEN any copy number loss; organ=Pancreas; 	case report	22025163						1				N/A						1	
PALB2	79728	PALB2 any mutation		Unknown	Adenocarcinoma	299	Mitomycin C	5746	response	Supports	PALB2 any mutation response	OHSU Import; PALB2 any mutation; organ=Pancreas; 	case report	21135251						1				N/A						1	
PALB2	79728	PALB2 any copy number loss		Unknown	Adenocarcinoma	299	Mitomycin C	5746	response	Supports	PALB2 any copy number loss response	OHSU Import; PALB2 any copy number loss; organ=Pancreas; 	case report	21135251						1				N/A						1	
AURKA	6790	AURKA amplification copy number gain		Unknown	Adenocarcinoma	299	AURK inhibitors	N/A	sensitivity	Supports	AURKA amplification copy number gain sensitivity	OHSU Import; AURKA amplification copy number gain; organ=Prostate; 	preclinical	22389870						1				N/A						1	
TMPRSS2	7113	TMPRSS2 rearrangement fusion gene		Unknown	Adenocarcinoma	299	DNA-PK inhibitors	N/A	response	Supports	TMPRSS2 rearrangement fusion gene response	OHSU Import; TMPRSS2 rearrangement fusion gene; organ=Prostate; 	preclinical	21575865						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Adenocarcinoma	299	everolimus	6442177	response	Supports	PTEN any mutation   response	OHSU Import; PTEN any mutation  ; organ=Prostate; 	early trials	23582881						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Adenocarcinoma	299	everolimus	6442177	response	Supports	PTEN any copy number loss response	OHSU Import; PTEN any copy number loss; organ=Prostate; 	early trials	23582881						1				N/A						1	
BRAF	673	BRAF rearrangement fusion gene		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	BRAF rearrangement fusion gene sensitivity	OHSU Import; BRAF rearrangement fusion gene; organ=Prostate; 	preclinical	20526349						1				N/A						1	
RAF1	5894	RAF1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	RAF1 rearrangement fusion gene sensitivity	OHSU Import; RAF1 rearrangement fusion gene; organ=Prostate; 	preclinical	20526349						1				N/A						1	
BRAF	673	BRAF rearrangement fusion gene		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	BRAF rearrangement fusion gene sensitivity	OHSU Import; BRAF rearrangement fusion gene; organ=Prostate; 	preclinical	20526349						1				N/A						1	
RAF1	5894	RAF1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	MEK inhibitors	N/A	sensitivity	Supports	RAF1 rearrangement fusion gene sensitivity	OHSU Import; RAF1 rearrangement fusion gene; organ=Prostate; 	preclinical	20526349						1				N/A						1	
AR	367	AR  amplification copy number gain		Unknown	Adenocarcinoma	299	AR antagonist	N/A	sensitivity	Supports	AR  amplification copy number gain sensitivity	OHSU Import; AR  amplification copy number gain; organ=Prostate; 	preclinical	21859989						1				N/A						1	
BRCA1	672	BRCA1 any mutation		Unknown	Adenocarcinoma	299	PARP inhibitors	N/A	response	Supports	BRCA1 any mutation response	OHSU Import; BRCA1 any mutation; organ=Prostate; 	case report	19553641						1				N/A						1	
BRCA2	675	BRCA2 any mutation		Unknown	Adenocarcinoma	299	PARP inhibitors	N/A	response	Supports	BRCA2 any mutation response	OHSU Import; BRCA2 any mutation; organ=Prostate; 	case report	19553641						1				N/A						1	
TMPRSS2	7113	TMPRSS2 rearrangement fusion gene		Unknown	Adenocarcinoma	299	PARP inhibitors	N/A	response	Supports	TMPRSS2 rearrangement fusion gene response	OHSU Import; TMPRSS2 rearrangement fusion gene; organ=Prostate; 	preclinical	21575865						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Adenocarcinoma	299	PI3K beta inhibitors	N/A	response	Supports	PTEN any mutation   response	OHSU Import; PTEN any mutation  ; organ=Prostate; 	case report	N/A						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Adenocarcinoma	299	PI3K beta inhibitors	N/A	response	Supports	PTEN any copy number loss response	OHSU Import; PTEN any copy number loss; organ=Prostate; 	case report	N/A						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors + AR antagonists	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Prostate; 	preclinical	21575859						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Adenocarcinoma	299	PI3K pathway inhibitors + AR antagonists	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Prostate; 	preclinical	21575859						1				N/A						1	
BRAF	673	BRAF rearrangement fusion gene		Unknown	Adenocarcinoma	299	sorafenib	216239	sensitivity	Supports	BRAF rearrangement fusion gene sensitivity	OHSU Import; BRAF rearrangement fusion gene; organ=Prostate; 	preclinical	20526349						1				N/A						1	
RAF1	5894	RAF1 rearrangement fusion gene		Unknown	Adenocarcinoma	299	sorafenib	216239	sensitivity	Supports	RAF1 rearrangement fusion gene sensitivity	OHSU Import; RAF1 rearrangement fusion gene; organ=Prostate; 	preclinical	20526349						1				N/A						1	
FLCN	201163	FLCN any mutation		Unknown	Clear cell carcinoma	7267	everolimus	6442177	response	Supports	FLCN any mutation response	OHSU Import; FLCN any mutation; organ=Kidney; 	case report	23995526						1				N/A						1	
FLCN	201163	FLCN any copy number loss 		Unknown	Clear cell carcinoma	7267	everolimus	6442177	response	Supports	FLCN any copy number loss  response	OHSU Import; FLCN any copy number loss ; organ=Kidney; 	case report	23995526						1				N/A						1	
TSC1	7248	TSC1 any mutation		Unknown	Clear cell carcinoma	7267	everolimus	6442177	response	Supports	TSC1 any mutation response	OHSU Import; TSC1 any mutation; organ=Kidney; 	case report	24622468						1				N/A						1	
TSC1	7248	TSC1 any copy number loss		Unknown	Clear cell carcinoma	7267	everolimus	6442177	response	Supports	TSC1 any copy number loss response	OHSU Import; TSC1 any copy number loss; organ=Kidney; 	case report	24622468						1				N/A						1	
MET	4233	MET amplification copy number gain		Unknown	Clear cell carcinoma	7267	MET inhibitors	N/A	response	Supports	MET amplification copy number gain response	OHSU Import; MET amplification copy number gain; organ=Kidney; 	early trials	23213094						1				N/A						1	
BAP1	8314	BAP1 any mutation		Unknown	Clear cell carcinoma	7267	PARP inhibitors	N/A	sensitivity	Supports	BAP1 any mutation sensitivity	OHSU Import; BAP1 any mutation; organ=Kidney; 	preclinical	22683710						1				N/A						1	
BAP1	8314	BAP1 any copy number loss 		Unknown	Clear cell carcinoma	7267	PARP inhibitors	N/A	sensitivity	Supports	BAP1 any copy number loss  sensitivity	OHSU Import; BAP1 any copy number loss ; organ=Kidney; 	preclinical	22683710						1				N/A						1	
RB1	5925	RB1 any mutation  		Unknown	Retinoblastoma	768	HDAC inhibitors	N/A	sensitivity	Supports	RB1 any mutation   sensitivity	OHSU Import; RB1 any mutation  ; organ=Soft tissue; 	preclinical	18483379						1				N/A						1	
RB1	5925	RB1 any copy number loss		Unknown	Retinoblastoma	768	HDAC inhibitors	N/A	sensitivity	Supports	RB1 any copy number loss sensitivity	OHSU Import; RB1 any copy number loss; organ=Soft tissue; 	preclinical	18483379						1				N/A						1	
RB1	5925	RB1 any mutation  		Unknown	Retinoblastoma	768	MDM2 inhibitors	N/A	sensitivity	Supports	RB1 any mutation   sensitivity	OHSU Import; RB1 any mutation  ; organ=Soft tissue; 	preclinical	17080083						1				N/A						1	
RB1	5925	RB1 any copy number loss		Unknown	Retinoblastoma	768	MDM2 inhibitors	N/A	sensitivity	Supports	RB1 any copy number loss sensitivity	OHSU Import; RB1 any copy number loss; organ=Soft tissue; 	preclinical	17080083						1				N/A						1	
MDM4	4194	MDM4 amplification copy number gain		Unknown	Sarcoma, NOS	5492	MDM2 inhibitors	N/A	sensitivity	Supports	MDM4 amplification copy number gain sensitivity	OHSU Import; MDM4 amplification copy number gain; organ=Soft tissue; 	preclinical	24336067						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Schwannoma	3192	bevacizumab	N/A	response	Supports	NF2 any mutation response	OHSU Import; NF2 any mutation; organ=Peripheral nerve; 	early trials	22805104						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Schwannoma	3192	lapatinib	208908	response	Supports	NF2 any mutation response	OHSU Import; NF2 any mutation; organ=Peripheral nerve; 	early trials	22844108						1				N/A						1	
NF2	4771	NF2 any mutation		Unknown	Schwannoma	3192	PAK inhibitors	N/A	response	Supports	NF2 any mutation response	OHSU Import; NF2 any mutation; organ=Peripheral nerve; 	early trials	23960073						1				N/A						1	
NF2	4771	NF2 any copy number loss		Unknown	Schwannoma	3192	PAK inhibitors	N/A	response	Supports	NF2 any copy number loss response	OHSU Import; NF2 any copy number loss; organ=Peripheral nerve; 	early trials	23960073						1				N/A						1	
RET	5979	RET PTC1 fusion gene		Unknown	Papillary thyroid carcinoma	3969	cabozantinib	25102847	sensitivity	Supports	RET PTC1 fusion gene sensitivity	OHSU Import; RET PTC1 fusion gene; organ=Thyroid; 	preclinical	21470995						1				N/A						1	
ALK	238	ALK rearrangement fusion gene		Unknown	Papillary thyroid carcinoma	3969	crizotinib	11626560	response	Supports	ALK rearrangement fusion gene response	OHSU Import; ALK rearrangement fusion gene; organ=Thyroid; 	case report	24687827						1				N/A						1	
FLCN	201163	FLCN any mutation		Unknown	Papillary thyroid carcinoma	3969	everolimus	6442177	response	Supports	FLCN any mutation response	OHSU Import; FLCN any mutation; organ=Thyroid; 	case report	25295501						1				N/A						1	
FLCN	201163	FLCN any copy number loss 		Unknown	Papillary thyroid carcinoma	3969	everolimus	6442177	response	Supports	FLCN any copy number loss  response	OHSU Import; FLCN any copy number loss ; organ=Thyroid; 	case report	25295501						1				N/A						1	
TSC2	7249	TSC2 any mutation		Unknown	Papillary thyroid carcinoma	3969	everolimus	6442177	response	Supports	TSC2 any mutation response	OHSU Import; TSC2 any mutation; organ=Thyroid; 	case report	25295501						1				N/A						1	
PIK3CA	5290	PIK3CA any missense mutation		Unknown	Papillary thyroid carcinoma	3969	PI3K pathway inhibitors	N/A	sensitivity	Supports	PIK3CA any missense mutation sensitivity	OHSU Import; PIK3CA any missense mutation; organ=Thyroid; 	preclinical	21289267						1				N/A						1	
PTEN	5728	PTEN any mutation  		Unknown	Papillary thyroid carcinoma	3969	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any mutation   sensitivity	OHSU Import; PTEN any mutation  ; organ=Thyroid; 	preclinical	21289267						1				N/A						1	
PTEN	5728	PTEN any copy number loss		Unknown	Papillary thyroid carcinoma	3969	PI3K pathway inhibitors	N/A	sensitivity	Supports	PTEN any copy number loss sensitivity	OHSU Import; PTEN any copy number loss; organ=Thyroid; 	preclinical	21289267						1				N/A						1	
RET	5979	RET PTC1 fusion gene		Unknown	Papillary thyroid carcinoma	3969	RET inhibitors	N/A	sensitivity	Supports	RET PTC1 fusion gene sensitivity	OHSU Import; RET PTC1 fusion gene; organ=Thyroid; 	preclinical	23056499						1				N/A						1	
RET	5979	RET PTC1 fusion gene		Unknown	Papillary thyroid carcinoma	3969	sunitinib	5329102	sensitivity	Supports	RET PTC1 fusion gene sensitivity	OHSU Import; RET PTC1 fusion gene; organ=Thyroid; 	preclinical	21470995						1				N/A						1	
NTRK1	4914	NTRK1 rearrangement fusion gene		Unknown	Papillary thyroid carcinoma	3969	TRK inhibitors	N/A	sensitivity	Supports	NTRK1 rearrangement fusion gene sensitivity	OHSU Import; NTRK1 rearrangement fusion gene; organ=Thyroid; 	preclinical	N/A						1				N/A						1	
RET	5979	RET PTC1 fusion gene		Unknown	Papillary thyroid carcinoma	3969	vandetanib	3081361	sensitivity	Supports	RET PTC1 fusion gene sensitivity	OHSU Import; RET PTC1 fusion gene; organ=Thyroid; 	preclinical	21470995						1				N/A						1	
TSC1	7248	TSC1 any mutation		Unknown	Urothelial carcinoma	6166	everolimus	6442177	response	Supports	TSC1 any mutation response	OHSU Import; TSC1 any mutation; organ=Bladder; 	early trials	22923433						1				N/A						1	
FGFR3	2261	FGFR3 any mutation		Unknown	Urothelial carcinoma	6166	FGFR inhibitors	N/A	response	Supports	FGFR3 any mutation response	OHSU Import; FGFR3 any mutation; organ=Bladder; 	early trials	N/A						1				N/A						1	
FGFR3	2261	FGFR3 rearrangement fusion gene		Unknown	Urothelial carcinoma	6166	FGFR inhibitors	N/A	response	Supports	FGFR3 rearrangement fusion gene response	OHSU Import; FGFR3 rearrangement fusion gene; organ=Bladder; 	case report	N/A						1				N/A						1	
